Technology - Investor's Business Daily00:45 Текст источника в новой вкладке

 
 
1. Red Hat Revenue, Profit Guidance Miss Expectations; Shares Tank00:21[−]

Red Hat ( RHT) Thursday reported fiscal first-quarter revenue and profit that topped estimates, but its current-quarter guidance missed expectations. Shares plunged in extended trading.

X

Red Hat said adjusted earnings were 72 cents a share, up 28% from a year ago, with revenue rising 20% to $814 million, topping analyst estimates.

A year earlier, the Raleigh, N.C.-based company earned 56 cents a share on sales of $677 million. Analysts expected the enterprise-software maker to report earnings of 68 cents on sales of $807 million for the period ended May 31.

For the current quarter, Red Hat forecast revenue of $826 million vs. estimates of $855 million, up 18% from a year earlier. The company said it expects adjusted profit of 81 cents a share. Analysts had projected 89 cents a share.

Red Hat Stock Falls

The company lowered its full-year, fiscal 2019 revenue outlook, citing currency exchange rates.

"We continue to expect strong demand for our hybrid cloud enabling technologies," Chief Financial Officer Eric Shander said in a news release. "Given the headwinds that have developed in foreign exchange rates since that time, we are adjusting our full-year total-revenue guidance by approximately $50 million, solely to account for the change in exchange rates."

Shares in the maker of open-source and cloud software plunged 10% to 148.98 in after-hours trading in the stock market today. Red Hat fell 2% in Thursday's regular session. Shares had soared 66% from a year ago as of Thursday's market close.

Red Hat is ranked No. 37 in the IBD 50 roster of fast-growing companies.

The company's Linux operating system runs servers in data centers operated by many large U.S. companies. Red Hat has pivoted from its core Linux business into building an app development platform for moving business workloads to public cloud service providers, such as Amazon.com ( AMZN).

RELATED:

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

The post Red Hat Revenue, Profit Guidance Miss Expectations; Shares Tank appeared first on Investor's Business Daily.


2. Data Storage Firm Smart Global Holdings Beats Earnings TargetЧт., 21 июня[−]

Computer memory and data storage subsystems maker Smart Global Holdings ( SGH) late Thursday beat Wall Street estimates for its fiscal third quarter, but offered mixed guidance for the current quarter.

X

The parent company of Smart Modular Technologies earned an adjusted $1.84 a share, up 100% year over year, in the quarter ended May 25. Sales rose 62% to $335.5 million. Analysts expected the Newark, Calif.-based company to earn an adjusted $1.77 a share on sales of $332 million.

For the current quarter, Smart Global expects to earn an adjusted $1.67 a share on sales of $370 million. Wall Street was modeling the firm to earn $1.67 a share on sales of $353 million in the quarter ending Aug. 31.

Smart Global shares alternated between slight gains and slight losses in after-hours trading on the stock market today. During the regular session, the stock fell 1.7% to close at 39.85. Smart Global went public in May 2017 at $11 a share.

Smart Global makes specialty memory, storage and hybrid subsystems for the electronics industry. Its customers make devices for the computing, networking, communications, data storage, mobile and industrial markets.

Penguin Computing Acquisition

Last week, Smart Global Holdings announced that it acquired Penguin Computing, a privately held company that makes specialty computing and storage systems targeting applications in artificial intelligence, machine learning and high-performance computing.

Smart Global agreed to buy Penguin for up to $85 million. That includes up to $25 million in performance-based payments, which will be made only if certain agreed-upon targets are achieved.

"Penguin is the cornerstone of our new business unit, Smart Specialty Compute & Storage Solutions," Smart Global CEO Ajay Shah said in a news release. The acquisition "greatly expands the markets and technologies where we can participate into areas requiring specialized computing platforms."

RELATED:

Micron Earnings Report Shows Strength Of Memory Chip Market

Data Storage Key Link In Emerging Data-Centered Computing Cycle

The post Data Storage Firm Smart Global Holdings Beats Earnings Target appeared first on Investor's Business Daily.


3. Biotech IPOs, Led By AvroBio, Show Double-Digit GainsЧт., 21 июня[−]

Five biotech companies held their initial public offerings Thursday, with the biggest gain coming from AvroBio ( AVRO), a stock that popped more than 60% on its first day of trading.

X

Other top-performing biotech IPOs Thursday include Aptinyx ( APTX), Kezar Life Sciences ( KZR) and Xeris Pharmaceuticals ( XERS).

AvroBio raised $99 million, pricing 5.2 million shares at an above-range price of 19. AvroBio shares closed at 31.20, soaring by 64.2% on the stock market today.

The clinical-stage biotech is developing stem-cell gene therapies to cure rare lysosomal storage disease.

Aptinyx shares closed at 20.20, surging 26.2%. It raised $102 million, pricing 6.4 million shares at 16, the high end of its range. Aptinyx is developing therapeutics for the treatment of brain and nervous system disorders.

Kezar Life Sciences raised $75 million, pricing 5 million shares at 15. Shares closed at 17.75, up 18.3%. The company is developing therapies for autoimmunity and cancer.

Biotech IPOs This Year

Xeris Pharmaceuticals raised $86 million, pricing 5.7 million shares at 15, the midpoint of its range. Xeris shares closed at 20.22, jumping 34.8%. The company is formulating an injectable hypoglycemia treatment.

Magenta Therapeutics ( MGTA), which is developing therapies for bone marrow transplants, raised $100 million, pricing 6.7 million shares at 15, the midpoint of its range.

Magenta shares fell 3.2%, to 14.52.

There have been 91 IPOs this year, up 34% from the same period last year. Biotech IPOs, along with health care and medical sector offerings, lead the way with 32, according to IPO research and ETF manager Renaissance Capital.

RELATED:

IBD Stock Of The Day: Dropbox Breaks Out As Software IPOs Surge

IBD Stock Of The Day: Hot New China IPO iQiyi Flashes This Key Technical Sign

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The post Biotech IPOs, Led By AvroBio, Show Double-Digit Gains appeared first on Investor's Business Daily.


4. E-Commerce Stocks Smacked By Supreme Court Ruling On State TaxesЧт., 21 июня[−]

Amazon ( AMZN) and other e-commerce stocks fell Thursday, following a closely watched U.S. Supreme Court decision saying states can collect taxes from retailers that do not have a physical presence there.

X

The decision in South Dakota vs. Wayfair is a victory for states who argued they were losing out on billions of dollars each year. That was due to an outdated Supreme Court decision on sales tax collection. Wayfair ( W) operates five online retail sites that sell a variety of goods for the home.

The 5-to-4 decision overturned a 1992 decision, Quill vs. North Dakota, that involved mail-order catalogs. That older case prevented states from collecting a sales tax from retailers without a physical presence in their state. This latest Supreme Court ruling said that earlier decision was obsolete in an era of explosive e-commerce.

Justice Anthony M. Kennedy, who wrote the majority decision, said the previous ruling unfairly disadvantaged traditional brick-and-mortar stores.

Amazon, Shopify ( SHOP), Etsy ( ETSY) and Wayfair and other e-commerce stocks all were down. But the decision was a boost for Avalara ( AVLR), which held its initial public offering last week. Avalara shares closed at 51.04, soaring by 13.5%, on the stock market today.

Navigating Tax Compliance

Avalara provides a cloud-based software platform to help its customers navigate the complicated and highly regulated world of tax compliance. The company automates the processes of determining taxability and applicable tax rates. It prepares and files returns, maintains tax records and manages compliance documents.

The Avalara IPO priced shares at 24 and popped 87% on its first day of trading.

Among e-commerce stocks, Amazon shares skidded 1.1% to 1,730.22. Shopify fell 4.8%, to 164.54. Etsy dropped 1.4% to 43.60. and Wayfair lost 1.6%, closing at 114.28.

Many big retailers already collect out-of-state taxes, including Amazon, Apple ( AAPL), Walmart ( WMT) and Target ( TGT).

The ruling is likely to have the biggest impact on small e-commerce companies.

RELATED:

Etsy Stock Hits Record High On Raised Revenue Guidance, New Initiatives

Retail And E-Commerce News And Stocks To Watch

Amazon (AMZN) Stock Quotes, Company News And Chart Analysis

The post E-Commerce Stocks Smacked By Supreme Court Ruling On State Taxes appeared first on Investor's Business Daily.


5. Intel CEO Resigns After Probe Of Improper Relationship With StafferЧт., 21 июня[−]

Intel ( INTC) Chief Executive Brian Krzanich resigned Thursday as CEO and board member after an investigation revealed that he had an improper relationship with an Intel employee. The board of directors named Chief Financial Officer Robert Swan as interim CEO, effective immediately.

X

The chipmaker also announced that it expects its second-quarter revenue and adjusted earnings per share to exceed its prior guidance. Plus, it believes 2018 will be a record year for the Santa Clara, Calif.-based company.

The board said Krzanich's past consensual relationship with an Intel employee violated the company's nonfraternization policy, which applies to all managers.

"The board believes strongly in Intel's strategy and we are confident in Bob Swan's ability to lead the company as we conduct a robust search for our next CEO," Intel Chairman Andy Bryant said in a news release. "Bob has been instrumental to the development and execution of Intel's strategy, and we know the company will continue to smoothly execute. We appreciate Brian's many contributions to Intel."

Intel shares fell 2.4% to close at 52.19 on the stock market today. Earlier in the session, the stock rose as much as 2%. It fell below its 50-day moving average, a key support level, on Monday. It hit an 18-year high of 57.60 on June 4.

Raised Quarterly Guidance

Intel now expects to earn an adjusted 99 cents a share on revenue of $16.9 billion in the second quarter. That would translate to year-over-year gains of 38% in earnings per share and 15% in sales. Wall Street was modeling 85 cents in earnings per share and $16.29 billion in revenue.

"With accelerating data-centric revenue, the company is off to an excellent start in the first half of the year and expects 2018 to be another record year," Intel said.

Intel will report second-quarter results and give its updated outlook on July 26.

Wall Street Reacts To CEO Resignation

The CEO resignation offsets the positive earnings pre-announcement, Needham analyst Quinn Bolton said in a report.

"We believe Mr. Krzanich was the driving force behind Intel's transition to a data-centric business," he said. The resignation comes at a time when Intel faces increased competition in server processors from Advanced Micro Devices ( AMD), Bolton said.

Bolton reiterated his buy rating on Intel, but cut his price target to 60 from 62.

RBC Capital Markets analyst Amit Daryanani thinks the second-quarter pre-announcement outweighs the CEO change. The sales and earnings upside bode well for data center and memory chip sales, he said in a report.

"We consider the pre-announcement a positive; however, the management change may cause some short-term turbulence," Daryanani said. He maintained his sector perform rating on Intel stock but upped his price target to 60 from 58.

Intel is in good hands with Swan at the helm, Evercore ISI analyst C.J. Muse said. But Intel faces a lot of challenges.

In addition to rising competition from AMD in servers, Intel must confront a changing computer landscape with Big Data and artificial intelligence, he said. Customers are shifting to graphics processing units from Nvidia ( NVDA) to handle large data processing needs, Muse said.

RELATED:

Micron Earnings Report Shows Strength Of Memory Chip Market

Chip Stocks To Watch And Semiconductor Industry News

The post Intel CEO Resigns After Probe Of Improper Relationship With Staffer appeared first on Investor's Business Daily.


6. Netflix Stock Rise Prompts Analysts To Raise Their Price TargetsЧт., 21 июня[−]

Netflix stock on Thursday notched its sixth record high in the last seven trading days, sending bullish analysts scrambling to revise their price targets.

X

Pivotal Research Group reiterated its buy rating on Netflix ( NFLX), and raised its price target to 500 from 420. Raymond James kept its outperform rating and upped its price target to 465 from 365.

Netflix shares spiked to an all-time intraday high of 423.21 in morning trading on the stock market today. Netflix ended the regular trading session down 0.3% to 415.44. The internet television network is due to report its second-quarter results on July 16.

Pivotal analyst Jeffrey Wlodarczak raised his price target on expectations for higher average revenue per user in international markets.

"We expect yet another solid result (and Q3 guidance) in the seasonally weaker Q2 driven by content launches, aggressive increases in marketing spend and the natural momentum of the business," he said in a report to clients.

AT&T Purchase Could Weaken HBO

Netflix also could benefit from the close of AT&T's ( T) purchase of Time Warner. The merger could weaken Netflix rival HBO as a global competitor as AT&T tries to integrate "two extremely disparate operating cultures," Wlodarczak said. HBO is a unit of Time Warner. Netflix might be able to pick up some Time Warner creative talent in the process, he said.

Similarly, bidding by Walt Disney ( DIS) and Comcast ( CMCSA) for 21st Century Fox ( FOXA) could weaken the eventual winner.

"Clearly, the Disney/Comcast play for Fox is about attempting to compete with Netflix in the medium/long term (and trying to offset the melting iceberg nature of their core business)," he said.

Legacy media's shift to over-the-top internet television highlights Netflix's inherent strengths, Raymond James analyst Justin Patterson said.

"Media consolidation and the shift to more over-the-top/direct-to-consumer models plays to Netflix's strengths and may provide a driver for price increases over time," he said. Netflix's strengths include personalization, year-round quality programming and service reliability, he said.

RELATED:

Netflix Stock Rockets To All-Time High On Price-Target Hikes

Apple To Spend $900 Million On Original Video Content This Year: Analyst

The post Netflix Stock Rise Prompts Analysts To Raise Their Price Targets appeared first on Investor's Business Daily.


7. Micron Earnings Report Shows Strength Of Memory Chip MarketЧт., 21 июня[−]

A beat-and-raise report from Micron Technology ( MU) late Wednesday for its fiscal third quarter eased investor worries about softening memory-chip pricing and sales.

X

Micron stock rose 0.8% to 59.44 on the stock market today. The Micron earnings report also boosted semiconductor equipment stocks including Applied Materials ( AMAT), up 0.8%, and Lam Research ( LRCX), up 0.9%.

Micron earnings also lifted other computer-memory makers such as Western Digital ( WDC), up 0.8%.

Micron earned an adjusted $3.15 a share, up 94% year over year, in the quarter ended May 31. Sales rose 40% to $7.8 billion. Analysts expected it to earn $3.12 a share on sales of $7.75 billion.

For the current quarter, Micron expects to earn an adjusted $3.30 a share on sales of $8.2 billion. That would translate to year-over-year growth of 63% in earnings per share and 34% in sales. Wall Street was modeling earnings of $3.16 a share on sales of $8.02 billion.

Data-Hungry Applications For Memory Chips

"Data-hungry applications are driving secular growth for memory and storage solutions," Micron Chief Executive Sanjay Mehrotra said on a conference call with analysts. "Importantly, our customers recognize the essential added value that memory and fast storage provide for the solutions they deliver to their end customers."

Micron stock received at least eight price-target increases from Wall Street analysts following its earnings report. The most bullish of the group was Rosenblatt Securities analyst Hans Mosesmann. He reiterated his buy rating and upped his target to 120 from 115.

"Micron is generating roughly $10 billion in free cash flow per year, has initiated a $10 billion repurchase program, and is executing near-flawlessly in a memory market that is structurally changed within a rationally oligopolistic industry," Mosesmann said in a report.

The company also is benefiting from such growing markets as solid-state drives for PCs and memory for cloud data centers.

Semtech Gets Price-Target Hikes

Elsewhere in the semiconductor industry, chipmaker Semtech ( SMTC) received at least four price-target increases to its stock on Thursday. The Camarillo, Calif.-based company held an analyst day briefing Wednesday in New York.

Semtech shares rose 2.2% to 51.20 on Thursday.

"Tone of the meeting was bullish as CEO Mohan Maheswaran laid out his plan to achieve $1 billion in organic sales by 2022," Oppenheimer analyst Rick Schafer said in a report. He upped his price target on the stock to 58 from 50 and kept his outperform rating.

A key takeaway from the analyst day was an increase in the company's long-term operating profit margin target, RBC Capital Markets analyst Mitch Steves said in a report. Semtech is now targeting 32% to 36%, vs. its prior target of 28% to 32%.

RELATED:

Micron Technology Stock Jumps On Sales, Earnings Guidance

The post Micron Earnings Report Shows Strength Of Memory Chip Market appeared first on Investor's Business Daily.


8. Will Murdoch Be Biggest Disney Shareholder Or Cash Out To Comcast?Чт., 21 июня[−]

Investors may be overlooking a big factor in who wins the takeover battle for 21st Century Fox ( FOXA) — whether the Murdoch family wants to be the biggest shareholders in the new company, or would they rather cash out?

X

The question is the proverbial elephant-in-the-room as a bidding war rages between Comcast ( CMCSA) and Walt Disney ( DIS) for a chunk of Rupert Murdoch's Fox media empire. Fox on Wednesday accepted Disney's sweetened, $71 billion cash-and-stock bid, at $38-a-share. That countered Comcast's $65 billion all-cash bid. Experts expect Comcast to fire back soon.

Murdoch, along with sons Lachlan and James — all three of them Fox board members — are legally bound recommend the best offer to shareholders. Whether Comcast or Disney prevails in the showdown over Fox likely boils down to the highest offer, tax issues and regulatory approval.

But a lurking concern is whether Murdoch and family want to stay in the pantheon of the media and entertainment industry. Murdoch owns 17% of Fox's outstanding shares. The family stands to be the biggest shareholders in a combined Disney-Fox. It's possible a Murdoch one day could run Disney.

The Murdochs, however, become smaller media industry players if Fox ultimately accepts Comcast's all-cash bid.

Could Murdoch Get Disney Board Seat?

Comcast and Disney are fighting over Fox's film and TV studios, cable networks, international TV business and a 39% stake in satellite broadcaster Sky. Not everything in Fox goes, however. Fox retains its news channel, TV stations, sports networks and other assets and spin it into a new company, with Lachlan Murdoch as CEO.

It's not clear if the Murdochs will get a Disney board seat if the Mouse prevails vs. Comcast, says Blair Levin, analyst at New Street Research. The reason: Disney owns a TV broadcaster, ABC, and the Murdochs still would have Fox.

Craig Moffett, a longtime industry analyst, on Thursday published a report saying Disney holds an edge over Comcast. He says Disney's mostly stock offer provides tax advantages. He notes that Fox shareholders have a choice of taking cash or stock. And, Moffett says Disney may have a better chance of getting regulatory approval, despite AT&T's ( T) recent court victory in the Time Warner acquisition.

Asked about Murdoch winding up as the biggest shareholder in Disney as a factor, Moffett replied in an email: "Yes, that too."

Disney Says No To Asset Split

Disney CEO Bob Iger said Wednesday the company has legally committed to not split Fox assets with Comcast. That raises the stakes for the Roberts family.

Ralph Roberts co-founded Comcast in the 1960s. A dual-class stock structure gives the Roberts family control of about a third of the company's voting power.

Comcast stock dropped 1.8% to close at 32.79 on the stock market today as Fox rose 0.5% to 48.34. Disney fell 1.2% to 105.89.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Will Murdoch Be Biggest Disney Shareholder Or Cash Out To Comcast? appeared first on Investor's Business Daily.


9. Why A Strong Painkiller Just Wounded Two Biotech StocksЧт., 21 июня[−]

Heron Pharmaceuticals ( HRTX) presents "a huge competitive threat" to Pacira Pharmaceuticals ( PCRX), an analyst said Thursday after Heron's painkiller outperformed another in knee replacement and breast-augmentation patients.

X

On the stock market today, Heron rocketed 30.3%, to 40, ending the day at its highest point since September 2015. Pacira tumbled 13.9%, to 34.25. Shares of Alkermes ( ALKS), another rival, plunged 15%, to 43.65. Biotech stocks collectively dipped less than 2%.

Heron tested its drug, HTX-011, in patients following knee-replacement surgery or breast augmentation. Across the board, HTX-011 and a combination using it proved better at staving off pain than a standard painkiller called bupivacaine.

Janney analyst Ken Trbovich argued that puts Pacira's painkiller, Exparel, at risk. Heron has said it will target hospitals and physicians already using Exparel. Later, it will go after those who use bupivacaine.

"We continue to view HTX-011, if approved, as a huge competitive threat that is likely to significantly alter the future trajectory for Pacira's Exparel," he said in a report.

He noted Exparel is difficult to administer. It must be mixed with standard bupivacaine and diluted to fill six separate syringes, all of which are injected multiple times in the case of knee replacement surgery. This requires no fewer than 50 needle sticks, he said.

"By comparison, HTX-011 is instilled into the surgical site via a needle-free syringe," he said. "As a result, it is unlikely to require special training to achieve optimal results."

Painkiller After Surgery

Chief Executive Barry Quart sees reducing opioid use as key to preventing addiction. The firm plans to ask the Food and Drug Administration to approve HTX-011 in the back half of 2018.

"With postoperative opioids serving as a gateway to addiction, there is a large unmet need for non-opioid pain alternatives," he said in a written statement. Heron now plans to submit its application for approval of HTX-011 in the U.S. in the second half of the year.

Heron split knee replacement patients into four groups to test the effects of HTX-011 — alone, in combination with painkiller ropivacaine, bupivacaine by itself and a placebo.

In knee replacement patients, the HTX-011 combination and HTX-011 alone resulted in pain reductions of 23% and 19%, respectively, 48 hours following surgery. The results were nearly double that of bupivacaine, which cut pain by 11% vs. a placebo.

At 72 hours following surgery, the combination reduced pain by 22%. HTX-011 cut pain intensity by 19% compared to a placebo. Bupivacaine reduced pain by 11%.

Using a more conservative assessment of pain, the combination and HTX-011 cut pain by a respective 16% and 12% at 48 hours vs. a placebo. Bupivacaine resulted in a 4% cut. At 72 hours, the combination and HTX-011 cut pain by 15% and 11%, respectively.

Reducing Opioid Use

Researchers tested HTX-011 as a nerve block — injecting it near key nerves — at three doses in breast augmentation. They tested bupivacaine and a placebo. Another study compared HTX-011 as an instillation — administered drop by drop — vs. a nerve block.

A day after undergoing breast augmentation, patients experienced 22% reductions in pain intensity after receiving 400-milligram doses of HTX-011 as either a nerve block or by instillation. Bupivacaine as a nerve block resulted in an 8% reduction.

With a more conservative measure of pain, HTX-011 by instillation cut pain by 24% a day after surgery. As a nerve block, it reduced pain intensity by 23%. A nerve block of bupivacaine resulted in a 12% reduction.

HTX-011 as a 400-milligram instillation was effective in reducing opioid use by 33%. As a nerve block it reduced the need for opioids by 26% compared to a placebo. Bupivacaine as a nerve block resulted in a 10% reduction.

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Invest In Stocks For Free: New Apps Aim For Beginners

Long-Term Retirement Investing Strategies With ETFs

The post Why A Strong Painkiller Just Wounded Two Biotech Stocks appeared first on Investor's Business Daily.


10. Paycom Stock Boost Seen From Direct-Sales Expansion, More OfficesЧт., 21 июня[−]

Paycom Software ( PAYC) is on track with its expansion of regional offices — a move expected to build up its direct-sales strategy, one analyst said Thursday.

X

The maker of human-resources and payroll-processing software has been adding regional offices to target small- and medium-size business customers. Paycom has added four regional offices so far this year vs. three in 2017. It has 49 regional offices and aims to grow the number to 90.

The effort is part of a battle that Paycom is waging with service bureaus Automatic Data Processing ( ADP) and Paychex ( PAYX) for customers.

"Even within some of its most mature markets, the consistency of the company's direct-sales office continues to impress," KeyBanc Capital Markets analyst Brent Bracelin said in a note to clients. "Even though Tulsa resides in the 54th largest area and it competes directly against ADP and Paychex offices, the Tulsa location was the second-highest performing office last quarter."

"Our new bottom-up forecast implies that revenue could double to $1 billion by 2021 and then double again to $2 billion by 2025 as office locations reach the earmarked 90 goal," added Bracelin. He has an overweight rating on the stock.

Shares Up 36%

Paycom stock fell 2.5% to close at 109.83 on the stock market today. Shares are up about 36% thus far in 2018.

Paycom is a member of IBD's Sector Leaders stock list. From a technical view, the stock has been forming a cup chart pattern and trades above its 50-day-moving-average. That's a positive signal, but Paycom is below a buy point of 118.55.

The company also competes with Ultimate Software ( ULTI) and Paylocity Holding ( PCTY), analysts say.

RELATED LINKS:

IBD Stock Of The Day: Paycom Nears Buy Point With Earnings Growth Set To Accelerate

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Paycom Stock Boost Seen From Direct-Sales Expansion, More Offices appeared first on Investor's Business Daily.


11. FANG Stocks News & Quotes: Facebook, Amazon, Netflix, GoogleЧт., 21 июня[−]

Collectively known as the FANG stocks, Facebook ( FB), Amazon ( AMZN), Netflix ( NFLX) and Google parent Alphabet ( GOOGL) are among the tech titans of our time.

X Facebook and Google alone capture the lion's share of all global online advertising, including in the fast-growing mobile format, while Amazon dominates e-commerce and cloud services with its Amazon Web Services business.

And although Netflix is facing increasing competition from Hulu and fellow FANG stocks — particularly Amazon and YouTube owner Google — its original programming and massive global expansion have cemented its leadership in the streaming industry.

Check this page regularly for ongoing coverage of the FANG stocks, including potential buy and sell signals.

FANG Stocks News & Quotes

Netflix Stock Rise Prompts Analysts To Raise Their Price TargetsNetflix stock on Thursday notched its sixth record high in the last seven trading days, sending bullish analysts scrambling to revise their price targets. Pivotal Research Group reiterated its buy rating on... Read More
Wall Street Gains Continue; 30 Reasons Why Nasdaq Keeps Flogging The Dow Jones Industrial AverageIn the dictionary, the letter D goes before the letter N. But in the current dictionary of trading on Wall Street, it's the exact opposite. To understand why, just view the Nasdaq... Read More
Alphabet Stock Rises But Bearish Analyst Sees YouTube Margin ProblemLook for Google-parent Alphabet's gross margins to take a hit from rising content costs at video website YouTube, says an analyst who has a market-perform rating on the FANG stock. "We estimate... Read More
If You're Long Netflix Or Square, Read ThisNetflix and Square are clear stock market leaders, with both extending gains Wednesday to hit new all-time highs. But if you have a position in one of these surging top stocks, you... Read More
These 2 FANG+ Stocks Are In Buy RangeThe Dow Jones industrial average, S&P 500 index and Nasdaq composite retreated Tuesday as President Donald Trump stepped up China trade war threats. Apple and Facebook fell back into buy range Tuesday, but... Read More
Index Funds: Facebook Hits New High; This FANG Stock In Buy ZoneKey stock index funds recovered some of their Tuesday losses, though the Dow Jones industrial average struggled to hold gains. SPDR Dow Jones Industrial Average was barely positive with less than two... Read More
These 4 Stocks Reach New Highs Amid Market Rally; Take Profits In Netflix?Tech stocks rallied squarely higher midday Wednesday as they recovered from Tuesday's trade-war-driven sell-off. The Nasdaq hit a record high. Meanwhile, two top names — Netflix and Square — are at profit-taking... Read More

RELATED:

Apple Stock Quotes & News

Tesla Stock Quotes & News

More Tech Stock News

Best Stocks To Buy And Watch

The post FANG Stocks News & Quotes: Facebook, Amazon, Netflix, Google appeared first on Investor's Business Daily.


12. Amazon (AMZN) Stock Quotes, Company News And Chart AnalysisЧт., 21 июня[−]
X


View AMZN Stock Quote Page
| View AMZN Ratings

Amazon Stock News & Analysis

These 2 FANG+ Stocks Are In Buy RangeThe Dow Jones industrial average, S&P 500 index and Nasdaq composite retreated Tuesday as President Donald Trump stepped up China trade war threats. Apple and Facebook fell back into buy range Tuesday, but... Read More
Amazon Alexa Embraced By Marriott For Use In Select HotelsMarriot International on Tuesday said it plans to use the Amazon.com Alexa voice-activated personal digital assistant in its hotels. Amazon announced Alexa for Hospitality, an updated version of the device that's programmed... Read More
Netflix Stock Rockets To All-Time High On Price-Target HikesA trio of Wall Street analysts on Tuesday raised their price targets on Netflix stock, saying the internet television service is likely to report strong subscriber gains in the second quarter. Netflix... Read More
Will Investors Eat Up The Fresh New Industry of Meal Kits?If meal delivery service companies could package the aromas their recipes create, and somehow relay those to first-time users, I'm convinced sales of meal kits would be even hotter than they are... Read More
Netflix Stock Spikes To Record High As Investors Ignore Short-Seller CallIn the battle between Wall Street bulls and bears over Netflix stock, the bulls are winning. Netflix shares spiked to an all-time high on Thursday, their second record high in as many... Read More

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Amazon (AMZN) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


13. Netflix (NFLX) Stock Quotes, Company News And Chart AnalysisЧт., 21 июня[−]
X


View NFLX Stock Quote Page
| View NFLX Ratings

Netflix Stock News & Analysis

Netflix Stock Rise Prompts Analysts To Raise Their Price TargetsNetflix stock on Thursday notched its sixth record high in the last seven trading days, sending bullish analysts scrambling to revise their price targets. Pivotal Research Group reiterated its buy rating on... Read More
If You're Long Netflix Or Square, Read ThisNetflix and Square are clear stock market leaders, with both extending gains Wednesday to hit new all-time highs. But if you have a position in one of these surging top stocks, you... Read More
These 2 FANG+ Stocks Are In Buy RangeThe Dow Jones industrial average, S&P 500 index and Nasdaq composite retreated Tuesday as President Donald Trump stepped up China trade war threats. Apple and Facebook fell back into buy range Tuesday, but... Read More
Top Tech Stocks Lead Market Rally; Netflix, Facebook Pace FANG GainsTop tech stocks were in the driver's seat just after midday Wednesday as FANG stocks Facebook and Netflix hit new highs. The Nasdaq composite was up 0.9% in early afternoon trade. It... Read More
Stocks Rebound: China Bolsters Confidence, Disney Sweetens Fox BidThe Nasdaq led as stocks rebounded briskly at Wednesday's open, after positive currency moves by China's central bank triggered gains across global markets. Winnebago and Walgreens Boots were early leaders. Netflix and... Read More

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Netflix (NFLX) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


14. Chip Stocks To Watch And Semiconductor Industry NewsЧт., 21 июня[−]

Chip stocks range from giants like Intel ( INTC), Qualcomm ( QCOM) and Taiwan Semiconductor ( TSM) down to lesser-known names like Qorvo ( QRVO) and Microchip Technology ( MCHP), providing the underpinnings for all types of devices, from giant servers down to smartphones.

X

The chipmakers power much of the world's technology, making it possible for loved ones to talk face-to-face from across an ocean or for Wall Street to move billions of dollars in the blink of an eye.

Never has the sector been more competitive, with more than 750 companies vying globally to build the insides of the next hot device or power future megacomputers. Investors will find it tricky to navigate the sector.

Bookmark this page to stay on top of the latest news on chip stocks and the semiconductor sector as a whole.

Chip Stocks & Semiconductor Industry News And Analysis

Data Storage Firm Smart Global Holdings Beats Earnings TargetComputer memory and data storage subsystems maker Smart Global Holdings late Thursday beat Wall Street estimates for its fiscal third quarter, but offered mixed guidance for the current quarter. The parent company... Read More
Intel CEO Resigns After Probe Of Improper Relationship With StafferIntel Chief Executive Brian Krzanich resigned Thursday as CEO and board member after an investigation revealed that he had an improper relationship with an Intel employee. The board of directors named Chief... Read More
Micron Earnings Report Shows Strength Of Memory Chip MarketA beat-and-raise report from Micron Technology late Wednesday for its fiscal third quarter eased investor worries about softening memory-chip pricing and sales. Micron stock rose 0.8% to 59.44 on the stock market... Read More
Index Funds: Dow Breaks Key Support As Intel Stock WeighsKey stock index funds were lower Thursday afternoon as the Dow Jones industrial average gapped down below its 50-day moving average. SPDR Dow Jones Industrial Average was on track to extend its... Read More
Stock Market Turns Lower; Supreme Court Ruling Hits Internet RetailersThe stock market opened mixed and mostly unchanged early Thursday, but sellers quickly took charge during the first 90 minutes of trading. The Dow Jones industrial average undercut its 50-day moving average,... Read More
Stocks Mixed After China Sell-Off; Oil Dives; Intel CEO OustedStocks staged an uneven open Thursday, fighting to resist sliding oil prices and heavy selling begun in China in response to tremors in the U.S.-China trade standoff. Intel quickly pared losses, recovering... Read More
Dow Jones Futures Reverse Lower: Micron Earnings Lift These 5 Memory-Chip PlaysDow Jones futures erased overnight gains to indicate a lower open, along with S&P 500 futures, amid China trade war fears and a looming OPEC meeting. Nasdaq futures edged higher. Micron Technology reported... Read More
View More Chip Stock News

RELATED:

Best Stocks To Buy And Watch

View More Tech News & Analysis

The post Chip Stocks To Watch And Semiconductor Industry News appeared first on Investor's Business Daily.


15. Micron Technology Stock Jumps On Sales, Earnings GuidanceЧт., 21 июня[−]

Memory-chip maker Micron Technology ( MU) late Wednesday narrowly beat Wall Street's targets for its fiscal third quarter. Micron stock initially fell in extended trading but rebounded into positive territory after the company gave upbeat guidance on its call with analysts.

X

Micron earned an adjusted $3.15 a share, up 94% year over year, in the quarter ended May 31. Its sales rose 40% to $7.8 billion. Analysts expected the company to earn $3.12 a share on sales of $7.75 billion in the period.

The Boise, Idaho-based company raised its sales and earnings targets significantly on May 21, citing strong execution and healthy industry conditions. The news sent Micron stock to an 18-year high, but shares pulled back in the days that followed.

Micron shares rose 2.5% in after-hours trading on the stock market today. During the regular session, Micron dipped 0.5% to 58.95.

"Micron delivered record results in financial performance for the third fiscal quarter, supported by strong execution and ongoing secular demand trends," Micron Chief Executive Sanjay Mehrotra said in a news release.

Posts Record Revenue

The company strengthened its competitive position and grew revenue across virtually all of its high-value products, Mehrotra said. It set records in revenue for solid-state drives, mobile-managed Nand and automotive systems. Memory chips for cloud and enterprise systems and DRAM memory also sold well, he said.

For the current quarter, Micron projected adjusted earnings per share of $3.23 to $3.37 on revenue of $8 billion to $8.4 billion. That beat the consensus average of analysts who forecast earnings of $3.16 a share on sales of $8.02 billion.

RELATED:

Stock Futures: Micron Earnings Lift These 5 Memory-Chip Plays

If You're Long Netflix Or Square, Read This

IBD Stock Of The Day: Online Payment Leader Hits Buy Zone

AMD Stock Target Raised While Intel Stock Target Trimmed

The post Micron Technology Stock Jumps On Sales, Earnings Guidance appeared first on Investor's Business Daily.


16. Why It Makes No 'Strategic Rationale' For Roche To Buy TesaroЧт., 21 июня[−]

A rumored buyout of drugmaker Tesaro ( TSRO) by Swiss drugmaker Roche ( RHHBY) — which sent shares of Tesaro soaring Wednesday — makes little sense from a strategic standpoint, one analyst says.

X

RBC analyst Kennen MacKay sees the combination as unlikely "given what we see as a lack of a compelling strategic rationale." Tesaro makes an ovarian cancer drug called Zejula, which competes against rival drugs from AstraZeneca ( AZN) and Clovis Oncology ( CLVS).

MacKay notes Tesaro's 2018 guidance for Zejula sales is in trouble as rivalries grow in ovarian cancer drug sales. He expects Tesaro to lower its full-year outlook. That would make a potential acquirer hesitant, he said in a report to clients.

Spanish website Intereconomia.com said late Tuesday that Roche is interested in acquiring Tesaro after it announced its plan to buy Foundation Medicine ( FMI). The site reports Roche could announce the acquisition of Tesaro in the next few days.

At the closing bell on the stock market today, Tesaro stock rocketed 16.3%, to 46.49. The stock popped as much as 19.6% in earlier trading. Roche lifted 2.1%, to 27.09. At the same time, biotech stocks rose less than 1.5%.

Ovarian Cancer Drugs

Further, Tesaro already has ongoing collaborations with Dow Jones component Merck ( MRK) in treating forms of breast cancer and ovarian cancer. It's also partnered with Johnson & Johnson ( JNJ) in developing Zejula to treat prostate cancer.

Roche, on the other hand, is collaborating with Roche's rival Clovis in treating gynecological tumors. Clovis makes an ovarian cancer drug called Rubraca. The duo is testing Rubraca with Roche's immuno-oncology drug called Tecentriq.

"With Roche's focus on developing/acquiring best-in-class molecules, we see Rubraca (with its in-line effectiveness and superior safety vs. Zejula) as a potentially better fit within the context of this strategy than Zejula," MacKay said.

Tesaro, too, already has partnerships with Zejula in markets outside the U.S. This may detract from the value of acquiring it for a global pharmaceutical company like Roche.

On the flip side, Roche and Tesaro do have an ongoing clinical collaboration to look at Roche's Tecentriq with Zejula in bladder cancer. Researchers are also combining Zejula and Roche's drug Avastin in a form of ovarian cancer.

RELATED:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

Investing Basics: How To Sell A Stock

Looking For The Next Nvidia? Start With This Simple Routine

The post Why It Makes No 'Strategic Rationale' For Roche To Buy Tesaro appeared first on Investor's Business Daily.


17. This Biotech Is Cratering On Sarepta's Success — But Could Be 'Superior'Ср., 20 июня[−]

Solid Biosciences ( SLDB) plunged Wednesday on high volume after rival Sarepta Therapeutics ( SRPT) reported strong data for its Duchenne muscular dystrophy treatment.

X

On the stock market today, Solid Biosciences crashed 17.1% to close at 35.67. Sarepta, which unveiled strong results for its gene therapy in muscular dystrophy on Tuesday, saw its stock pop 6.8%, to 153.69. Biotech stocks collectively rose less than 1.5%.

Both biotech companies are working on treatments for Duchenne muscular dystrophy, a muscle-wasting disease with a genetic component. The condition is tied to mutations in the gene that makes dystrophin, a protein related to muscle fiber function.

Despite Solid Biosciences' plummet Wednesday, analysts said the smaller biotech actually has the better Duchenne muscular dystrophy treatment. Instinet analyst Christopher Marai attributes this to the way Solid Biosciences constructs its drug, SGT-001.

"We recommend accumulating Solid Biosciences as the Duchenne muscular dystrophy gene therapy field becomes increasingly de-risked, and we see potential upside, as SGT-001 could become best-in-class with the differentiated (formula)," he said in a note.

Gene Therapy In Muscular Dystrophy

Marai kept his buy rating and 37 price target on Solid Biosciences. Earlier in the week, the Food and Drug Administration lifted a clinical hold keeping the biotech company from enrolling patients in a study.

It's likely that Solid Biosciences will report some data from the study earlier than guidance for the second half of 2019, Marai said. Solid Biosciences is competing against Sarepta and Dow Jones component Pfizer ( PFE). But the market could support all three, he said.

"We view the (Duchenne muscular dystrophy) market as being large enough to support multiple gene therapies and solutions," he said.

Chardan analyst Gbola Amusa similarly sees Sarepta's report on Tuesday as having a positive impact on Solid Biosciences. Solid stock skyrocketed 46.4% on Tuesday as Sarepta shares ramped up 36.8% to close at a record high.

"We see this as a positive read-across to Solid, based on the similarities between the approaches but, to us, (there are) superior elements of the Solid microdystrophin construct," Amusa said in a report to clients.

Further, it's possible SGT-001 "may demonstrate even more (effectiveness) to what was seen (Tuesday) from Sarepta," Amusa said. He kept his buy rating and 37.50 price target on Solid shares.

RELATED:

How Much Money Do You Need To Start Investing?

Long-Term Retirement Investing Strategies With ETFs

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post This Biotech Is Cratering On Sarepta's Success — But Could Be 'Superior' appeared first on Investor's Business Daily.


18. Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA DrugsСр., 20 июня[−]

PTC Therapeutics ( PTCT) spiked Wednesday after an analyst suggested it and Roche ( RHHBY) could rout Biogen ( BIIB) and Ionis Pharmaceuticals ( IONS) in treating spinal muscular atrophy.

X

At the close on the stock market today, PTC shares popped 7.2%, at 35.64. Ionis climbed 1.4%, at 44.03, recovering from an earlier 4.3% pitfall. Biogen lifted 1.7%, to 296.86. Roche advanced 2.1%, to 27.09.

Barclays analyst Gena Wang upgraded PTC to an equal weight rating and lifted her price target to 40 from 26. She cited data PTC issued from a recent study of its drug dubbed risdiplam in treating babies with spinal muscular atrophy.

"Given initial comparable if not better (effectiveness) data, similar therapeutic approach and oral delivery, risdiplam could be disruptive to Ionis/Biogen's Spinraza, in addition to (being a) gene therapy threat," she said in a report to clients.

Treating Spinal Muscular Atrophy

In a study from PTC, more than 90% of babies with spinal muscular atrophy treated with risdiplam achieved a greater than four-point increase on a measure of motor milestone development at day 182. A video showed the babies controlling their heads, rolling or sitting.

"The survival data and (motor milestone development) scores are very promising since babies with Type 1 spinal muscular atrophy typically do not experience functional motor milestone improvement based on natural history," PTC Chief Executive Stuart Peltz said in a prepared statement.

Risdiplam works by restoring a piece of RNA missing in spinal muscular atrophy patients. It's taken orally, giving it an advantage over Biogen and Ionis' Spinraza, which is delivered via an injection. Still, Spinraza remains the only drug approved to treat spinal muscular atrophy.

Wang expects risdiplam to get rapid adoption in treating spinal muscular atrophy after it hits the market, likely in 2020. Though she notes it will also experience competition from the likes of a gene therapy by Novartis ( NVS). Novartis acquired Avexis for its gene therapy, AVXS-101.

So far, AVXS-101 "still showed better (effectiveness) in young patients," she said.

Spinraza Sales Flatten

Meanwhile, Biogen and Ionis saw flattening Spinraza sales in the first quarter. That's likely due to the way Spinraza is dosed. Patients start out with four loading doses and then move to less frequent maintenance doses.

"In addition to AVXS-101 gene therapy threat, we see potentially quick erosion of Spinraza revenue upon risdiplam launch, which could occur in 2020," Wang said. She downgraded Ionis to an underweight rating and cut her price target to 45 from 52.

PTC, though, is likely to face other challenges, Wang said. The biotech company is also working on a treatment for Duchenne muscular dystrophy. Shares toppled 30.6% on Tuesday after Sarepta Therapeutics ( SRPT) had strong data for its Duchenne muscular dystrophy gene therapy.

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

Investing Basics: How To Sell A Stock

The post Why Biogen, Ionis Could Be In Trouble As Others Move Into SMA Drugs appeared first on Investor's Business Daily.


19. PayPal Stock Rises As Acquisitions Forge Global Payments PlatformСр., 20 июня[−]

Shares of PayPal Holdings ( PYPL) climbed Wednesday as analysts said the company is gaining scale against such rivals as Square ( SQ) with the help of its latest acquisition, Hyperwallet Systems for $400 million.

X

Announced late Tuesday, PayPal's Hyperwallet purchase is expected to expand its global payments platform. Hyperwallet operates an online that enables e-commerce firms to make payments to contractors, business partners, and others. Its platform converts currencies. The deal comes on the heels of PayPal's May purchase of iZettle, a mobile digital-payments processor, for $2.2 billion.

"After multiple acquisitions year-to-date, PayPal still has $10 billion in its war chest," Wedbush analyst Moshe Katri said in a report to clients. "Strategically, the iZettle and Hyperwallet acquisitions place PayPal at par competitively with Square and Adyen."

Shares in PayPal climbed 1.7% to close at 85.95 on the stock market today. In intraday trading, PayPal stock rose above a technical buy point of 86.42 before pulling back. One rival, Square, gained 2.5% to 67.59. That payment processor's stock has doubled thus far in 2018.

PayPal Sheds EBay Worries

Worries over the phaseout of its relationship with former parent eBay ( EBAY) pressured PayPal stock earlier this year. The stock has gained momentum since the company reported first-quarter earnings that topped expectations.

PayPal said it expects the Hyperwallet deal to close in the December quarter.

"Other players in this space are Payoneer, Earthport, and even Western Union, which can be considered a cross-border payout network albeit an expensive one," Mizuho Securities analyst Thomas McCrohan said in his note to clients.

Ingenico Group also had been interested in Hyperwallet, whose clients include Home Away and Expedia Group ( EXPE).

RELATED LINKS:

PayPal Buddies Up To Visa, Mastercard — And New Accounts Roll In

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post PayPal Stock Rises As Acquisitions Forge Global Payments Platform appeared first on Investor's Business Daily.


20. T-Mobile, Sprint Merger Faces Test In Senate Hearing Next WeekСр., 20 июня[−]

Now that AT&T's ( T) purchase of Time Warner finally has passed government muster, T-Mobile US ( TMUS) and Sprint ( S) will run their own proposed merger before the regulatory gauntlet next week as they go before a U.S. Senate antitrust panel.

X

It's not clear whether Republicans or Democrats support the deal.

T-Mobile and Sprint, analysts say, aim to win merger approval by convincing regulators that they'll increase competition by selling 5G residential broadband services. Their 5G wireless services would compete with phone companies' broadband in rural areas. It would also compete with cable TV companies in urban and suburban settings.

In their regulatory filing, the companies noted that "as a combined company, the carrier will have the luxury of deploying all of Sprint's 2.5 (gigahertz) spectrum for 5G. If Sprint were a stand-alone, the carrier would need some of its 2.5 (gigahertz) for (4G) wireless," Cowen & Co. analyst Colby Synesael said in a report to clients.

T-Mobile and Sprint, in a regulatory filing on Tuesday, said they need to merge to create a stronger competitor to Verizon Communications ( VZ) and AT&T. AT&T closed its purchase of Time Warner last week as it won an antitrust case vs. the Department of Justice.

A merger of the T-Mobile and Spring would combine the third- and fourth-largest U.S. wireless firms.

Verizon Targeting 5G To Homes

Verizon is also forging ahead with 5G wireless, and is targeting broadband services to homes.

The DOJ and Federal Communications Commission are reviewing the T-Mobile-Sprint merger. They announced the deal on April 29.

Sprint and T-Mobile also need to convince regulators and lawmakers that consumer prices will not rise if they merge. In their regulatory filing, the companies said cable TV firms led by Comcast ( CMCSA) are pushing into wireless services. Companies that lease network capacity, called mobile virtual network operators, are another source of competition, the companies said.

"(The filing) contains some arguments that we don't think will get very far with the DOJ or FCC staff, such as cable and MVNOs being counted as competitors," said Blair Levin, analyst at New Street Research.

T-Mobile edged down 0.3% to 60.34 on the stock market today. Sprint slipped 1.1% to 5.47.

RELATED LINKS:

Telecom Stocks To Watch And Industry News

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post T-Mobile, Sprint Merger Faces Test In Senate Hearing Next Week appeared first on Investor's Business Daily.


21. AMD Stock Target Raised While Intel Stock Target TrimmedСр., 20 июня[−]

Wall Street analysts adjusted their price targets on two big-name chipmakers Wednesday as Advanced Micro Devices ( AMD) received a hike and Intel ( INTC) got a cut.

X

Morgan Stanley raised its price target on AMD to 11 from 8, but reiterated its underweight rating. AMD stock broke out of a 44-week consolidation period at a buy point of 15.75 on June 7. It fell 1% to 16.52 on the stock market today.

AMD has upside potential in processor sales for servers, Morgan Stanley analyst Joseph Moore said in a report Wednesday. But it faces headwinds in graphics chips, he added.

In graphics chips, AMD could see a sales decline related to cryptocurrency mining. It also faces a new product launch soon from rival Nvidia ( NVDA), Moore said.

"AMD's future looks brighter than it has in over a decade, but it remains a portfolio of businesses, some growing and some with challenges," Moore said.

Intel Stock Gets Price-Target Cut

Cowen trimmed its price target on Intel stock to 54 from 55 and maintained its market perform rating. Intel climbed 1% to 53.46 on Wednesday.

Supply-chain checks indicate "continued strong server market conditions," Cowen analyst Matthew Ramsay said in a report. However, Intel's delay of its 10-nanometer chip production into 2019 could result in heightened competition from Taiwan Semiconductor Manufacturing ( TSM), he said. Taiwan Semi is ramping its 7-nanometer chip production for AMD and Nvidia.

Dialog Semiconductor Circles Synaptics

Elsewhere in the chip sector, U.K.-based Dialog Semiconductor is in talks to buy Synaptics ( SYNA), a maker of human interface technologies such as touchpads and display drivers.

Synaptics confirmed late Tuesday that it is in discussions with Dialog about a possible acquisition.

Synaptics stock soared 11.5% to 54.46 on Wednesday.

RELATED:

Chip Stocks To Watch And Semiconductor Industry News

The post AMD Stock Target Raised While Intel Stock Target Trimmed appeared first on Investor's Business Daily.


22. Oracle Stock Dives As Quarterly Earnings Guidance Falls ShortСр., 20 июня[−]

A disappointing outlook and concerns over its developing cloud business sent Oracle ( ORCL) shares reeling to a 15-month low Wednesday as Wall Street lowered its expectations for the tech icon.

X

After it reported fiscal fourth-quarter results late Tuesday, Oracle stock initially rose, then fell on disappointing guidance. The company said fiscal first-quarter revenue should be about $9.4 billion, below Wall Street estimates of roughly $9.5 billion. Shares of Oracle tumbled to 42.82, down 7.5%, on the stock market today, hitting a level not seen since March 2017.

Oracle is undergoing a shift in its product portfolio, away from a traditional model of licensing and maintenance to a subscription-based cloud-computing business while trying to sustain profit margins that have been under pressure.

Analysts, however, were doubtful about its progress. The database software company received price target cuts from RBC Capital Markets, to 52 from 55, and Stifel Nicolaus, to 50 from 53. Meanwhile, Wedbush downgraded Oracle to neutral from outperform.

"Given the strong quarterly results across our software coverage this earnings season, we felt Oracle's call had a less enthusiastic tone given the lack of upside in the cloud, a change in reporting format, lower than expected deferred revenue and a muted outlook," Monness Crespi Hardt analyst Brian White said in a note to clients.

Hitting Another New Low

Oracle's Relative Strength line fell to its lowest level since April 2008. The RS Rating tracks a stock's share price performance over the last 52 weeks. It then compares the result to that of all other stocks.

Oracle reported fiscal fourth-quarter revenue of $11.25 billion, up 3% from the year-ago quarter. That slightly beat the consensus estimate of $11.2 billion.

It reported adjusted earnings of 99 cents per share, up 11%. That beat the consensus of 94 cents for the three-month period ended May 31.

The company did say it expects to achieve higher revenue growth rates for its current fiscal year over the comparable year-ago period.

Reporting Changes

During the conference call, Oracle also announced a change to its reporting format. The company will do away with breaking out its various cloud computing segments. Instead, Oracle will combine its various cloud computing sectors into one package, which disappointed some analysts.

"We believe completely ridding of this metric is short sighted," Monness's White wrote. He said Oracle has become more frugal in providing cloud-related metrics.

Credit Suisse analyst Brad Zelnick maintained an outperform rating on Oracle and price target of 60.

"We believe Oracle remains well positioned with underappreciated durability," Zelnick said.

RELATED:

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

The post Oracle Stock Dives As Quarterly Earnings Guidance Falls Short appeared first on Investor's Business Daily.


23. Alphabet Stock Rises But Bearish Analyst Sees YouTube Margin ProblemСр., 20 июня[−]

Look for Google-parent Alphabet's ( GOOGL) gross margins to take a hit from rising content costs at video website YouTube, says an analyst who has a market-perform rating on the FANG stock.

X

"We estimate content acquisition costs associated with YouTube were $6.8 billion in 2017 and see this growing to $15.3 billion by 2020," BMO Capital Markets analyst Daniel Salmon said in a report to clients Wednesday. He's one of three analysts with a hold or market-perform rating on Google out of 44 surveyed by Reuters.

"We expect total company gross margins to decline from 58.9% in 2017 to 56% in 2018, 54.4% in 2019, and 53.2% in 2020," added Salmon. "Despite gross margin deterioration, we expect gross profit dollars to increase from $65.3 billion in 2017 to $76.7 billion in 2018, $88.5 billion in 2019, and $101.1 billion in 2020. This is consistent with management's longer-term focus on growing profit dollars."

Shares in Alphabet stock rose 0.5% to close at 1,184.07 on the stock market today. From a technical chart perspective, Alphabet stock has climbed above a 1,161.20 buy point from a handle in a double-bottom base.

Google has been the weakest performer of the FANG stocks, a group that also includes Facebook ( FB), Amazon.com ( AMZN), Netflix ( NFLX). Google is up 20% from a year ago, while Facebook has gained 28%, Amazon 73% and Netflix 161%. Facebook and Netflix closed at record highs on Wednesday.

Google's Rising Content Costs

Google launched a live broadcast TV streaming service last year. It introduced a new music streaming service in May, taking on Spotify ( SPOT) and Apple ( AAPL). Google also pays for content on YouTube Red, a subscription service.

"We believe investors need to focus less on revenue ex-TAC (traffic acquisition costs) and more on gross profit," added Salmon. "This is largely due to the fact that revenue share/other content costs associated with YouTube show up in other cost of revenue and not in TAC."

Alphabet in April reported first-quarter earnings and revenue Monday that topped expectations but the company said traffic costs shot up again.

RELATED LINKS:

This Is What Google Won't Tell You About YouTube's Financials

These 2 FANG+ Stocks Are In Buy Range

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Alphabet Stock Rises But Bearish Analyst Sees YouTube Margin Problem appeared first on Investor's Business Daily.


24. Box Stock Rally Continues As Shares Climb Past A Buy PointСр., 20 июня[−]

Box ( BOX) stock popped on Thursday, continuing a rally in the online data storage and file-sharing service provider.

X

Shares in Box surged 3.1% to close at 29.01 on the stock market today, jumping over a technical buy point of 28.78. It had rallied 5.7% earlier in the day.

Box has expanded from data storage into business-collaboration services, where it competes against Atlassian ( TEAM) and well-funded startup Slack. Atlassian is ranked No. 35 in the IBD 50 roster of growth stocks.

Redwood City, Calif.-based Box has bounced back after a slow start in 2018. The stock fell in January after its guidance disappointed. Shares gained on April 23 after Chamath Palihapitiya, chief executive of venture firm Social Capital, called out Box as a play on artificial intelligence stocks.

Dropbox Trades Down

In early June Box acquired privately held Progressly, which sells an intelligent workflow platform for large enterprises.

Box has forecast a profit on an adjusted basis in fiscal 2019 and revenue of $605 million at its midpoint of guidance.

The company is a rival of Dropbox ( DBX), which went public in March. Dropbox belongs to IBD's Leaderboard, a screen of high-performing stocks. That company's stock slipped 0.5% to 39.49 on Wednesday.

Dropbox launched its IPO with shares priced at 21 on March 23. Shares hit a high of 42 on June 18. They've traded down the last two sessions.

Atlassian rose 1% in midday trading on Wednesday. It's below a technical buy point of 68.85, having formed an ascending base chart pattern.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Box Stock Rally Continues As Shares Climb Past A Buy Point appeared first on Investor's Business Daily.


25. Biotech Stocks To Watch And Pharma Industry NewsСр., 20 июня[−]

One minute Dow Jones industrial average component Merck ( MRK) might be doing battle with fellow drugmaker Bristol-Myers Squibb ( BMY) over drugs that can ward off cancer.

X

The next, biotech giants like Amgen ( AMGN) and Sanofi ( SNY) are tussling in court over the fate of cholesterol-busting drugs. Meanwhile, a company like Gilead Sciences ( GILD) might be raked over the coals in Congress for charging $1,000 a day to treat hepatitis.

It's a brave – and contentious – new world for pharmaceutical and biotechnology companies. It's a realm where science is trying to develop landmark medicines that cure cancer, hepatitis and other life-threatening illnesses.

All the while it does a delicate dance with Wall Street and regulators – balancing public health issues with the demands of shareholders. Investors will find it tricky to navigate the sector, as companies can rise and fall at the drop of a hat.

Bookmark this page to stay on top of the latest news in the biopharma sector.

Biotech And Pharma News

Why A Strong Painkiller Just Wounded Two Biotech StocksHeron Pharmaceuticals presents "a huge competitive threat" to Pacira Pharmaceuticals, an analyst said Thursday after Heron's painkiller outperformed another in knee replacement and breast-augmentation patients. On the stock market today, Heron rocketed 30.3%,... Read More
5 Ways To Profit As Trump Threats Boost Small-Cap Stock PlaysSmall-cap stock funds have been rocketing as investors bail out of industrials and other big-cap ETFs amid heightened trade-war fears. SPDR Industrial Select Sector finished flat on Wednesday, after sliding nearly 5%... Read More
Stock Upgrades: Adamas Pharmaceuticals Shows Rising Relative StrengthOn Thursday, Adamas Pharmaceuticals earned a positive adjustment to its Relative Strength (RS) Rating, from 67 to 73. When you're researching the best stocks to buy and watch, keep a close on... Read More
Sangamo Therapeutics Shows Rising Price Performance With Jump To 85 RS RatingOn Thursday, Sangamo Therapeutics reached an important performance benchmark, with its Relative Strength (RS) Rating climbing into the 80-plus percentile with an upgrade to 85, an increase from 73 the day before.... Read More
Stocks Showing Market Leadership: Supernus Pharmaceuticals Earns 93 RS RatingWhen looking for the best stocks to buy and watch, focus on those with rising relative price strength. One stock that fits that bill is Supernus Pharmaceuticals, which saw a positive improvement... Read More
Stock Upgrades: Spark Therapeutics Shows Rising Relative StrengthSpark Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 90 to 93. When looking for the best stocks to buy and watch, one... Read More
Why It Makes No 'Strategic Rationale' For Roche To Buy TesaroA rumored buyout of drugmaker Tesaro by Swiss drugmaker Roche — which sent shares of Tesaro soaring Wednesday — makes little sense from a strategic standpoint, one analyst says. RBC analyst Kennen MacKay... Read More

View More Biotech And Pharma Stock News

RELATED:

Best Stocks To Buy And Watch

The post Biotech Stocks To Watch And Pharma Industry News appeared first on Investor's Business Daily.


26. Cloud Computing: Find Top Cloud Stocks And Track Industry TrendsСр., 20 июня[−]

Cloud computing offers investors a wide range of opportunities that span internet infrastructure, as well as consumer and business services delivered via fast connections to the web. The industry leaders and top cloud stocks cover a similarly wide range, from Amazon.com ( AMZN) and Google parent Alphabet ( GOOGL) to Microsoft ( MSFT), Alibaba ( BABA) and Oracle ( ORCL).

X

To visualize the internet cloud, think of warehouse-sized data centers packed with computer servers and data storage systems. Then think of the cloud supply chain.

Companies such as Intel ( INTC), artificial intelligence (AI) leader Nvidia ( NVDA) and Micron Technology ( MU) sell chips built into servers. Fiber-optic device makers sell parts for high-speed communications networks. Seagate Technology sells solid-state data storage systems. Arista Networks ( ANET) and Cisco Systems ( CSCO) sell specialized network switches and routers that make the cloud superfast.

Cloud Computing And Top Cloud Stocks

IBD Stock Of The Day: Hot Tech Makes Bullish Move Toward Buy Point, Defying Sell-OffEven with the Nasdaq composite logging losses Thursday, IBD Stock Of The Day Interxion is bucking tech-stock weakness and retaking a key technical level in heavy volume. Interxion Stock Action Interxion stock... Read More
Best Cybersecurity Stocks: Email, Mobile Apps Protector Proofpoint May Hack New Buy ZoneCybersecurity stocks Palo Alto Networks, Qualys and CyberArk Software have been rising as cyberattacks on cloud networks, email and mobile apps have increased. Now fellow security software firm Proofpoint is trying to... Read More
Oracle Stock Dives As Quarterly Earnings Guidance Falls ShortA disappointing outlook and concerns over its developing cloud business sent Oracle shares reeling to a 15-month low Wednesday as Wall Street lowered its expectations for the tech icon. After it reported fiscal... Read More
Dow Jones Futures Tumble As Trump Escalates China Trade War; These 4 Top Techs Hit Buy ZonesDow Jones futures tumbled Tuesday morning after President Donald Trump said he has instructed the U.S. Trade Representative to identify another $200 billion in Chinese goods for tariffs, ratcheting up the U.S.-China... Read More
Will This Big-Cap Cloud Stock Break Out, Or Run Into Foul Weather?Arista Networks is a four-year-old cloud stock, a toddler that quickly rose to big-cap status. The coming two quarters presents a test, as the company runs up against two quarters of steep... Read More
View More Cloud Computing Articles

Cloud Computing Services

The biggest buyers of data center infrastructure are Amazon Web Services, Microsoft's Azure and Alphabet's Google, as well as consumer-facing companies like Apple ( AAPL) and Facebook ( FB).

Cloud computing services are new growth engines for AWS, Microsoft and Google. Companies rent their powerful computers and software platforms to process business workloads remotely via the web. Apple relies on cloud infrastructure for its fast-growing services business, whisking music and other content to iPhones.

Companies like Salesforce.com ( CRM) that offer subscription-based software-as-a-services (SaaS) arrived before the term cloud computing was coined. Many SaaS companies are now working with AWS and other cloud vendors to reach new markets.

YOU MAY ALSO LIKE:

AI News: Artificial Intelligence Trends And Top AI Stocks

FANG Stocks News: Facebook, Amazon, Netflix, Google

Best Stocks To Buy And Watch

The post Cloud Computing: Find Top Cloud Stocks And Track Industry Trends appeared first on Investor's Business Daily.


27. Tesla Lawsuit Targets Former Employee, Claims He Hacked InformationСр., 20 июня[−]

A Tesla lawsuit filed Wednesday claims a former employee hacked the company's confidential and trade secret information, transferring several gigabytes of data to outside entities.

X

The Tesla lawsuit claims Martin Tripp stole data that included dozens of confidential photographs. He also allegedly stole a video of the company's manufacturing system, the lawsuit claims. Tripp worked at the Nevada Gigafactory as a process technician since October.

Tesla ( TSLA) says Tripp also lied to the media about the information, claiming, for example, that punctured battery cells were used in vehicles.

The Tesla lawsuit was filed in Nevada federal court. Tesla shares were up 1.7% to 358.50 in afternoon trading on the stock market today.

'First True Test'

Meanwhile, Wall Street brokerage Oppenheimer said that Tesla will face the "first true test" of its market position in 2019.

"Bulls point to nearing Model 3 production run-rate targets on revised timelines as a critical bench mark in disrupting the transportation market. Bears point to production inefficiencies inhibiting achievement of sustainable operational cash flow," a group of Oppenheimer analysts, led by Colin Rusch, said in a note to clients. "We believe Tesla, as a manufacturer, must show meaningful progress toward margin targets to justify increased capital investments."

The note says Tesla bulls see impressive market share for the company's existing Models S and X. They also see a large backlog for the mass-produced Model 3. Meanwhile, bears see increasing competition from Tata Motors' ( TTM) Jaguar, Volkswagen's ( VLKAY) Porsche, Germany's BMW ( BMWYY) and Daimler's ( DDAIF) Mercedes in luxury electric vehicles.

Further, it seems unlikely that Tesla can go without additional capital infusion, the analysts said. Chief Executive Elon Musk has said the company will seek no more capital.

"While management indicated it wouldn't need additional capital from the equity markets, we believe both bulls and bears expect (Tesla) to raise money for growth capital and to reconcile the $2.3 billion delta between current assets and liabilities," the note said.

Bloomberg News contributed to this report.

RELATED LINKS:

Tesla Stock Falls As It Confronts Saboteur's Impact On Operations

Elon Musk Once Again Presents Heady Expectations For Tesla

Tesla Cutting 9% Of Staff As It Tries To Ramp Up Model 3 Output

The post Tesla Lawsuit Targets Former Employee, Claims He Hacked Information appeared first on Investor's Business Daily.


28. Oracle Stock Up As Earnings Top Views On Cloud Migration GrowthСр., 20 июня[−]

Oracle ( ORCL) stock rose late Tuesday as it reported fiscal fourth-quarter earnings after the market close that beat on the top and bottom lines, thanks to more customers moving toward its high-margin cloud business.

X

The database software giant reported revenue of $11.25 billion, up 3% from the year-ago quarter. That slightly beat the consensus estimate of $11.2 billion. Oracle also reported adjusted earnings of 99 cents per share, up 11%. That beat the consensus of 94 cents for the three-month period ended May 31.

Shares of Oracle were up 0.9%, near 46.70, during after-hours trading on the stock market today.

The company is undergoing a shift in its product portfolio, away from a traditional model of licensing and maintenance to a subscription-based cloud-computing business while trying to sustain profit margins that have been under pressure. Oracle said cloud services and license support revenue were up 8% to $6.8 billion from the year-ago period.

"Some of our largest customers have now begun the process of moving their on-premise Oracle databases to the Oracle Cloud," Oracle Chairman Larry Ellison said in prepared remarks with the earnings release. For example, he said, AT&T ( T) is moving "thousands of databases and tens of thousands of terabytes of data" into the Oracle Cloud.

Dividend Declared

The company also declared a quarterly cash dividend of 19 cents per share of outstanding common stock.

For the full fiscal year 2018, Oracle revenue reached $39.8 billion, up 6% from the prior year. Cloud services and license support revenue rose 10% to $26.3 billion.

RELATED:

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

The post Oracle Stock Up As Earnings Top Views On Cloud Migration Growth appeared first on Investor's Business Daily.


29. How A Merger Will Help These Two Firms Tailor Cancer TreatmentsВт., 19 июня[−]

Foundation Medicine ( FMI) rocketed to a record high Tuesday after Swiss drugmaker Roche ( RHHBY) agreed to buy it in a pharmaceutical merger for $2.4 billion.

X

The pharmaceutical merger will allow Foundation Medicine to join forces with Roche as "an independent operating company," Foundation's chief executive said. Foundation Medicine makes genomic profiling tests to help biopharma companies identify genetic traits to personalize cancer treatments.

On the stock market today, Foundation shares flew 28.5% to close at 136.75. Roche stock lifted 0.5%, to 26.53. Broadly, shares of biotech companies rose 1.8% as stocks of pharmaceutical companies advanced 0.8%.

Roche Chief Executive Daniel O'Day praised the deal, which allows Foundation Medicine to maintain its autonomy "while supporting them in accelerating their progress." Foundation said it will continue collaborating with other biopharmas after the pharmaceutical merger.

"This is important to our personalized health strategy as we believe molecular insights and the broad availability of high quality comprehensive genomic profiling are key enablers for the development of, and access to, new cancer treatments," O'Day said in a written statement.

Genomic Profiling Key

Under the terms of the cash deal, Roche will pay $137 per share of Foundation Medicine. This will allow it to acquire all outstanding stock it doesn't already own. The pharmaceutical merger is expected to close in the second half of 2018, Foundation Medicine said in a news release.

The deal represents a 29% premium to Foundation Medicine's closing price on Monday. It also represents premiums of 47% and 68% to the stock's respective 30-day and 90-day volume-weighted share price.

Foundation Medicine Chief Executive Troy Cox noted the need to provide patients with their personalized genetic background. This helps physicians identify tailored cancer treatments.

"Joining forces with Roche as an independent operating company allows Foundation Medicine to continue its collaboration with Roche, as well as our biopharma partners, to drive ubiquitous access to (comprehensive genomic profiling) testing and innovative data services," he said in a statement.

RELATED:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Best Stocks To Buy And Watch? Start Here

The post How A Merger Will Help These Two Firms Tailor Cancer Treatments appeared first on Investor's Business Daily.


30. Sarepta Gets 'Rousing Applause' And Rockets On Gene TherapyВт., 19 июня[−]

Investors met Sarepta Therapeutics ( SRPT) with "rousing applause" Tuesday after the biotech company presented data from a gene therapy that could help young boys with a muscle-wasting disease.

X

Sarepta tested its gene therapy, called micro-dystrophin, in Duchenne muscular dystrophy patients ages 4 to 7. Leerink analyst Joseph Schwartz called the data a "home run." On average, the three patients showed an 87% reduction of an enzyme tied to the disease by day 60.

The data far outstripped analysts' expectations. Sarepta stock ended the day at a record high, up 36.8%, at 143.93. In earlier action on the stock market today, shares bounded as high as 176.50. This helped the Direxion Daily S&P Biotech Bull 3X ( LABU) exchange-traded fund to fly 4.6%, to 107.68. Biotech stocks advanced 1.8%.

Duchenne muscular dystrophy is a severe form of muscular dystrophy that mostly affects boys. In general, patients suffer progressive and irreversible muscle damage. By their teen years, patients often become unable to walk. The condition generally also affects the heart and lungs.

"We note the data was met with gasps, rousing applause, and to add additional drama to the event, the surprise appearance of all three treated children walking to the stage to a standing ovation by the investor/analyst audience," RBC analyst Brian Abrahams said in a report to clients.

Gene Therapy Tops Views

Sarepta presented the data during its R&D Day. Duchenne muscular dystrophy is tied to mutations in the gene that makes dystrophin. Dystrophin is a key protein in muscle fiber integrity and function. The treatment aims to boost the amount of micro-dystrophin in patients' muscles.

By one measure, patients reached an average of 38.2%-53.7% micro-dystrophin levels compared to normal levels. This beat the biotech company's guidance for 5%-10% and the 10% analysts expected for a "potentially successful" gene therapy, Abrahams wrote.

Leerink's Schwartz said 15% micro-dystrophin levels would be a home run and saw north of 50% as possible. But the biotech company beat both viewpoints. This "should position Sarepta as a leader in this field," he said in a report.

On another measure, average gene expression — or measuring the ability of a gene to produce dystrophin — was 76.2%. The average intensity of positive micro-dystrophin fibers was 74.5%. Sarepta had guided to 10% positive fibers and analysts predicted 30% would be successful, RBC's Abrahams said.

No Serious Side Effects

The treatment also cut the levels of creatine kinase by an average 87% at day 60. Creatine kinase is an enzyme associated with muscle damage. Patients with Duchenne muscular dystrophy generally have high levels of the enzyme. A fourth patient had his level drop to almost normal, analysts said.

Sarepta noted there were no serious adverse events in the study. Two patients had elevated levels of an enzyme that can cause damage to the liver or bile ducts. Physicians increased patients' steroid levels to resolve the issue. Doctors also treated increased nausea with steroids.

"Wrapping up the presentation, the three boys marched up to the front of the room to a standing ovation," JMP Securities analyst Liisa Bayko said in a report. She also noted "a video of boys showed improved stair climbing and running."

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

Looking For The Next Nvidia? Start With This Simple Routine

The post Sarepta Gets 'Rousing Applause' And Rockets On Gene Therapy appeared first on Investor's Business Daily.


31. Tesla Stock Falls As It Confronts Saboteur's Impact On OperationsВт., 19 июня[−]

Tesla ( TSLA) stock fell Tuesday, halting a seven-day run, after Chief Executive Elon Musk disclosed an alleged saboteur in the company's ranks and warned short-sellers that their position was going to "explode."

X

Musk, in an email to staff late Sunday and first reported by CNBC on Monday, said an unnamed employee, who has since been caught, reportedly conducted "extensive and damaging sabotage" to company operations." This included "exporting large amounts of highly sensitive data to unknown third parties."

According to the Musk email, "The full extent of his actions are not yet clear, but what he has admitted to so far is pretty bad," he wrote. "His stated motivation is that he wanted a promotion that he did not receive."

Musk did not identify the person but said the investigation will continue in depth this week.

"As you know, there are a long list of organizations that want Tesla to die. These include Wall Street short-sellers, who have already lost billions of dollars and stand to lose a lot more. Then there are the oil & gas companies, the wealthiest industry in the world — they don't love the idea of Tesla advancing the progress of solar power & electric cars," he wrote.

Tesla Stock Run

Tesla stock ended the day down 4.9%, closing at 352.55 on the stock market today. That halted a seven-day run to 370.83. Before Tuesday's decline, Tesla shares were up 27% since the company's annual shareholder meeting on June 5.

Musk sent another email to employees on Monday morning about a small factory fire on Sunday night that halted production for several hours. He suggested that employees look out for negligence or sabotage. The Tesla paint shop at its Fremont, Calif., factory has had at least four fires since 2014, according to CNBC.

Musk also sent a tweet aimed at short-sellers, on Sunday, giving them a warning. "They have about three weeks before this short position explodes," Musk wrote.

The tweet was in response to a question that referenced short sellers being concerned about Tesla's recent manufacturing expansion.

The three-week time frame coincides with the end of the second quarter and would be about the time Tesla typically reports quarterly vehicle deliveries. A number above expectations could send shares soaring. That would be bad news for short-sellers, who make money when the stock falls.

Model 3 Production

Musk is racing to double production of its critical Model 3 sedan to 5,000 cars a week. Short sellers are skeptical the company can achieve that.

Tesla stock received a price target increase two weeks ago by a Wall Street analyst who believes gross margins for the automaker's Model 3 will improve as it scales to higher production, thus helping it achieve profitability.

Also potentially creating tension on the stock Tuesday is the escalating trade war between the U.S. and China.

President Donald Trump has threatened tariffs on $250 billion worth of China goods. That's nearly double what China imports from the U.S. But Tesla could interrupt American business in China in other ways.

Tesla is eager to significantly expand its business in China. China could pose penalties such as customs delays, tax audits and increased regulatory scrutiny if Trump delivers on his threat of bigger duties on Chinese trade.

RELATED:

Tesla Cutting 9% Of Staff As It Tries To Ramp Up Model 3 Output

Tesla Stock Jumps As Elon Musk Once Again Presents Heady Expectations

The post Tesla Stock Falls As It Confronts Saboteur's Impact On Operations appeared first on Investor's Business Daily.


32. Why This Biotech Company Could Shock 2019 Sales ExpectationsВт., 19 июня[−]

Biotech company Alexion Pharmaceuticals ( ALXN) surprised Wall Street on Tuesday when it asked the Food and Drug Administration for an expedited review of its newest rare-disease drug, ALXN1210.

X

On the stock market today, Alexion lifted 2.7% to close at 121.91. Shares are consolidating with a buy point at 149.44. Biotech stocks collectively rose less than 2%.

The biotech company is using a priority review voucher for ALXN1210. It aims to treat a rare blood disease called paroxysmal nocturnal hemoglobinuria. A priority review voucher allows for an eight-month FDA review period as opposed to 12 months.

RBC analyst Kennen MacKay says this could add to 2019 expectations. He models $34 million in U.S. 2019 sales, while analysts see $35 million.

"While 2019 consensus estimates are not split by quarter, our U.S. estimate is based on a midyear launch, and we see an early launch likely leading to upside revisions," he said in a report to clients.

ALXN1210 Follows Soliris

The drug is a follow-up to Alexion's blockbuster drug Soliris, a treatment for rare blood diseases and a neuromuscular disorder. But Soliris is likely to face competition in 2020 after its patent expires in Europe. Soliris has patent protection in the U.S. through 2023.

The biotech company also is preparing to submit applications for ALXN1210 in Europe by midyear and in Japan in the second half of the year. These applications will also be in the same rare blood disease.

MacKay has an outperform rating on Alexion stock.

Leerink analyst Geoffrey Porges is similarly bullish on ALXN1210. Alexion presented updated data for ALXN1210 at the European Hematology Association annual meeting. ALXN1210 appears to offer more consistent effectiveness with less frequent dosing, he said in his note to clients.

"After this presentation, it's clear to us that ALXN1210 is even more differentiated than we had anticipated and is likely to dominate treatment of newly diagnosed paroxysmal nocturnal hemoglobinuria," Porges said.

RELATED:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

Long-Term Retirement Investing Strategies With ETFs

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post Why This Biotech Company Could Shock 2019 Sales Expectations appeared first on Investor's Business Daily.


33. Red Hat Downgraded, Cloud Computing Growth May Hit Legacy SoftwareВт., 19 июня[−]

Red Hat ( RHT) is getting a boost from growth in cloud computing but it may be coming at the expense of older software products as customers shift spending, says one analyst who downgraded the stock ahead of earnings on Thursday.

X

Michael Turits, analyst at Raymond James, says that customers may be buying less of the company's JBoss middleware tools. That could be the result of a transition to cloud products, such as OpenShift, he said.

Turits downgraded Red Hat to market-perform.

"Checks with U.S. and European resellers were mostly strong," Turits said in a note to clients Tuesday. "However, they did confirm company warnings that legacy middleware (1% of fiscal 2018 subscription revenue) is slowing as applications move to containers and cloud, lowering visibility into growth this year."

The company's Linux operating system runs servers in data centers operated by many large U.S. companies. Red Hat has pivoted from its core Linux, open source business into building a cloud-friendly app development platform.

Red Hat Earnings Due

By using Red Hat's software containers, corporate developers build custom apps in private data centers and move workloads to public clouds.

The enterprise software maker reports fiscal first-quarter earnings late Thursday. Analysts estimate profit growth of 21% to 68 cents a share, with revenue rising 19% to $897 million.

At its analyst day in May, the company said its emerging technology segment now has an annual $200 million run rate. Most of that comes from cloud revenue, such as OpenShift.

Shares in Red Hat slipped 3.2% to close at 170.64 on the stock market today amid a broad sell-off in technology firms. Investors worry a U.S.-China trade war may be coming.

RELATED LINKS:

How Red Hat Morphed From Linux Pioneer Into Cloud-Computing Player

Software Stocks Flying High, IPOs Drive Up Valuations, M&A May Suffer

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Red Hat Downgraded, Cloud Computing Growth May Hit Legacy Software appeared first on Investor's Business Daily.


34. Square, Shopify Price Targets Hiked On E-Commerce Market StrengthsВт., 19 июня[−]

Square ( SQ) and Shopify ( SHOP) are enabling their merchant customers to be more competitive, says one analyst who hiked his price targets on both e-commerce companies.

X

"Emerging brands on Shopify are getting larger, and more established brands are gravitating to Shopify to be more nimble," KeyBanc Capital Markets analyst Brett Andress said in a report to clients Tuesday. He raised Shopify's price target to 182 from 170.

Andress also hiked Square's price target to 70 from 55. The KeyBanc analyst is upbeat on Square Cash.

He expects Square to develop add-on revenue sources for Square Cash, a free person-to-person mobile app that is often used to send money to friends or family.

Square Cash More Than Peer-To-Peer

"The cash app was initially focused on (peer-to-peer) money transfer, yet is transforming into a full-fledged financial service offering with new loyalty features like Boost, direct deposit, and a physical Cash Card," Andress said.

The San Francisco-based firm makes credit-card readers that plug into mobile phones and tablets. Square also provides software for point-of-sale and back offices in order to manage inventory and other tasks. It also offers customer relationship management software so businesses can do targeted marketing to their clients.

Shopify sets up e-commerce websites for small businesses, and partners with others to handle digital payments and shipping.

Shopify fell 1.3% to close at 170.61 on the stock market today amid a broad tech sell-off tied to worries over a U.S.-China trade war. Square slipped 0.4% to 65.96.

From a year ago, Shopify has gained 94% as of Monday's market close. Square has shot up nearly 176% over the last 12 months.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Square, Shopify Price Targets Hiked On E-Commerce Market Strengths appeared first on Investor's Business Daily.


35. Amazon Alexa Embraced By Marriott For Use In Select HotelsВт., 19 июня[−]

Marriot International ( MAR) on Tuesday said it plans to use the Amazon.com ( AMZN) Alexa voice-activated personal digital assistant in its hotels.

X

Amazon announced Alexa for Hospitality, an updated version of the device that's programmed for use in hotels, vacation rentals and other hospitality locations. Guests can ask Alexa for hotel information, request guest services, play music and more.

Alexa can provide information, such as pool hours or fitness center location or call the concierge. Hospitality providers or guests configure Amazon Alexa by controlling and adjusting in-room devices like lights, thermostats, blinds and TVs.

Amazon is the market leader in voice-controlled speakers that respond to questions on a wide range of topics. It can play music on request, be used for online shopping, check package delivery statuses and more.

The Amazon Echo line of devices, all voiced by Alexa, competes primarily against Alphabet's ( GOOGL) Google. The main competitor to the Amazon Echo is the Google Home device by Alphabet.

Amazon Alexa Experience

For hotels, Alexa for Hospitality helps deepen guest engagement through seamless voice-first experiences that offer new ways for guests to access services and amenities during their stay, Amazon said.

It's available to hospitality providers by invitation starting today, with Marriott International introducing the new Alexa experience at select properties in Marriott Hotels, Westin Hotels & Resorts, St. Regis Hotels & Resorts, Aloft Hotels, and Autograph Collection Hotels starting this summer.

Amazon shares added 0.6% to close at 1,734.78 Tuesday. Marriott shares fell 1.5% to 136.58.

RELATED:

Amazon Confirms Echo Smart Speaker Recorded, Sent Private Conversation

Will Amazon Tap Alexa To Challenge PayPal In Money Transfers?

The post Amazon Alexa Embraced By Marriott For Use In Select Hotels appeared first on Investor's Business Daily.


36. Netflix Stock Rockets To All-Time High On Price-Target HikesВт., 19 июня[−]

A trio of Wall Street analysts on Tuesday raised their price targets on Netflix stock, saying the internet television service is likely to report strong subscriber gains in the second quarter.

X

Netflix ( NFLX) shares surged 3.7% to 404.98, a new closing high, on the stock market today. Its intraday high was 405.29.

The Los Gatos, Calif.-based company is scheduled to report second-quarter results after the market close on July 16. Netflix said it expects to add 6.2 million subscribers worldwide, giving it a total of 131.2 million.

GBH Insights analyst Daniel Ives raised his price target on Netflix to 500 from 400. He reiterated his "highly attractive" rating on the stock.

"Netflix has a number of growth levers which should fuel the company's next phase of strategic penetration among both U.S. and especially international consumers," Ives said in a note to clients.

'Eye-Popping Disparity'

The average Netflix user is watching the streaming video service more than 10 hours a week, which is nearly double its nearest competitors Amazon ( AMZN) and Hulu, which average closer to 5 hours a week, he said. That's "an eye-popping disparity," Ives said.

"Our bullish thesis on Netflix is based on our belief that the company's competitive moat, franchise appeal, ability to increase international streaming customers through 2020, and original content build out will translate into robust profitability and growth as the next phase of this story plays out over the coming year," he said.

Monness Crespi Hardt analyst Brian White raised his price target on Netflix stock to 460 from 375. He maintained his buy rating.

"The combination of engaging new content, momentum in overseas markets and a business model that scales globally increasingly sets Netflix apart from its legacy competitors," White said in his report to clients.

Piper Jaffray analyst Michael Olson upped his price target on Netflix to 420 from 367 and kept his overweight rating.

He forecasts "a solid Q2" for Netflix with potential upside for international subscriber gains, he said.

RELATED:

These 3 FANG+ Stocks Are In Buy Range Right Now

Apple To Spend $900 Million On Original Video Content This Year: Analyst

Netflix Stock Spikes To Record High As Investors Ignore Short-Seller Call

Netflix Smashes First-Quarter Subscriber Target; Stock Jumps

The post Netflix Stock Rockets To All-Time High On Price-Target Hikes appeared first on Investor's Business Daily.


37. Can This Small Medtech Rival Giants With New Skin Graft Method?Пн., 18 июня[−]

A tiny player is looking to swipe share from giants like Medtronic ( MDT), Zimmer Biomet ( ZBH) and Integra Lifesciences ( IART) with "a clever adaptation" of standard bone and skin graft technology.

X

Salt Lake City-based PolarityTE ( COOL) is aiming to do this with a new medical technology called SkinTE. The medtech flips the paradigm of tissue engineering on its head, Chief Executive Denver Lough told Investor's Business Daily.

In traditional tissue engineering, a stem cell is combined with a skin cell, given a cocktail of growth factors and placed on what is called a scaffold — a structure that provides the foundation for skin growth, similar to a trellis. It may seem sophisticated, but it's a tall order, Lough says, since the last time a single stem cell created a complex tissue system in most humans was when the sperm met the egg.

And it can seem more like a violent kidnapping than an effort to heal, he said.

"We wake him up, pull him out of his bed, rip off some of his clothes, chop off parts of his arms and legs, throw some chemicals on him, push him through a mesh screen door and push him out in the middle of the Atlantic Ocean," Lough said. "He's not going to function. He's bleeding out and just trying to survive."

Lough says PolarityTE's product doesn't remove a single layer of skin or attempt to separate stem cells from skin cells. Instead, it takes the entire "village" of supportive cellular elements that command the stem cell to function in a certain way.

Familiar Settings

The idea is to make the skin-regeneration process a little more pleasant than a kidnapping.

"Let's move his entire house from New York over to San Francisco," Lough said. "So when he wakes up in the morning he has his entire family with him. He has his bathroom, his cellphone, his computer. So when he wakes up he can function like (himself)."

Lough is bullish on PolarityTE's prospects. The Food and Drug Administration registered SkinTE in October and the company began a slow rollout in December. So far, around a handful of centers have SkinTE on site. Eventually, the company expects that to be in the thousands.

If that's the case, SkinTE could make a big dent in the skin graft market. Sizing that market is a challenge. Research and Markets expects the U.S. skin graft market to reach about $522.5 million by 2025, growing at a compounded annual rate of 7.6%.

Market Research Future sees the global skin graft market being worth $7.5 billion by the end of 2023. It estimates the market hitting a compound annual growth rate of 13.5% from 2017-23.

Eventually, Lough says, the medtech plans to expand into other tissue regeneration including bone and muscle. SkinTE was just proof of concept. But the platform can be much bigger, he said.

Treating Open Wounds

Dr. Mark Granick is a professor and chief of plastic surgery at Rutgers New Jersey Medical School, and a paid member of PolarityTE's board of advisors. Granick was an early adopter of SkinTE and calls it "a clever adaptation" of traditional skin graft technology. He expects it to replace all forms of skin grafts in the future.

Granick has used SkinTE on four patients. Two of those cases involved patients with scars that limited their movement. Granick removed the scar from one man's hand, replacing it with SkinTE. He's since regained full use of his hand, Granick told Investor's Business Daily.

In another case, Granick treated a 39-year-old man who suffered a recurring wound for two years after a motorcycle wreck shaved the skin from his legs. That man, known in a news release as Devon, went through two failed skin grafts before trying SkinTE.

"If I had to choose between SkinTE and another skin graft, I would choose SkinTE every time because it is actually working," Devon said in a written statement. "And you don't have a huge area of healthy skin removed that also then needs to heal, like with traditional skin grafts."

Granick says the difference between the skin grafts on one leg and the SkinTE on the other leg is remarkable. SkinTE works to regenerate full-thickness, hair-bearing skin, which differs from a traditional skin graft which doesn't regenerate hair follicles or sweat glands.

"The skin that grew back looks remarkably normal," Granick said. "It seems to have much more normal skin than the graft on his other leg."

Healing Within A Week

PolarityTE is preparing to scale its production and says its Apple ( APPL)-like box of tools can be used anywhere to take a small sample of skin. A physician then sends that sample to PolarityTE's manufacturing facility, where it is used to create a personalized regrowth solution.

"When the providers get it back, they deploy it like icing on a cake or ketchup on a hot dog," Lough said.

The wound begins to heal within five days. Patients are typically discharged within six weeks because the skin is growing on them directly. Plus, there's no second wound from a donor site to heal in the case of SkinTE, Lough said.

Granick noted the expansion is "enormous" for SkinTE. It's a "small piece of skin" and can be used to regenerate skin for a large area. He notes it's very effective in closing open wounds, such as was the case for Devon.

"Even at this early stage it's a game-changer in terms of how we manage wounds," he said.

Unique Business Model

PolarityTE's business model is somewhat unique. It provides the tool kit to wound centers and other care providers for free. Traditional skin substitute systems cost $100-$260 per square centimeter. SkinTE costs about $60 per square centimeter.

The idea is to foster adoption, Lough said. Sales in the first quarter were $13,000. PolarityTE wouldn't go into its expectations for the current quarter.

Investors seem to be perking up to the idea, though its origins are a tad unique for a medtech. It went public through a reverse merger with gaming company Majesco Entertainment in 2017. It sold off all gaming assets in June 2017.

Since then, its stock has been on been on a tear. Shares of the medtech jumped 12.2% Monday to close at 30.30. In recent weeks, the stock has trended up even more rapidly, spiking 48% in May alone as it added a number of new executives and managers.

Dr. Granick says patients are lining up for SkinTE.

"This particular process is a game-changer," he said. "It's an improvement in appearance, quality of the skin function and with minimal donor site size. It's a clever adaptation."

RELATED LINKS:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Tame A Volatile Swing Trade With A Half Position

New Option Strategy Limits Risk Around Earnings

The post Can This Small Medtech Rival Giants With New Skin Graft Method? appeared first on Investor's Business Daily.


38. This Biotech Stock Soared On Tests For Experimental TreatmentПн., 18 июня[−]

PTC Therapeutics ( PTCT) shares soared by nearly a fourth Monday to their highest price since August 2015 after the biotech stock said its experimental drug for rare-disease spinal muscular atrophy helped the vast majority of babies who got the treatment.

X

The company said after 182 days of treatment, 91% of babies on the drug showed marked improvement. The babies gained more than four points on a scale that measures motor milestone developments for those with a form of SMA.

The company presented the data at the SMA Researcher Meeting in Dallas. It showed footage of the babies rolling, sitting and controlling their head movements.

Shares of the South Plainfield, N.J.-based biotech company jumped 27.5% to close at 47.88 on the stock market today. Shares earlier rose as much as 41% for the stock's biggest intraday gain since Nov. 11, 2016.

1 In 11,000 Babies Affected

Spinal muscular atrophy progressively takes away people's physical strength and their ability to walk, eat and breathe. It affects approximately 1 in 11,000 babies. It's also the No. 1 genetic cause of death for infants, according to Cure SMA, a nonprofit advocacy group.

Another biotech stock, Biogen ( BIIB), which sells a treatment for spinal muscular atrophy called Spinraza, saw its shares drop by 5.2% to 289.12. Biogen's business partner on Spinraza, Ionis Pharmaceuticals ( IONS), tumbled 6.4% to close at 43.61.

PTC's drug is taken orally. Other companies are developing gene-therapy treatments that could eventually repair the fundamental genetic causes of the disease.

"While we think gene therapy is the most important competitor, given they could be on the market in 2020 and a one-time infusion, of course an oral would be a major competitor as well if the data is at least similar to" Biogen's drug Spinraza, said Michael Yee, an analyst with Jefferies Group. Yee has a hold rating on Biogen shares.

The post This Biotech Stock Soared On Tests For Experimental Treatment appeared first on Investor's Business Daily.


39. Software Stocks Flying High, IPOs Drive Up Valuations, M&A May SufferПн., 18 июня[−]

Acquisitions by Salesforce.com ( CRM) and Workday ( WDAY) — as well as initial public offerings by DocuSign ( DOCU), Zscaler ( ZS) and Smartsheet ( SMAR) — are driving up valuations of computer software stocks to a point where a pullback may be needed to drive further deal-making, says Morgan Stanley.

X

"With fewer high-quality assets at attractive valuations, we believe a pullback in multiples across the software stocks group could enable the pace of M&A to re-accelerate," said Keith Weiss, a Morgan Stanley analyst in a report.

Salesforce acquired MuleSoft in March for $5.5 billion, marking its biggest acquisition ever. Workday this month agreed to buy Adaptive Insights for $1.55 billion ahead of the startup's planned IPO.

Both Salesforce.com and Workday acquired firms at historically high prices, says Morgan Stanley. The investment bank notes 52 software acquisitions in 2018 thus far. That includes purchases of private firms. Companies bought 36 and 37 software firms, respectively, in the prior two years.

What's Driving Software Mergers

"M&A appears to be benefiting a very good software demand environment, and strong strategic rationale for consolidation of functionality across software subsectors," Weiss said in a report to clients. He added that some companies may have more cash because of new tax rules.

Salesforce.com rose 1% to close at 139.80 on the stock market today. Workday climbed 2.4% to near 131.13, while Atlassian rose 0.7% to 66.61. ServiceNow ( NOW) inched up a fraction to 186.41.

Aside from DocuSign, Zscaler and Smartsheet, recent software IPOs include Pivotal Technologies ( PVTL), Zuora ( ZUO) and Carbon Black ( CBLK).

Hot Software IPOs

"Recent IPOs (DocuSign, Zuora, Carbon Black, Pivotal, Zscaler, Smartsheet) are up an average of 28% in the last month alone vs. our software universe, (which is) up 13% in the same time period," Weiss said.

IBD's Computer-Software Enterprise group ranks No. 2 out of 197 groups. Salesforce.com and ServiceNow have the highest Composite Ratings in the computer software stocks group.

IBD's Computer-Software Specialty Enterprise group ranks No. 10. There, RealPage ( RP) and Appfolio ( APPF) have the highest Composite Ratings.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Software Stocks Flying High, IPOs Drive Up Valuations, M&A May Suffer appeared first on Investor's Business Daily.


40. Oracle Earnings Will Place Spotlight On Cloud-Computing TransitionПн., 18 июня[−]

Database software giant Oracle ( ORCL) is set to report fiscal fourth-quarter earnings after the market close Tuesday, with investors focusing mainly on its migration to a cloud-computing business model that is taking longer than expected.

X

The company is undergoing a shift in its product portfolio, away from a traditional model of licensing and maintenance to a subscription-based cloud-computing business while trying to sustain profit margins that have been under pressure.

Analysts project Oracle will report revenue of $11.2 million, up 3% from the year-ago quarter. The consensus on adjusted earnings is 94 cents per share, up 6%.

The company has struggled to meet high expectations for its shift to the cloud, and is in a growing war with Amazon ( AMZN) and its Amazon Web Services division. Peers Microsoft ( MSFT), Salesforce.com ( CRM) and Amazon are growing faster.

"We continue to view Oracle as facing challenges to grow its technology business given multifaceted headwinds," RBC Capital Markets analyst Ross MacMillan wrote in a note to clients. He has a sector perform rating on the company and a price target of 55.

Positive On Oracle

Credit Suisse analyst Brad Zelnick has an outperform rating on the company and price target of 60.

"We remain positive on Oracle," Zelnick wrote in his report to clients. He says the company is achieving larger strategic deals, in addition to showing solid momentum in support renewals.

Oracle shares closed at 46.52, down 0.5% on the stock market today. The stock fell below its 50-day moving average on June 14. Shares are down 13% since hitting a record high of 53.48 on March 14.

RELATED:

Cloud Computing: Find Top Cloud Stocks And Track Industry Trends

Micron, Red Hat, Oracle Earnings; OPEC Meeting: Investing Action Plan

The post Oracle Earnings Will Place Spotlight On Cloud-Computing Transition appeared first on Investor's Business Daily.


41. Video Game Stocks Get Price-Target Hikes Post-E3 ShowПн., 18 июня[−]

Video game stocks received price-target increases following the annual E3 trade show last week in Los Angeles. Major publishers Activision Blizzard ( ATVI), Electronic Arts ( EA) and Take-Two Interactive Software ( TTWO) are looking healthy heading into the back half of 2018, Wall Street analysts say.

X

Benchmark analyst Mike Hickey raised his targets on Activision, EA and Take-Two following meetings at the three-day conference, which ended Thursday. He rates all three stocks as buy.

He upped his target on Activision to 93 from 80, on EA to 164 from 141, and on Take-Two to 156 from 135.

Activision rose 0.6% to 77.87 on the stock market today. EA fell 1.2% to 144.86 and Take-Two slid 0.7% to 120.69.

Activision's upcoming shooter game "Call of Duty: Black Ops 4" is likely to continue the momentum of last year's successful "Call of Duty: WWII" game, Hickey said.

No Single-Player Campaign For 'Black Ops 4'

One knock on "Black Ops 4" is that it doesn't have a single-player campaign. The game has bet the farm on multiplayer online play. Activision also has added a battle-royale mode called "Blackout," which should add to player excitement, Hickey said. "Black Ops 4" comes out on Oct. 12.

However, gamers are complaining on social media about Activision charging for additional maps as part of a downloadable content pass. That could end up splitting the community of players, GameRevolution reported.

Meanwhile, EA's game slate looks solid, including "Battlefield 5," due out Oct. 19; "Anthem," out Feb. 22; plus its annual FIFA, Madden NFL and NBA Live games, Hickey said.

Take-Two's focus is on the release of its highly anticipated Western game "Red Dead Redemption 2," due out Oct. 26, as well as "NBA 2K19," out Sept. 7.

Video Game Stocks Get More Praise

KeyBanc Capital Markets analyst Evan Wingren upped his price targets on Activision and EA after the E3 show.

He raised his target on Activision to 90 from 83 and on EA to 168 from 152. He maintained his target of 152 on Take-Two. Wingren rates all three as overweight.

"After a week at E3 meeting with management teams, investors, and industry contacts, we are incrementally positive on the setup for the group," he said in a report Sunday.

Cowen Is Cautious On Group

Meanwhile, Cowen analyst Doug Creutz put out a cautious report on video game stocks.

"While we continue to like industry fundamentals, we think share prices (at least on the AAA game side) are becoming ever more divorced from underlying business realities, and remain cautious," he said. "We expect summer to continue to provide its usual lift to the group, but think this fall could prove difficult for further price appreciation."

Creutz rates Activision, EA and Take-Two stocks as market perform. He has a price target of 66 on Activision, 114 on EA and 96 on Take-Two.

RELATED:

These Stocks Got The Biggest Bounce From E3 Video Game Expo

E3 2018 Expo News

The post Video Game Stocks Get Price-Target Hikes Post-E3 Show appeared first on Investor's Business Daily.


42. HPE Sets Analyst Day As Cloud-Computing War Heats Up Vs. Cisco, DellПн., 18 июня[−]

HP Enterprise ( HPE), or HPE, hosts an analyst day Tuesday where it's expected to update its financial guidance and strategy amid stiff competition with Cisco Systems ( CSCO), Dell Technologies ( DVMT) and others.

X

The company is battling Cisco and Dell as customers shift to cloud-computing technologies. That's driving down spending on traditional information-technology hardware and software.

The analyst day is being held along with a three-day user conference called HPE Discover 2018. Chief Executive Antonio Neri plans to deliver a keynote address late Tuesday. Neri took over as CEO from Meg Whitman in February.

"We expect the general session keynote will highlight products that are most relevant for building a next-gen hybrid (information technology) or edge computing environment, such as software-defined networking," said a Morgan Stanley report.

HPE Cloud-Computing Focus

Neri's keynote could also address "cloud-based predictive analytics platform Infosight, high-performance computing, and hyperconverged infrastructure," the report said.

Shares in the maker of computer servers, networking equipment and data storage gear fell a fraction to 15.91 on the stock market today. The stock has risen 11% this year. But, shares in HPE are down from 19.41 in March amid questions over revenue growth.

The company in February announced a new $7 billion stock buyback.

HPE last year sold its software business to U.K.-based Micro Focus International. HPE spun off its enterprise services business, which merged with Computer Sciences to create DXC Technology ( DXC).

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post HPE Sets Analyst Day As Cloud-Computing War Heats Up Vs. Cisco, Dell appeared first on Investor's Business Daily.


43. JD.com, Google Forge Alliance Spanning Online Shopping, RetailПн., 18 июня[−]

JD.com ( JD) and Google-parent Alphabet ( GOOGL) forged a wide-ranging alliance on Monday, with the U.S. internet search giant taking a small stake in the Chinese e-commerce firm.

X

Alphabet will invest $550 million in cash for a 1% stake in JD. It's China's No. 2 e-commerce company behind Alibaba Group Holding ( BABA).

As a part of the partnership, JD.com will make a selection of its products available for sale through Google Shopping across multiple regions.

"We think the addition of JD should strengthen Google Shopping," said Youssef Squali, analyst at SunTrust Robinson Humphrey in a report. "Google has worked over the past 12-18 months to increase the number of partners available on its shopping site and through its smart assistant to include the likes of Target ( TGT), Walmart ( WMT), Home Depot ( HD), and Costco ( COST)."

Next-Gen Retail Infrastructure

Google and JD.com said they will explore joint development of " retail infrastructure" products in Southeast Asia, the U.S. and Europe.

"By applying JD's supply chain and logistics expertise and Google's technology strengths, the two companies aim to explore the creation of next generation retail infrastructure solutions, with the goal of offering helpful, personalized and friction-less shopping experiences," Google and JD.com said in a release.

JD.com gained a fraction to close at 43.76 on the stock market today after rising nearly 6% in earlier trading. JD.com in May reported first-quarter revenue that topped estimates while profit missed. The stock has rallied from a low of 35 in March and formed a cup pattern. Still, JD.com is trading below a technical buy point of 50.78.

E-Commerce Rival Of Alibaba

Alphabet will buy newly issued Class A shares at $20.29 per share, equivalent to $40.58 per ADS, the companies said in a joint statement Monday.

Alibaba and JD.com are the two largest e-commerce companies in China, but with different business models. Alibaba is the largest in terms of gross merchandise volume, while JD.com handles more direct sales.

In China, the company has been testing self-driving delivery vehicles the size of shopping carts and trucks for improved logistics.

Google climbed 2.1% to 1,183.58. The stock passed a buy point of 1,161.20 last week. Shares in Google are up more than 11% in 2018. Alibaba stock has gained nearly 20% this year.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post JD.com, Google Forge Alliance Spanning Online Shopping, Retail appeared first on Investor's Business Daily.


44. Apple To Spend $900 Million On Original Video Content This Year: AnalystСб., 16 июня[−]

Apple ( AAPL) is likely to spend about $900 million on video content this year as it ramps up production of original TV shows to take on Netflix ( NFLX) and others in subscription video on demand, a prominent analyst said Friday.

X

Apple has yet to announce a streaming video service. Hollywood media outlets, however, have reported it has 16 shows in the works. That's comparable to Netflix in its first year of original programming in 2013. At that time, it released 13 originals, Gene Munster, managing partner of Loup Ventures, said in a blog post Friday.

On Friday, Apple announced a multiyear content partnership with Oprah Winfrey. It didn't, however, provide details about where people will watch that content.

"Together, Winfrey and Apple will create original programs that embrace her incomparable ability to connect with audiences around the world," Apple said in a news release. "Winfrey's projects will be released as part of a lineup of original content from Apple."

Munster expects Apple to spend about $900 million on TV content in 2018, growing to $4.2 billion by 2022.

Going To 20% Of Revenue

The company's video plans are part of its major push into services, which include Apple Music and other offerings. Services will account for about 14% of Apple's revenue this calendar year, growing to 20% by 2023, Munster said.

"Content is an emerging part of the (company's) services pillar, as evidenced by the success of Apple Music, now with over 50 million paying subscribers," Munster said. "Original video content is a new category for Apple and represents optionality to services revenue growth and is not yet reflected in the value of Apple shares."

Munster believes Apple will start generating revenue from its video service in 2019 or 2020.

Apple Video Service Advantage

The Cupertino, Calif.-based company is late to the subscription video business. However, its huge hardware installed base gives it an edge.

"What separates Apple is the company's access to 1.3 billion active devices through which they can subtly encourage adoption," Munster said. "Apple Music's market share gains over the past two years are a testimony to the power of coupling services with widely adopted hardware."

Apple's original content orders include series from filmmakers Steven Spielberg and M. Night Shyamalan, various reports have said. It also has shows coming from "Battlestar Galactica" remake developer Ronald Moore and actresses Jennifer Aniston and Reese Witherspoon.

Apple shares were down 1% to 188.84 on the stock market today.

RELATED:

Netflix Stock Spikes To Record High As Investors Ignore Short-Seller Call

Apple Services Business Faces Skepticism From Wall Street Analyst

The post Apple To Spend $900 Million On Original Video Content This Year: Analyst appeared first on Investor's Business Daily.


45. AT&T Closes Time Warner Deal, Analyst Sees Digital Advertising BoostСб., 16 июня[−]

AT&T ( T) on Friday closed its $85 billion acquisition of Time Warner, three days after winning its court battle with the Department of Justice, with the combined company eyeing a push into digital advertising.

X

The telecom and media conglomerate now expects to achieve annualized cost synergies of $1.5 billion in three years, up from its previous estimate of $1 billion. AT&T said it expects $1 billion in annualized revenue synergies by 2021. One analyst says a boost should come from digital advertising.

AT&T plans to meld Time Warner content with its wireless and broadband distribution. The company in 2017 hired Brian Lesser, an executive for a decade with WPP-owned GroupM, to lead its advertising and analytics division.

"Since joining AT&T, Lesser has built up a significant team under him," said Jennifer Fritzsche, a Wells Fargo analyst, in a report published on Friday. "Lesser's role is to help bring AT&T into the digital advertising world to compete with the likes of Facebook ( FB) and Google — and using the Time Warner content assets combined with AT&T's far reaching distribution to do this."

AT&T stock a laggard

Verizon Communications ( VZ), which acquired AOL and Yahoo's internet business, also plans to compete in digital advertising versus Alphabet's ( GOOGL) Google and Facebook.

Shares in AT&T gained 1.9% to 33.15 on the stock market today. The company's stock is down nearly 17% from a year ago. Time Warner shareholders will receive 1.437 AT&T shares for each Time Warner share held.

AT&T and Time Warner announced their merger in October 2016. The combined company has $180 billion in debt.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post AT&T Closes Time Warner Deal, Analyst Sees Digital Advertising Boost appeared first on Investor's Business Daily.


46. Biotech Funds Tacked On $76 Million This Week — Are They Recovering?Сб., 16 июня[−]

Biotech funds tacked on $76 million this week, adding to more than $500 million in net inflows over the past two weeks — a phenomenon biotech stocks haven't seen in nine months.

X

But activity within exchange-traded funds lent a heavy helping hand. Outside ETFs, the flow of biotech funds was negative, Raymond James analyst Laura Chico said. Still, overall biotech net assets increased 0.11% as "all equities" saw net outflows representing 0.13% in total assets.

Chico questioned whether three weeks could make a trend. The once red-hot biotech group stood eighth out of 197 industry groups tracked by Investor's Business Daily just 13 weeks ago. It slid to the 32nd slot four weeks ago and today it's ranked No. 17.

"Staying in the black for yet another week," Chico said in a note. "This follows two consecutive weeks of net inflows of about $546 million, a trend not seen since September 2017."

Biotech Funds Positive

Piper Jaffray analyst Christopher Raymond noted the three-week trend in net inflows could signal a change in biotech stocks' fortunes. The data represent 101 healthcare and biotech funds with $73 billion in collective assets.

"As we see it, this is a key dynamic to monitor as periods of net inflows historically correspond with biotech outperformance while periods of net outflows correspond with sector underperformance," he said in a report.

Amid the biotech stocks' performance, all equities saw outflows for the second week running, he said. This marks the third week of outflows across all equities out of the past nine weeks.

But year to date, biotech funds remain negative with net outflows at about $2 billion, Raymond James' Chico said. Quarter to date, biotech funds have seen about $34 million in net inflows.

"The second quarter historically has been a more variable period for biotech fund flows with $2 billion in net outflows in 2016 and $1.3 billion in net inflows in 2017," she said.

Biotech ETFs Help

Activity within biotech ETFs didn't change this week. Considering the breadth of ETF activity in the biotech group, this is "a key metric to watch," Chico said.

The ProShares Ultra Nasdaq Biotechnology ETF ( BIB) climbed 1.9% this week. It's consolidating with an entry point at 69.72. The iShares Nasdaq Biotechnology Index ( IBB) rose 1%, moving closer to a buy point at 119.40. Shares of the SPDR S&P Biotech ETF ( XBI) were flat this week.

On the stock market today, biotech stocks tracked by IBD were close to flat. Shares within three major biotech ETFs dipped less than 1%.

Excluding the impact of ETFs, biotech funds have seen just four weeks of inflows since the start of 2018. None of those weeks were in the second quarter, Chico said.

"We continue to see biotech sector being influenced by several drivers: data readouts, commercial execution, (mergers and acquisitions) potential and capital market accessibility," she said. "Biotech fund inflows — including ETF activity — remain a key driver to watch."

RELATED:

Looking For The Best Stocks To Buy And Watch? Start Here

New Option Strategy Limits Risk Around Earnings

How Much Money Do You Need To Start Investing?

The post Biotech Funds Tacked On $76 Million This Week — Are They Recovering? appeared first on Investor's Business Daily.


47. Teva Scraps A Study In Cluster Headaches — And This Rival BenefitsСб., 16 июня[−]

Alder Biopharmaceuticals ( ALDR) stock gapped up Friday after rival Teva Pharmaceutical ( TEVA) scrapped a late-stage study of its anti-CGRP migraine prevention drug in chronic cluster headaches.

X

At the closing bell on the stock market today, Alder popped 6.7%, to 17.65. Shares of Teva dipped a fraction, to 23.76. Rival Eli Lilly ( LLY) rose a fraction and Amgen ( AMGN), which was the first to get a migraine prevention drug to market, dipped 0.4%.

Teva studied fremanezumab in chronic and episodic cluster headaches, as well as a long-term safety study. Researchers found fremanezumab is unlikely to work in chronic cluster headaches during the 12-week treatment period, and ended that study.

Fremanezumab belongs to a class called anti-CGRP drugs, which aim to block a specific peptide associated with migraines. It's possible anti-CGRP drugs could have other uses, Teva spokesperson Tushar Shah said in a statement.

"While we are disappointed with this outcome, we remain optimistic that fremanezumab could have clinical benefits in additional conditions, beyond migraine, where calcitonin gene-related peptide plays a contributory role in their pathophysiology," he said.

Other Anti-CGRP Drugs

Amgen and partner Novartis ( NVS) grabbed approval in May for anti-CGRP drug Aimovig in migraine prevention. For the week ended June 8, Aimovig prescriptions grew 102% week over week to 2,129, RBC analyst Kennan MacKay said in a note.

Alder is testing its drug, eptinezumab, as a preventive treatment for episodic and chronic migraines. It also has a migraine prevention drug in preclinical studies. Lilly's galcanezumab is under review in migraine prevention and is also being studied in cluster headaches.

Meanwhile, Biohaven Pharmaceutical ( BHVN) has an anti-CGRP drug in development as an acute treatment for migraines. It's also testing another anti-CGRP drug to treat and prevent migraines. Allergan ( AGN), too, has an anti-CGRP in development as an acute treatment for migraines.

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How Much Volume Should You Look For In A Stock?

Investing Basics: How To Sell A Stock

The post Teva Scraps A Study In Cluster Headaches — And This Rival Benefits appeared first on Investor's Business Daily.


48. Avalara IPO Soars As Cloud Software Company Prices HighПт., 15 июня[−]

Shares of cloud software company Avalara ( AVLR) jumped more than 87% on its first day of trading Friday with an initial public offering that raised $185 million, which was far more than expected.

X

Avalara priced shares at 24 and opened at 35 as trading began. Shares closed at 44.94 on the stock market today.

The initial price range was 19 to 21, before being upwardly revised. The company sold 7.5 million shares.

Avalara provides a cloud-based software platform to help its customers navigate the complicated and highly-regulated world of tax compliance. The company was founded in 2004 and is based in Seattle.

"We estimate that the addressable market in the United States alone for the solutions we offer today is over $8 billion," the company said in its IPO prospectus.

Avalara says the growth of e-commerce and international trade, paired with the taxation and reporting obligations on local, regional, state and national levels, has increased the complexity of the tax compliance landscape. It sells solutions mainly on a subscription basis.

Automate Tax Processes

The company automates the processes of determining taxability and applicable tax rates. It also prepares and files returns, maintains tax records and manages compliance documents. The company has more than 20,000 customers of all sizes.

Avalara reported revenue of $213 million in 2017, up 27% from the prior year. It showed a net loss of $64 million. In the first quarter, it reported revenue of $61.3 million, up 25%, with a net loss of $15.2 million.

Goldman Sachs and JPMorgan were the lead underwriters.

RELATED:

Pluralsight Pops As Trading Begins; IPO Raises $310.5 Million

Carbon Black IPO Pops In Hot Cybersecurity Market

DocuSign IPO Prices Above Range As Stock Jumps By Double-Digits

The post Avalara IPO Soars As Cloud Software Company Prices High appeared first on Investor's Business Daily.


49. These Stocks Got The Biggest Bounce From E3 Video Game ExpoПт., 15 июня[−]

The annual E3 show in Los Angeles this week electrified video game fans as well as publicly traded companies in the sector.

X

Announcements at E3, short for Electronic Entertainment Expo, lifted shares of game software and hardware peripherals firms. The three-day show, which ended Thursday, attracted more than 69,200 attendees, show owner Entertainment Software Association said Friday. Millions of people worldwide watched the week's events online, ESA said.

The stock that got the biggest boost from E3 was gaming headset maker Turtle Beach ( HEAR). It rose 9% from Monday through Thursday. At the show, the San Diego-based company announced new headsets designed for casual gamers who want to play battle royale games "Fortnite" and "PlayerUnknown's Battlegrounds."

The major U.S. video game publishers also got a boost from the show. Shares of Take-Two Interactive Software ( TTWO) rose 7.4% in the week through Thursday. Electronic Arts ( EA) rose 4.7% and Activision Blizzard ( ATVI) climbed 4.6%.

By comparison, the S&P 500 index rose 1.2% during the same four-day period.

Investor Interest In Game Stocks

"After a week of E3, the bottom line is that there is clearly still significant investor interest in video games," Macquarie analyst Benjamin Schachter said in a report Thursday. "The group remains a focus for media, tech and consumer investors, in addition to those who have traditionally followed the industry in the past. There are perhaps more global investors interested than usual as well."

Other firms exhibiting at E3 got a lift, too. They included gaming headset and keyboard maker Logitech ( LOGI), up 3.8%, and graphics-chip makers Advanced Micro Devices ( AMD), up 6.6%, and Nvidia ( NVDA), up 1.8%.

Not all video game industry players fared well during E3, however. The three major console makers all saw their shares decline during the event. U.S. shares of Nintendo ( NTDOY) tumbled 10.4%. Sony ( SNE) dropped 1.7% and Microsoft ( MSFT) dipped 0.2%.

E3 2018 Major Themes

This year's E3 show spotlighted major software titles coming soon from top game publishers. They included "Call of Duty: Black Ops 4" from Activision, "Assassin's Creed: Odyssey" from Ubisoft and "Fallout 76" from Bethesda. Other big titles were Nintendo's "Pokemon" games for its Switch console, and Sony's "The Last of Us: Part 2" and "Marvel's Spider-Man" for the PlayStation 4 console.

Esports were a major topic at this year's show with tournaments for games such as "Fortnite: Battle Royale" from Epic Games and "Super Smash Bros." from Nintendo.

The rise of subscription services, such EA's Origin Access Premier and Microsoft's Xbox Game Pass, also was a hot topic, as was the future of streaming for video games.

RELATED LINKS:

Headset Maker Turtle Beach Riding High From 'Fortnite Effect'

E3 2018 Expo News

The post These Stocks Got The Biggest Bounce From E3 Video Game Expo appeared first on Investor's Business Daily.


50. Avalara IPO Prices Above High End Of Range, Raises $180 MillionПт., 15 июня[−]

Cloud software company Avalara ( AVLR) priced its initial public offering late Thursday at 24, above an upwardly revised range of 21 to 23 and raising $180 million.

X

The stock is to trade on the New York Stock Exchange on Friday morning under the ticker AVLR.

Institutional investors showed strong interest in the IPO, pushing the price up from an initial range of 19 to 21. According to research and advisory firm IPO Boutique, channel checks revealed that the deal was "exponentially" oversubscribed, meaning the request for shares was higher than the 7.5 million being made available.

Avalara provides a cloud-based software platform to help its customers navigate the complicated and highly-regulated world of tax compliance. The company was founded in 2004 and is based in Seattle.

Avalara says the growth of e-commerce and international trade, paired with the taxation and reporting obligations on local, regional, state and national levels, has increased the complexity of the tax compliance landscape. It sells solutions mainly on a subscription basis.

Automates Tax Process

The company automates the processes of determining taxability and applicable tax rates. It also prepares and files returns, maintains tax records and manages compliance documents. The company has more than 20,000 customers of all sizes.

"We estimate that the addressable market in the United States alone for the solutions we offer today is over $8 billion," the company said in its IPO prospectus.

Avalara reported revenue of $213 million in 2017, up 27% from the prior year. It showed a net loss of $64 million. In the first quarter, it reported revenue of $61.3 million, up 25%, with a net loss of $15.2 million.

Goldman Sachs and JPMorgan are the lead underwriters.

RELATED:

Pluralsight Pops As Trading Begins; IPO Raises $310.5 Million

Carbon Black IPO Pops In Hot Cybersecurity Market

DocuSign IPO Prices Above Range As Stock Jumps By Double-Digits

The post Avalara IPO Prices Above High End Of Range, Raises $180 Million appeared first on Investor's Business Daily.


51. Adobe Beats Wall Street's Second-Quarter Targets, Guides HigherЧт., 14 июня[−]

Digital media and marketing software firm Adobe Systems ( ADBE) late Thursday beat Wall Street's targets for its fiscal second quarter and guided higher for the current quarter, but shares fell in extended trading.

X

Adobe Systems earned an adjusted $1.66 a share, up 63% year over year, for the period ended June 1. Sales rose 24% to $2.20 billion. Analysts expected the San Jose, Calif.-based company to earn an adjusted $1.54 a share on sales of $2.16 billion.

For its current fiscal third quarter, Adobe expects to earn an adjusted $1.68 a share on sales of $2.24 billion. Wall Street was modeling Adobe to earn $1.61 a share on sales of $2.22 billion.

"In Q4, we anticipate normal seasonal strength and a strong finish to the year," Adobe Chief Financial Officer John Murphy said in written remarks.

Adobe shares fell 2.4% in after-hours trading on the stock market today. The stock hit a record high of 258.91 in intraday trading on Thursday. It is up 47% year to date through Thursday's closing price of 258.10.

Recurring Revenue Grows

Adobe's annualized recurring revenue from its digital media businesses grew to $6.06 billion exiting the quarter, a quarter-over-quarter increase of $343 million. The company's Digital Experience marketing business sales rose 18% year over year to $586 million.

"Adobe delivers all the capabilities to enable transformative digital experiences, including content creation and management, predictive analytics and commerce," Chief Executive Shantanu Narayen said in a news release. "Our record results in Q2 reflect continued execution against this significant opportunity where Adobe is the clear market leader."

The company's stock is currently ranked No. 27 on the IBD 50 list of top-performing growth stocks.

RELATED:

Adobe's 3 Investing Lessons; These 3 Hot IPOs Keep Moving Late

Adobe Systems Seen Bumping Heads With Salesforce.com

The post Adobe Beats Wall Street's Second-Quarter Targets, Guides Higher appeared first on Investor's Business Daily.


52. Etsy Stock Hits Record High On Raised Revenue Guidance, New InitiativesЧт., 14 июня[−]

Etsy ( ETSY) stock soared to a record high Thursday after the online retailer raised 2018 revenue guidance and announced new subscription packages and higher seller fees, among other initiatives.

X

For 2018, the company now expects revenue in the range of $582 million to $591 million. That's growth of 32% to 34%, up from previous guidance of 22% to 24%.

Shares of Etsy catapulted more than 26% to close at 41.65 on the stock market today. The company held its initial public offering in April 2015, pricing shares at 16.

The retailer provides a platform used by creators of arts and crafts and handmade goods to sell their products. It has 2 million active sellers on its platform and 35 million active buyers.

Etsy raised the transaction fees it collects from sellers to 5% from 3.5%, which will support increased investments in improving the user experience. It plans to spend at least $110 million on direct marketing in 2018, up 40% from last year.

Accelerated Growth

The changes come as Etsy has posted three consecutive quarters of accelerated growth. In the first quarter it reported revenue of $120.9 million, up 25% from the year-ago quarter, and an adjusted profit of 10 cents per share. It showed gross merchandise volume of $861 million, up 20% from the year-ago quarter.

The company also rolled out two subscription packages for new and experienced users.

"Our 2 million active sellers have individual business goals and aspirations, and we want to support them no matter where they are on their journey," said Chief Executive Josh Silverman, in a prepared statement.

RELATED:

Etsy Stock Soars More Than 20% On Price-Target Hikes, Results

The post Etsy Stock Hits Record High On Raised Revenue Guidance, New Initiatives appeared first on Investor's Business Daily.


53. Netflix Stock Spikes To Record High As Investors Ignore Short-Seller CallЧт., 14 июня[−]

In the battle between Wall Street bulls and bears over Netflix stock, the bulls are winning.

X

Netflix ( NFLX) shares spiked to an all-time high on Thursday, their second record high in as many days. The stock jumped 3.4% to close at 392.87 on the stock market today. Earlier in the session, it notched a new high of 395.03.

Year to date, Netflix stock is up 105%. Last year, shares of the internet television network rose 55%.

Netflix stock rose despite short-seller Citron Research trying to take it down with a new report. Citron said Thursday that it expects Netflix to dip back to 340 in the "near term" regardless of high praise coming from such corners as brokerage Goldman Sachs.

"Despite the cheerleading from Goldman Sachs," Citron said, "this week has seen a change in the media industry that cannot be ignored by any long-term Netflix investor."

Citron said the approval of AT&T's ( T) acquisition of Time Warner ( TWX) "is the first step in traditional media's efforts to compete against Netflix in the new streaming world."

Threats to Netflix's dominance include a combined AT&T and Time Warner as well as Walt Disney's ( DIS) proposed purchase of 21st Century Fox Entertainment ( FOXA), Citron said. Meanwhile, Amazon ( AMZN), Apple ( AAPL) and Alphabet's ( GOOGL) Google are stepping up their game in the streaming video market, it noted.

Netflix Stock Cheerleading

On Wednesday, Goldman Sachs pounded the table for Netflix. Analyst Heath Terry raised his 12-month price target on Netflix to 490 from 390 and reiterated his buy rating.

Citron trolled Goldman for its Netflix cheerleading. "The fact that Netflix hasn't created a series called 'Goldman' just means that it must have been killed in development," Citron said.

Goldman's Terry thinks 2018 will mark the negative cash flow bottom for Netflix. He expects shares to benefit as cash flow inflects positively in the coming years.

Netflix revenue growth should begin to outpace content spending growth next year, he said. That's ahead of significant positive cash generation in 2022, he added.

RELATED:

Comcast Launches Bid For Fox, Can All-Out War With Disney Be Avoided?

AT&T Can Buy Time Warner; Court Ruling To Ignite Comcast, Disney Brawl

The post Netflix Stock Spikes To Record High As Investors Ignore Short-Seller Call appeared first on Investor's Business Daily.


54. Grubhub Price Target Hiked, Restaurant Partnering For Mobile Apps SeenЧт., 14 июня[−]

Look for Grubhub ( GRUB) to partner with restaurant chains to provide ordering functionality on their mobile phone apps, one analyst said Thursday.

X

Under the "white label" partnerships, the company would also provide assistance in loyalty programs and digital marketing, Oppenheimer analyst Jason Helfstein said in a report to clients.

The analyst hiked his price target on the takeout-food delivery service to 130 from 100. Grubhub stock climbed 3.4% to close at 119.86 on the stock market today.

Shares in the company have shot up 66% in 2018. It ranks No. 4 in the IBD 50 roster of growth companies.

"Grubhub can leverage capabilities in personalization and loyalty already developed with its own platform while contributing incremental data to chain partners," Helfstein wrote. "And, Grubhub can leverage its capabilities in direct-to-consumer digital marketing to help white-labeled applications onto consumers' phones."

UberEats, DoorDash are rivals

The company operates an online and mobile platform for restaurant pickup and delivery orders. It competes with UberEats, Postmates and DoorDash.

Yum Brands ( YUM) recently spent $200 million to acquire a 3% stake in Grubhub, which also has delivery deals with privately held Subway, Papa John's ( PZZA) international business and The Cheesecake Factory ( CAKE).

"We believe this application will be leveraged for takeout and in-store ordering," added Helfstein in the report. "We note Grubhub is planning to offer a white-labeled mobile application as part of the Yum deal, which we believe is an important component, and has been overlooked by the street."

RELATED LINKS:

Big Restaurant Brands Dive Into Grubhub Era Of Delivery Rivalry

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Grubhub Price Target Hiked, Restaurant Partnering For Mobile Apps Seen appeared first on Investor's Business Daily.


55. How Trade Desk Stock Will Get A Boost From Google Regulatory WoesЧт., 14 июня[−]

Trade Desk ( TTD) is getting a boost from European regulatory pressure on Alphabet's ( GOOGL) Google and also could see long-term upside from AT&T's ( T) purchase of Time Warner ( TWX), Susquehanna Financial Group said Thursday.

X

Shyam Patil, a Susquehanna analyst, raised his price target on the provider of automated advertising technology to 105 from 81. Trade Desk stock has been on a tear since May 10 when it reported first-quarter results that blew past estimates. Trade Desk is ranked No. 5 in the IBD 50 roster of growth stocks.

"We think regulation has caused Trade Desk's top competitor, (Google's) Doubleclick, to make changes, which appear to be leading to global share losses to Trade Desk and others," Patil said in a report to clients.

Google acquired Double-Click for $3.1 billion in 2007, increasing its clout in the digital ad market. Trade Desk enables agencies and other ad buyers to purchase online advertising through its self-service platform.

Patil said Susquehanna checks show, "Google is extremely focused on avoiding any regulatory issues and is prioritizing protecting its core search and YouTube businesses over the seemingly lesser important advertising tech business."

AT&T Diversification A Plus

Shares in Trade Desk rose 0.5% to close at 90.53 on the stock market today. Trade Desk has nearly doubled in 2018. The stock popped 43% after it reported first-quarter profit and revenue that topped expectations.

The Susquehanna analyst also sees potential upside from AT&T's purchase of media firm Time Warner. AT&T aims to grow advertising revenue by melding its wireless business with content.

"Trade Desk is quickly becoming the best way to play the linear-to-digital-TV ad budget shift," said Patil. "We believe the AT&T/Time Warner deal is likely to be good news for the continued ramping of connected TV, and a positive for the programmatic space."

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post How Trade Desk Stock Will Get A Boost From Google Regulatory Woes appeared first on Investor's Business Daily.


56. Apple Services Business Faces Skepticism From Wall Street AnalystЧт., 14 июня[−]

Apple's ( AAPL) services business, a growth engine in recent quarters, is likely to encounter diminished returns soon, a skeptical Wall Street analyst said Thursday.

X

One of the most significant drivers of the company's services revenue has been AppleCare warranty programs. But that segment has grown largely because of price increases, Raymond James analyst Chris Caso said in a report. Caso rates Apple stock as market perform, or hold.

Another main services driver, the App Store, "is likely to suffer from a law-of-large-numbers problem," Caso said. As the installed base of iPhones matures, growth will be harder to come by, he said.

The company's services growth has been impressive, but is still tied to hardware sales, which are slowing, he said.

"Net, we find it difficult to argue services will be able to replace hardware sales as a growth driver" for Apple, Caso said.

Revenue Up 31%

In the March quarter, services revenue increased 31% year over year to $9.19 billion. The company's total sales rose 16% to $61.14 billion in its fiscal second quarter.

"Services growth was the element that has allowed Apple to beat numbers despite maturing iPhone sales, and has become the biggest element of the bull case" for the stock, he said.

The company has set a goal of reaching about $48 billion in services revenue by fiscal 2020. Caso believes that goal is "reasonably attainable" because it assumes a moderation in services growth to the low double-digit range.

The Cupertino, Calif.-based company doesn't break out the components of its services business. Caso believes it gets about 30% of its services revenue from AppleCare and about 35% from the App Store.

A Third Of Growth

Caso estimates AppleCare accounted for about a third of incremental services revenue growth over the past two years, while the App Store contributed about 40% of revenue growth in the same period.

Other services include Apple Pay, Apple Music and iCloud.

If the company wants to maintain the current pace of its services growth, it will need new services, Caso said. Advertising and a Netflix ( NFLX)-like streaming video service are possible growth drivers, he said.

Shares of the iPhone maker rose a fraction to close at 190.80 on the stock market today.

RELATED:

Apple iPhone Production Pullback Hits Chip Suppliers

The post Apple Services Business Faces Skepticism From Wall Street Analyst appeared first on Investor's Business Daily.


57. Qualys Stock Jumps On Revenue Outlook, Market ExpansionЧт., 14 июня[−]

Qualys ( QLYS) stock jumped after one brokerage raised its price target on the cybersecurity firm Thursday following the company's analyst day.

X

Qualys stock surged 6.4% to close at 94.80 on the stock market today. Needham on Thursday raised its price target to 105 from 95.

"Qualys effectively raised guidance by offering long-term (2021) guidance of sustained 20% top-line growth as their cloud continues to expand its functionality and drives both security and network management capabilities," Needham analyst Alex Henderson said in a report to clients.

The company, which sells security vulnerability management services, held its analyst day Wednesday. Watch a webcast of the company's analyst day here.

Qualys Taps Cloud Architecture

Morgan Stanley also raised its price target on Qualys but kept it below its current level, lifting it to 81 from 74. The brokerage maintained an equal-weight rating on shares.

"With its highly scalable cloud architecture, Qualys has been quick to market with additional solutions that span beyond vulnerability management, positioning Qualys well for the trend of greater consolidation of functionality in security," said a Morgan Stanley report.

IBD's Computer-Software Security group is ranked No. 7 out of 197 industry groups. Fortinet ( FTNT), Palo Alto Networks ( PANW) and Qualys have the highest Composite Ratings.

Qualys in April reported first-quarter revenue and earnings that topped views and forecast in-line June quarter profit and sales.

For its second quarter, Qualys forecast adjusted profit of 34 cents a share, in line with estimates. The cybersecurity firm said it expects revenue in a range of $66.8 million to $67.3 million, with the midpoint above estimates of $66.9 million.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Qualys Stock Jumps On Revenue Outlook, Market Expansion appeared first on Investor's Business Daily.


58. Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIVЧт., 14 июня[−]

GlaxoSmithKline ( GSK) popped to an 11-month high Thursday after its two-drug HIV treatment proved non-inferior to a three-drug regimen using medicine from Gilead Sciences ( GILD).

X

On the stock market today, Glaxo shares jumped 1.9% to close at 41.94. Glaxo stock is forming a cup base with a buy point at 44.63. Gilead shares lifted 0.6% to close at 71.15.

But analysts say Glaxo is unlikely to get much share from Gilead in HIV. A dual regimen looks competitive under ideal circumstances. In the real world, even very sick patients don't always take their medicine. This means they could become resistant to the drugs.

"We think concerns over potential for resistance emergence with real-world use will limit the adoption of this dual regimen," RBC analyst Brian Abrahams said in a note to clients. "We do not see much incentive for physicians to prescribe dual HIV cocktails and take any chances."

Comparing HIV Treatments

Glaxo and ViiV Healthcare tested a combination of their drugs Tivicay and Epivir, respectively, in a group of never-before-treated HIV patients. It compared that regimen to another using a two-drug combo from Gilead called Truvada plus its own Tivicay.

Tivicay plus Epivir was not inferior to the three-drug regimen at 48 weeks. None of the patients who experienced virological failure developed treatment-related resistance, Glaxo said in a news release. Virological failure occurs when the treatment doesn't sufficiently suppress the virus.

But "key details such as the rates of virological failure, which would be important to understand how competitively this regimen behaves, were not yet disclosed," Abrahams said. Glaxo said to expect further data at an upcoming medical conference.

From a real-world perspective, it will be important to look at patients who didn't always take their medicine, Evercore analyst Umer Raffat said in a report.

Safety Concerns

Abrahams notes it's in ViiV's best interest to push a two-drug regimen. The biotech previously tested a three-medicine combination that included abacavir. Abacavir had safety issues including hypersensitivity and the potential for cardiovascular risks.

"Gilead's triple regimens, such as Biktarvy, do not share these liabilities," he said. "And with the advent of (Gilead's tenofovir alafenamide), long-term renal/bone safety issues for Gilead's regimens have been mitigated."

Further, there have been questions regarding liver toxicity and birth defects tied to Glaxo's drug Tivicay. This could also limit the appeal of any new regimens containing Tivicay, he said.

RELATED:

How To Invest In Stocks For Free: New Apps Aim For Beginners

New Option Strategy Limits Risk Around Earnings

Still The No. 1 Rule For Stock Investors: Always Cut Your Losses Short

The post Glaxo Pops But Analysts Say It's Unlikely To Swipe Gilead Share In HIV appeared first on Investor's Business Daily.


59. How Atlassian Stacks Up Versus ServiceNow, Microsoft In EnterpriseЧт., 14 июня[−]

Atlassian ( TEAM) is making inroads into ServiceNow's ( NOW) customer base while Microsoft's ( MSFT) recent acquisition of GitHub will not pose a big problem for the software maker, one analyst said Thursday.

X

Microsoft on June 4 agreed to buy GitHub, a leading software development platform, for $7.5 billion in stock, which means Microsoft could compete more directly with Atlassian. But William Blair analyst Bhavan Suri says Atlassian might get a boost because "some GitHub customers have started looking for alternative solutions after hearing the Microsoft news."

"We believe the company is seeing acceleration in larger deployments of Jira service desk," Suri said in a report to clients. "Not only are these deployments driving current growth, but also we believe these larger customers could serve as a significant source of expansion in the future. Although some of the product functionalities are similar to ServiceNow, both Jira service desk and ServiceNow can be deployed side-by-side within an organization."

U.K.-based Atlassian sells project-management and collaborative software in the enterprise market — large companies and government agencies. It ranks No. 29 in the IBD 50 roster of growth stocks while ServiceNow is ranked No. 16.

More Mergers?

Suri expects Atlassian to make more acquisitions. The company bought Trello in early 2017 for $425 million.

Atlassian climbed 0.5% to close at 66.49 on the stock market today. Atlassian is trading 3% below a technical buy point of 68.85 coming from an ascending base chart pattern.

The enterprise software maker's stock is up 93% from a year ago. Suri says the stock can climb further, despite a high trading multiple.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post How Atlassian Stacks Up Versus ServiceNow, Microsoft In Enterprise appeared first on Investor's Business Daily.


60. Headset Maker Turtle Beach Riding High From 'Fortnite Effect'Чт., 14 июня[−]

LOS ANGELES – Turtle Beach ( HEAR), the leading maker of video-game headsets, has been riding high thanks to esports and what it calls "the Fortnite effect."

X

The growth in online multiplayer gaming, most recently with "Fortnite: Battle Royale," has fueled the need for headsets so players can communicate with teammates and listen for approaching enemies.

San Diego-based Turtle Beach felt the impact of the Fortnite phenomenon in its first-quarter financial results.

On May 9, the company reported a 185% year-over-year increase in sales, to $40.9 million in the March quarter. Its gross profit margin more than doubled to 36.8% vs. 15.4% a year earlier. Turtle Beach earned 16 cents a share in the first quarter, vs. a year-earlier loss of 81 cents a share.

Turtle Beach also significantly increased its outlook for the rest of the year.

758% Gain

Its stock has been on a tear since the company completed a 1-for-4 reverse split effective April 6. Since then, it has risen 758% through Thursday, when it closed at 21.67, down 3%.

Turtle Beach credited market share gains on top of a very strong overall market, propelled by the successes of "Fortnite" and similar game "PlayerUnknown's Battlegrounds" from Bluehole. Those games have brought new gamers to the market.

Turtle Beach has had more than 40% market share in console gaming headsets for nine straight years, company spokesman MacLean Marshall said at the E3 video game conference Wednesday. The three-day video game trade show ends Thursday.

"There are more competitors in the space today but we're still maintaining our market share," he said. "We have the biggest headset variety for gamers of all walks of life."

It has entry-level headsets for casual gamers that cost $60 or less, on up to premium headsets for esports professionals that cost $300.

Competitors include HyperX, Logitech ( LOGI), Razer, Sennheiser and SteelSeries.

Turtle Beach Launches New Headsets At E3

On Tuesday at E3, Turtle Beach announced its latest low-cost headsets with advanced technologies that have migrated down from more expensive models. The Recon 200 and Stealth 300 models are priced at $59.95 and $79.95, respectively.

Both are well suited for the battle royale genre of games with "high-quality audio, crystal-clear chat, and unmatched comfort and durability," the company said in a press release.

Headset makers like Turtle Beach hope the launch of "Fortnite" on Nintendo's ( NTDOY) Switch console will attract even more headset buyers. Nintendo announced Tuesday that it had brought the popular title to Switch. That console can convert from a living-room game machine to a portable device with its built-in display.

"There hasn't been a need for headsets on the Switch until now," Marshall said.

Like other headset makers, Turtle Beach has partnered with esports teams and prominent gaming video streamers to bolster its reputation.

For full-year 2018, Turtle Beach now expects net revenue to increase 37% to $205 million, vs. its March outlook for $157 million. It predicts earnings per share of 95 cents, compared with its earlier forecast for a loss of 12 cents a share. It lost 26 cents a share in 2017.

RELATED:

'Red Dead' Game Not Threatened By Stiff Competition, Take-Two CEO Says

Nintendo, Sony, Ubisoft Bring Out Big Guns At E3 Video Game Show

Esports, Video Conferencing Trends Fuel Logitech Gains

The post Headset Maker Turtle Beach Riding High From 'Fortnite Effect' appeared first on Investor's Business Daily.


61. Investors Should Cut Mylan 'Some Slack' On Delayed Generic — But Haven'tЧт., 14 июня[−]

Investors didn't cut Mylan ( MYL) any slack Thursday after the company announced that U.S. regulators will likely delay its generic version of blockbuster asthma inhaler Advair.

X

On the stock market today, Mylan tumbled 5.2% to close at 39.51. Meanwhile, shares of generic pharmaceutical companies dipped 0.8%. GlaxoSmithKline ( GSK), which developed asthma inhaler Advair, advanced 1.9% to 41.94.

The Food and Drug Administration found "minor deficiencies" in Mylan's application for its generic Advair. It will likely issue a complete response letter, rejecting the application. The news isn't entirely surprising, Mizuho analyst Irina Koffler said.

Koffler argued that the announcement is a "cosmetic setback" after Mylan gained approval for a biosimilar of Amgen's ( AMGN) Neulasta. The drug is a bone marrow stimulant that generated north of $4.5 billion in 2017 sales.

"If your corporate strategy is trailblazing complex generics and high-value biosimilars, it's only natural to have a more difficult pathway," she said in a report. "We say cut them some slack."

Small Chance Of Lengthy Delay

Koffler kept her buy rating and 51 price target on Mylan, and still models $71.5 million in 2018 sales of generic Advair. In 2020, she sees generic Advair sales hitting a peak at $365.3 million. Mylan kept its outlook for 2018 total sales of $11.75 billion to $13.25 billion.

Mylan's application for generic Advair received a priority designation from the FDA. That means it could grab approval prior to the standard 90-day time period after Mylan responds to the minor deficiencies.

"Though we don't currently know how long it will take the company to gather the information to compile the response, and what it will entail, we believe that risk associated with a lengthy delay is modest at this point," Koffler said.

Glaxo's full-year guidance assumes that a competitor will bring generic Advair to market in mid-2018. In that scenario, it models about $998 million in U.S. sales of Advair for the year. Adjusted earnings per share is expected to be flat to down 3% on a constant-currency basis.

Advair brought in about $4.17 billion in global sales in 2017. Of that, about $2.14 billion came from the U.S.

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Next Nvidia? Start With This Simple Routine

The post Investors Should Cut Mylan 'Some Slack' On Delayed Generic — But Haven't appeared first on Investor's Business Daily.


62. AI News: Artificial Intelligence Trends And Leading StocksЧт., 14 июня[−]

Investors beware: there's plenty of buzz around artificial intelligence (AI) as more and more companies say they're using it. In some cases, companies are using older data analytics tools and labeling it as AI for a public relations boost. But identifying companies actually getting material revenue growth from AI can be tricky.

X AI uses computer algorithms to replicate the human ability to learn and make predictions. AI software needs computing power to find patterns and make inferences from large quantities of data. The two most common types of AI tools are called "machine learning" and "deep learning networks."

Nvidia ( NVDA) is one company that can lay claim to AI-driven growth. Internet and tech companies buy its processors for cloud computing. Nvidia's AI chips also are helping guide some self-driving cars in early trials.

Startups are racing to build AI chips for data centers, robotics, smartphones, drones and other devices. Tech giants Apple ( AAPL), Google-parent Alphabet ( GOOGL), Facebook ( FB) and Microsoft ( MSFT) have forged ahead in applying AI software to speech recognition, internet search, and classifying images. Amazon.com's AI prowess spans cloud-computing services and voice-activated home digital assistants.

Then, there are tech companies that embed AI tools in their own products to make them better. Those include video streamer Netflix ( NFLX), payment processor PayPal ( PYPL), Salesforce.com ( CRM) and Facebook.

Customers of tech companies — spanning banks and finance, health care, energy, retail, agriculture and other sectors — are expected to increase spending on AI to get productivity gains or a strategic edge on rivals.

Bookmark this page to stay on top of the latest AI trends and developments.

Artificial Intelligence News

Intel CEO Resigns After Probe Of Improper Relationship With StafferIntel Chief Executive Brian Krzanich resigned Thursday as CEO and board member after an investigation revealed that he had an improper relationship with an Intel employee. The board of directors named Chief... Read More
AI And Blockchain Can Get Rid Of Marketing's 'Creep Factor'"Monica Kusaka in the redbrick brownstone on N. Damen Ave. across from the park, this lamp is for you. It combines your two favorite things: warm lighting and llamas." This was a... Read More
When It Comes to Data, Measure What Matters Businesses are collecting more data than ever before. But only 4% of companies use that data to its full potential, according to a PricewaterhouseCoopers and Iron Mountain report. Would you believe that... Read More
AI And Robotics Are Taking Robotic Surgery To New LevelsWith artificial intelligence now firmly entrenched in many hospital operating rooms, the field of robotic surgery is starting to get competitive. Giant companies like Alphabet, Johnson & Johnson and Medtronic are training... Read More
AI-Powered Stock Picks, Internet Giants Among New ETF LaunchesEquBot on Wednesday launched AI Powered International Equity, its second exchange traded fund that uses artificial intelligence to make its stock picks. The actively managed ETF invests in companies in foreign developed... Read More
Google's New Slogan: Don't Fight EvilThe original slogan of Google was "Don't be evil." When Google changed its corporate name to Alphabet in 2015, it changed the slogan to "Do the right thing." If it were to... Read More
Top Chip Stocks On The Move: Nvidia, Broadcom, IntelSeveral top chip stocks rocked on Wednesday amid positive data points including Broadcom, Intel and Nvidia. Broadcom shares climbed above their 200-day moving average after Longbow Research initiated coverage of the chipmaker... Read More

RELATED:

Technology Stocks And Related News

Looking For The Next Nvidia? Start With This Simple Investing Routine

The post AI News: Artificial Intelligence Trends And Leading Stocks appeared first on Investor's Business Daily.


63. Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster InhalerЧт., 14 июня[−]

Mylan ( MYL) shares plunged late Wednesday after the Food and Drug Administration identified "minor deficiencies" in its application for an Advair generic, a copy of GlaxoSmithKline's ( GSK) blockbuster asthma inhaler.

X

The generic drugmaker now expects the FDA to issue a formal complete response letter, which would delay approval for the Advair generic. Mylan said it would determine after it received the letter if there will be an impact on its 2018 outlook.

In after-hours trading on the stock market today, Mylan toppled 4.1%, near 40. The stock ended the regular trading session down 0.5%, at 41.67. Glaxo stock jumped 1.6%, near 41.80, after wrapping the regular session down 0.2%. Generic pharmaceutical stocks rose 0.5% at the closing bell.

Advair and Seretide — the drug's name outside North America — brought in about $4.19 billion in sales in 2017.

RELATED LINKS:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Best Stocks To Buy And Watch? Start Here

The post Mylan Tumbles On Likely Delay For Its Copycat Of Blockbuster Inhaler appeared first on Investor's Business Daily.


64. Comcast Launches Bid For Fox, Can All-Out War With Disney Be Avoided?Ср., 13 июня[−]

Comcast ( CMCSA) launched a takeover bid for 21st Century Fox Entertainment ( FOXA) on Wednesday, offering $65 billion in cash for Rupert Murdoch's entertainment company and at a 19% premium over Walt Disney's ( DIS) offer.

X

Comcast's takeover bid had been expected in the wake of AT&T's ( T) court victory late Tuesday that cleared its purchase of Time Warner ( TWX). The nation's largest cable TV firm has been waiting for a ruling on the AT&T-Time Warner merger before announcing a formal bid for Fox.

Comcast, which also owns NBCUniversal, has already bid $31 billion for satellite TV broadcaster Sky, in which Fox holds a 39% stake.

Disney, however, in November agreed to buy Fox — including its stake in broadcaster Sky — for $54.4 billion in an all-stock deal.

Can Bidding War Be Avoided?

Comcast fell 0.7% to 32 in after-hours trading on the stock market today while Disney slipped 0.3% to 105.90. Fox rose 1.6% to 44.13. In Wednesday's regular session, Fox popped 7.4% to 43.41. Comcast edged down 0.2% to 32.32. Disney gained 1.9% to 106.30.

While Wall Street fears a bidding war, one scenario is that the companies carve up Fox, with Comcast getting Sky as well as video streaming service Hulu and perhaps other assets.

Disney's deal includes Fox's stake in U.K.-based Sky, a film studio, cable networks and other assets. It excludes the Fox Broadcasting Network. Disney already owns broadcaster ABC.

One obstacle to a truce is the history between the companies. A much smaller Comcast tried to buy Disney in 2004 but was rebuffed.

AT&T Stock Falls

Meanwhile, AT&T fell 6% to 32.22, despite its court victory. One analyst said AT&T's fall may be tied to arbitrage over the Time Warner transaction. MoffettNathanson also downgraded AT&T to sell.

The Department of Justice sued in November 2017 to block AT&T's $85 billion acquisition of Time Warner on grounds that the merger could hurt competition in the pay-TV industry.

Shares in CBS ( CBS), Lions Gate Entertainment ( LGF), Discovery Communications ( DISCA) and other media firms rose in the wake of AT&T's ( T) court victory.

The landmark antitrust victory over the U.S. Department of Justice is expected to open the door to more acquisitions of media assets by telecoms or even internet companies, such as Amazon.com ( AMZN).

Media Stocks Gain

Viacom ( VIA) gained 0.7% to 33.55 while CBS was up 3.6% to 54.27. Discovery rose 1.6% to 24.41. Lions Gate closed up 3% to 24.87 after jumping nearly 9% earlier. Media and cable TV industry baron John Malone owns stakes in Discovery, Lionsgate and Starz.

Malone is chairman of Liberty Media ( LSXMA). Malone's Liberty Broadband ( LBRDA), meanwhile, is the biggest shareholder in Charter Communications ( CHTR). Charter fell 2% to 285. Charter is the second-biggest cable TV firm behind Comcast.

Shares in Dish Network ( DISH) climbed 1.4% to 32.86.

Verizon Communications ( VZ) fell 3% to 47.40. Verizon has stated that it's not interested in buying large media assets.

RELATED LINKS:

How Big Is The AT&T-Time Warner Ruling? Even These Stocks Are Rallying

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Comcast Launches Bid For Fox, Can All-Out War With Disney Be Avoided? appeared first on Investor's Business Daily.


65. Biotech Stock Loses Steam, But Analysts Still Bullish On Depression DrugСр., 13 июня[−]

Sage Therapeutics ( SAGE) lost some of its steam Wednesday, but analysts remained bullish on the biotech company's plans for an acute depression treatment.

X

On the stock market today, Sage dipped 3.6% to close at 169.52. Earlier, shares fell as much as 5.7%. The stock is consolidating with a buy point at 188.92. On Tuesday, it jumped nearly 20% at the close, wrapping the session at 175.76. That was due to bullish sentiment on Wall Street over Sage's drug, SAGE-217.

Researchers are looking at the drug as a treatment for major depressive disorder and postpartum depression. Doctors would administer it over a short period of time — like an antibiotic — rather than chronically.

"We view SAGE-217 as a potential game-changer if the company successfully demonstrates that depression can be treated episodically vs. current practice that relies on chronic treatment," Canaccord analyst Sumant Kulkarni wrote in a note to clients.

FDA Backs Development Plans

The biotech company already has backing from the Food and Drug Administration for its development plans. It will run a single additional study in major depressive disorder. Then it can use an ongoing study in postpartum depression to support its approval for that use.

FDA officials will also consider Sage's brexanolone as a postpartum depression treatment in December. But Kulkarni sees data from a study of SAGE-217 for the same use as the bigger stock catalyst given the insights it could lend to its use in major depressive disorder.

"While the results of the earlier (major depressive disorder) trial were very robust, we note trials involving drugs targeting central nervous system indications have historically tended to be relatively more unpredictable in their outcomes," he said.

Kulkarni boosted his expectations for Sage-217 getting approval in postpartum depression and major depressive disorder to 55% from 50%. He also sees Sage as 50% likely to get approval for the drug as an insomnia treatment.

He reiterated his buy rating and upped his price target to 220 from 210.

Changing Depression Treatment Strategy

Raymond James analyst Laura Chico is similarly bullish. She has a strong buy rating on the biotech company.

"We acknowledge that changing the face of depression treatment and shifting toward an acute model is no small undertaking," she said in her report to clients. "That being said, should Sage demonstrate Phase 3 success, we think they will have a compelling asset to make just such an argument."

RELATED:

How Much Volume Should You Look For In A Stock?

Long-Term Retirement Investing Strategies With ETFs

Still The No. 1 Rule For Stock Investors: Always Cut Your Losses Short

The post Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug appeared first on Investor's Business Daily.


66. Two Top Chip-Gear Stocks Hit With Downgrades While One UpgradedСр., 13 июня[−]

A Wall Street analyst on Wednesday downgraded top semiconductor-equipment stocks Applied Materials ( AMAT) and Lam Research ( LRCX), but upgraded a third, ASML Holding ( ASML).

X

RBC Capital Markets analyst Mitch Steves sees demand softening for wafer fabrication equipment and organic light-emitting diode, or OLED, display gear, negatively impacting Applied Materials and Lam. But ASML will benefit from deployments of extreme ultraviolet (EUV) lithography equipment for etching chips, he said.

Steves lowered his rating on Applied Materials to sector perform from outperform and cut his 12-month price target to 55 from 64. He downgraded Lam to sector perform from outperform as well and slashed his price target to 210 from 245.

Applied Materials stock gained 0.2% to close at 50.98 on the stock market today. Lam shares fell 1.3% to 184.59.

Steves upgraded ASML to outperform from sector perform and raised his price target to 235 from 218.

ASML shares climbed 2.1% to 213.75.

Positive Outlook Longer Term

Steves has a positive outlook on chip-equipment stocks longer term, but thinks 2019 will be "a muted year before returning to growth."

He expects wafer fab equipment spending will be flat to down next year. However, one significant area of growth in the industry will be in EUV systems from ASML, he said.

"For investors that need exposure to the group, we would recommend buying ASML," he said in a report. "With potential monopoly pricing due to EUV we think the near-term headwinds in semi-cap will be offset by this opportunity."

RELATED:

Apple iPhone Production Pullback Hits Chip Suppliers

Broadcom Beats Wall Street's Fiscal Second-Quarter Targets

The post Two Top Chip-Gear Stocks Hit With Downgrades While One Upgraded appeared first on Investor's Business Daily.


67. Banking Industry's Zelle Seen Outgrowing Square Cash, PayPal's VenmoСр., 13 июня[−]

Zelle, a person-to-person mobile payment service launched by 30 U.S. banks, is poised to grow faster than competing apps from Square ( SQ) and PayPal Holdings ( PYPL), says a market researcher.

X

Zelle's backers include JP Morgan ( JPM), Bank of America ( BAC), Wells Fargo ( WFC), U.S. Bancorp ( USB), and Capital One Financial ( COF).

The banks launched Zelle last year, taking on PayPal's Venmo app, Square Cash and Apple ( AAPL).

Research firm eMarketer estimates that Zelle will end 2018 with 27.4 million users, up from 15.8 million last year. PayPal's Venmo will have 22.9 million users vs. 17.3 million a year earlier, says eMarketer.

Square Cash will have 9.5 million users, up from 6.9 million, it says. EMarketer does not have a forecast for Apple's P2P app.

Zelle lead to grow by 2022

By 2022, eMarketer estimates that Zelle will have 56.1 million users vs. 38.7 million for Venmo and 16.2 million for Square Cash.

While the money-transfer services are mostly free for consumers, PayPal and Square aims to get fees from merchants that accept the money transfers as payment.

Shares in JP Morgan, Bank of America, Wells Fargo, U.S. Bancorp, and Capital One all edged down fractionally on the stock market today.

Square dipped 1.1% to close at 62.50 while PayPal gained 0.3% to 85.27. Square has surged 159% from a year ago. PayPal has popped 64%.

PayPal stock has been consolidating is trading just below a technical buy point of 86.42. Square's chart has formed a cup-with-handle pattern.

RELATED LINKS:

PayPal Buddies Up To Visa, Mastercard — And New Accounts Roll In

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Banking Industry's Zelle Seen Outgrowing Square Cash, PayPal's Venmo appeared first on Investor's Business Daily.


68. 'Red Dead' Game Not Threatened By Stiff Competition, Take-Two CEO SaysСр., 13 июня[−]

LOS ANGELES — The release schedule looks crowded for major video games this fall, but that shouldn't be a problem for "Red Dead Redemption 2" from Take-Two Interactive Software ( TTWO), its chief executive says.

X

Take-Two CEO Strauss Zelnick told Investor's Business Daily he isn't concerned about the plethora of triple-A game releases set for the holiday season.

"A handful of big properties in the fall strikes me as probably good for the market," he said Wednesday at the E3 video game expo in Los Angeles. "One might argue that big hits in the marketplace increase the size of the market."

The company's highly anticipated Wild West action game "Red Dead Redemption 2" comes out on Oct. 26. Other big game releases include "Assassin's Creed: Odyssey" from Ubisoft on Oct. 5, "Call of Duty: Black Ops 4" from Activision Blizzard ( ATVI) on Oct. 12 and "Battlefield 5" from Electronic Arts ( EA) on Oct. 19.

"I think people believe as we do that 'Red Dead' will be a big release and are not anxious to crowd the release date," he said.

When there are a lot of great movies in theaters, people go more often, Zelnick said. When there are a lot of great new games, people will consume more, he said.

For instance, Take-Two reported record sales last fiscal year for two big game franchises — "NBA 2K" and "Grand Theft Auto Online" — even while "Fortnite" from Epic Games racked up big usage numbers, he said.

Not Copying 'Fortnite'

Speaking of "Fortnite," Take-Two isn't interested in copying that battle royale game and its ilk, Zelnick said.

"Being derivative of other people's properties is not a recipe for success in entertainment," he said. "We've had battle royale modes in our games before and I imagine we will in the future. But we're not going to redefine our product line through the lens of someone else's success."

Take-Two hopes to imitate its own success in"GTA Online" by creating an online subscription service for "Red Dead" players.

"There will be an online offering for 'Red Dead,'" he said. "(Game studio) Rockstar hasn't given out a lot of detail yet on what that will look like, but I'm quite certain it will stand alone and it will look like nothing you've seen before."

Take-Two's Esports Plans

A big topic at E3 this year has been the growth of esports and professional video gaming. Take-Two has partnered with the National Basketball Association for the NBA 2K League.

Take-Two isn't planning any more esports offerings, Zelnick said.

"We're focused on NBA 2K," he said. "Right now, the esports business is largely driven by 'League of Legends' in terms of revenue and the business. 'Overwatch' and others have made some headway."

"We think in the fullness of time, there will be about five big esports businesses," Zelnick said. "We would very much like to be one of them."

RELATED:

This Video Game Tries To Stand Out From The Usual Esports Crowd

Take-Two Outlook Seen Bright Thanks To 'Red Dead' Game

The post 'Red Dead' Game Not Threatened By Stiff Competition, Take-Two CEO Says appeared first on Investor's Business Daily.


69. Stryker Says It's Not Planning To Acquire Boston ScientificСр., 13 июня[−]

Medtech player Stryker ( SYK) said Wednesday it isn't in discussions to acquire Boston Scientific ( BSX), prodding Stryker shares to pop as Boston Scientific stock toppled.

X

"Stryker is not in discussions with Boston Scientific Corporation regarding a potential acquisition," the firm said in a filing with the Securities and Exchange Commission.

On the stock market today, Stryker shares climbed 2.5% to close at 166.90. Its stock had slid 9.2% over the previous two sessions. Boston Scientific, on the other hand, tumbled 6.2% to 31.73. That reversed two days of gains.

RBC analyst Glenn Novarro noted the recent stock decline would have made a potential Boston deal less favorable financially. He had expected the medical supplier would have to pay $40 per share or more in the deal.

"Assuming a 50%/50% split between debt/equity for the deal, we estimate the decline in Stryker's shares post the (Wall Street Journal) story would have forced Stryker to issue an additional 17 million in shares for the potential Boston Scientific deal," he said in a note.

Value Challenges

Overall, there was some strategic rationale for the deal, but creating value would have been a challenge, Novarro said. He reiterated his outperform rating on Stryker. He also called the pullback on Monday and Tuesday a "buying opportunity."

Dow Jones component Johnson & Johnson ( JNJ) is a better acquirer for Boston, he said. Further, valuations on potential pure-play spine targets could move higher "as Stryker still has firepower and the appetite for deals," he said.

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How Much Money Do You Need To Start Investing?

When To Sell Great Stocks: Take Profits Regularly, Mostly At 20%-25%

The post Stryker Says It's Not Planning To Acquire Boston Scientific appeared first on Investor's Business Daily.


70. This Video Game Tries To Stand Out From The Usual Esports CrowdСр., 13 июня[−]

LOS ANGELES — Esports are a big theme at this year's E3 video game expo, but the primary focus has been on fighting games. The NBA 2K League is trying to stand out from the crowd with its professional esports league built around Take-Two Interactive Software's ( TTWO) popular basketball simulation game.

X

The NBA 2K League, a joint venture of the National Basketball Association and Take-Two, brought league officials and three top players to E3 Tuesday for a media roundtable.

Now in its inaugural season, the NBA 2K League has faced a good amount of skepticism. Critics wonder whether fans will want to follow a virtual sport when a real-world version of the game already exists.

Brendan Donohue, NBA 2K League managing director, said the league has a number of business advantages compared with other esports for games like "League of Legends" from Tencent ( TCEHY)-owned Riot Games or "Overwatch" from Activision Blizzard ( ATVI).

"Compared to other (esports) games, we are rated E, so partners feel comfortable putting their brand next to the NBA 2K brand," he said. Games rated E for "everyone" by the Entertainment Software Rating Board are suitable for players of all ages.

NBA 2K League partners include Intel ( INTC), Dell's Alienware division, State Farm, Jordan Brand at Nike ( NKE), New Era Cap, HyperX and Scuf Gaming.

Also, the rules of basketball are understood worldwide, so the esport version is easy to follow, Donohue said.

"With a lot of traditional esports, if you don't play that game, it can be pretty intimidating in terms of actually understanding what's going on," Donohue said. "We're lucky that our game is globally recognizable."

Esports At E3 2018

Several companies were hosting esports competitions at E3 this week. They included Epic Games with "Fortnite: Battle Royale" and Tencent with "Arena of Valor." Nintendo ( NTDOY) held tournaments for its games "Splatoon 2" and "Super Smash Bros."

Research firm Newzoo expects the global esports industry to grow to more than $900 million in revenue this year and $1.4 billion by 2020. By 2021, the global esports audience is forecast to exceed 550 million people.

Top NBA 2K League Players Meet Fans

NBA 2K League brought three of its top players to E3 to meet with fans, media and sponsors; Shaka Browne, known as "Yeah I Compete," of Jazz Gaming; Artreyo Boyd, or "Dimez," of Mavs Gaming; and Dayne Downey, or "OneWildWalnut," of Blazer5 Gaming.

Those professional gamers are "great ambassadors for the league," Donahue said.

The NBA 2K League features the 102 best NBA 2K players in the world, he said. The 17 teams in the league chose them following two stages of qualifying and out of 72,000 hopefuls.

Teams compete in five-on-five gameplay using unique characters, not existing NBA players. The Season 1 matches are taking place in a studio in New York City. Teams fly in weekly from their respective cities. Games are streamed on Amazon ( AMZN)-owned Twitch.

The season runs for 17 weeks, beginning in May and ending in August. There are 12 weeks of weekly matchups, followed by three weeks of in-season tournaments and two weeks of postseason play.

Plans For Second Season Underway

The league is already planning for the second season, Donohue said. It is looking to add more teams, perhaps even outside the U.S., he said.

"Our NBA owners are extremely bullish on esports," Donohue said, and not just in the NBA 2K League. Riot Games recently sold 10 franchises for a "League of Legends" professional league in North America and seven of those have NBA ownership, he said. "League of Legends" is a multiplayer battle arena game with fantasy and horror elements.

"The esports space is growing very fast and the 2K game itself has exploded," he said.

Take-Two sold about 9 million copies of "NBA 2K17" worldwide. The current edition, "NBA 2K18," is on pace to be the best-selling release in the history of the game franchise.

NBA 2K has 1.6 million daily active users and 5 million monthly users.

RELATED:

Nintendo, Sony, Ubisoft Bring Out Big Guns At E3 Video Game Show

Esports, Videoconferencing Trends Fuel Logitech Gains

Global Esports Revenue Forecast To Top $905 Million In 2018

The post This Video Game Tries To Stand Out From The Usual Esports Crowd appeared first on Investor's Business Daily.


71. AT&T Can Buy Time Warner; Court Ruling To Ignite Comcast, Disney BrawlСр., 13 июня[−]

AT&T ( T) can go ahead with its acquisition of Time Warner ( TWX), a U.S. District Court judge said late Tuesday, in a ruling that ignited a wave of late trading in telecom and media stocks.

X

U.S. District Judge Richard Leon made the ruling after U.S. stock markets closed on Tuesday. Leon set no conditions on the AT&T takeover.

Despite the win, AT&T fell 1.8% to 33.74 in after-hours trades. Time Warner rose 4.7% to 100.70. One analyst said AT&T's slip may involve arbitrage related to the Time Warner transaction.

The Department of Justice sued in November 2017 to block AT&T's $85 billion acquisition of Time Warner on grounds that the merger could hurt competition in the pay-TV industry. AT&T argued that it needs Time Warner's assets to compete with Netflix ( NFLX), Amazon.com ( AMZN) and Alphabet's ( GOOGL) Google in the entertainment business.

If the Justice Department were to appeal a ruling favorable to AT&T, that could be a problem for the telecom conglomerate. In that event, Time Warner would have the option of walking away from the deal or renegotiating terms with AT&T. The merger agreement expires on June 21.

Leon late Tuesday said he wouldn't grant a stay if the government requested one.

Comcast, Disney Effects

The ruling in the landmark antitrust case sent shares in Comcast ( CMCSA) and Walt Disney ( DIS) down as investors now anticipate a bidding war over 21st Century Fox ( FOXA). Fox rose 4.8% to 42.50, while Comcast fell 3.6% to 31.25. Shares in Disney were down 1.9% to 102.34.

Judge Leon's ruling is expected to open the door to more acquisitions of media firms by telecom companies that distribute content over broadband and wireless networks.

Comcast could launch an all-cash bid for Rupert Murdoch's Fox as soon as Wednesday. Disney in November agreed to buy Fox — including its stake in Sky — for $54.4 billion in an all-stock deal.

Comcast, which already owns NBCUniversal, has reportedly arranged financing for an all-cash bid. The nation's largest cable TV firm has been waiting for a ruling on the AT&T-Time Warner merger before announcing a formal bid for Fox. Comcast has already bid $31 billion for satellite TV broadcaster Sky, in which Fox holds a 39% stake.

The court ruling sent other media stocks up in late trades. CBS ( CBS) rose 1.8% to 53.35. John Malone's Discovery Communications ( DISCA) climbed 2.9% to 24.72. Lions Gate Entertainment ( LGF) shot up 5.6% to 25.48. Charter Communications ( CHTR) climbed 1.5% to 295.50.

Also, shares in Verizon Communications ( VZ) edged up 0.3% to 49. Verizon has stated it's not interested in buying large media assets. But Sprint ( S) and T-Mobile ( TMUS) have stated their interest in a marriage. Sprint jumped 3.8% to 5.50 while T-Mobile climbed 1.6% after hours and was near 59.

Too Much Clout?

AT&T and Time Warner announced their merger in October 2016.

Many analysts had expected AT&T to prevail. Before the court ruling, Time Warner stock traded 10% below AT&T's 107.50-per-share offer. That indicated some investors still thought a DOJ win possible.

In Tuesday's regular session, AT&T shares gained 0.5% to close at 34.35 on the stock market today. Time Warner ticked up less than 0.1% to 96.22.

RELATED LINKS:

How Big Is The AT&T-Time Warner Ruling? Even These Stocks Are Rallying

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post AT&T Can Buy Time Warner; Court Ruling To Ignite Comcast, Disney Brawl appeared first on Investor's Business Daily.


72. AI And Robotics Are Taking Robotic Surgery To New LevelsСр., 13 июня[−]

With artificial intelligence now firmly entrenched in many hospital operating rooms, the field of robotic surgery is starting to get competitive.

X

Giant companies like Alphabet ( GOOGL), Johnson & Johnson ( JNJ) and Medtronic ( MDT) are training their sights on Intuitive Surgical ( ISRG), the king of robotic surgery companies. But analysts say the booming medical technology segment has lots of room to run.

Robotic surgery is an area that could grow by billions of dollars as more machines are used to treat patients. Intuitive commands the space with $3.3 billion in annual sales. Its signature da Vinci robotic surgeons, however, are limited in the types of procedures they handle. The multi-limbed da Vinci can be used in a variety of procedures — including cardiac, colorectal, gynecological, head and neck, thoracic and urologic surgeries — but only as long as they're minimally invasive.

How big the market could be is still unclear, yet analysts agree the potential has yet to be tapped. So more players are moving in, and quickly.

"I think investors need to understand that the robotics and AI (artificial intelligence) revolution is happening, and it's touching every sector of the economy," said Jeremie Capron, the director of research and managing partner for Robo Global, an index and advisory firm specializing in robotic industry investments. "This is a technological revolution that investors can't afford to miss."

Medical Technology Applications

Analysts say that in March, Auris Health became the first company to pose a formidable threat to Intuitive when its catheter-based Monarch Platform gained U.S. approval. Intuitive will counterpunch by seeking approval for a flexible catheter similar to the Auris device, likely this year, RBC analyst Brandon Henry said in a recent report.

Meanwhile, others are working in areas where Intuitive Surgical doesn't have a foothold. Smith & Nephew ( SNN) has a robotic assistant for knee replacements. Stryker ( SYK) has a robotic joint replacement system. Mazor Robotics ( MZOR) and Zimmer Biomet ( ZBH) have robotic offerings in brain and spinal surgery. Mazor alone could see around $3 billion in sales just from its systems.

But these players have a long way to go to take Intuitive Surgical's throne.

In 2005, Intuitive had a market cap of $1.3 billion. Today, it's worth nearly $52 billion. Capron calls Intuitive "an amazing stock."

"I think the investment community has been scratching their heads trying to figure out the impact of those new entrants for Intuitive Surgical," he told Investor's Business Daily. "We feel pretty relaxed about it. The size is big enough for small players to come in."

Intuitive Surgical: A 'Blowout' Quarter

Shares of medical tech companies have been relatively insulated from the woes frustrating biotech and pharmaceutical stocks of late. The stocks of medical equipment makers such as Intuitive and Mazor have collectively spiked 15% year to date.

Intuitive's "blowout quarter" in April helped to spur excitement, Evercore analyst Vijay Kumar said in a recent note to clients. Recent investor days from J&J and Medtronic are helping to drive that frenzy.

"Robotic surgery is the topic currently in medtech with a blowout quarter from Intuitive Surgical hinting that the pace of manual-to-robotic transition might be picking up," Kumar said. "The topic of competition elicits various responses from investors."

Intuitive Surgical stock is up 33% this year, after climbing 78% in 2017. Kumar expects Intuitive Surgical's competition to become more apparent over the next 12 to 18 months. Intuitive's da Vinci Surgical System now boasts "five million patients and counting."

The da Vinci systems are also moving deeper into hernias and are seeing early-stage adoption in bariatrics surgery performed to induce weight loss.

Intuitive Surgical Opportunities

Myriam Curet, executive vice president and chief medical officer for Intuitive, noted in an email to IBD that an estimated 82% of prostatectomies in the U.S. are performed via robotic-assisted surgery. The same is true for about 80% of malignant hysterectomies.

"General surgery is our fastest-growing specialty, and one where we are still in early stages of adoption for procedures such as ventral and inguinal hernia repair, colorectal and bariatric surgery," she said. "We believe there is substantial opportunity to expand robotic usage in these categories, and we are developing additional tools and technologies to do so."

For the year, Intuitive guided on its first-quarter earnings conference call to 12%-15% growth in the number of procedures performed with its systems this year. That followed what many considered a strong fourth quarter in which recurring revenue — including instruments and accessories for its da Vinci systems — grew 11%. Recurring revenue represents 73% of the sales pie.

Still, even Intuitive Surgical sees itself in the early innings and expects robotic surgery to present a huge total addressable market. The number of da Vinci procedures performed each year grew nearly 68% from 2013 to 2017.

Among other robotic surgery companies, Intuitive's closest competitor, Auris, doesn't trade publicly. Until recently it was in "stealth mode," Kumar said. But in May the medical technology company signed a commercialization agreement with a division of J&J. The agreement came two months after Auris' Monarch system grabbed approval in the U.S.

Competition In Medical Technology

Monarch is a flexible catheter. Surgeons thread it through a patient's mouth and into the lungs by remote control. Before its approval, investors believed "credible competitors" to Intuitive would be years away, Kumar says. But Monarch got approval months ahead of views. Intuitive Surgical plans to seek approval of its own flexible catheter later this year.

On its website, Auris says Monarch's first target is lung cancer. Some experts estimate half a million lung biopsies are performed in the U.S. each year. Surgeons could also use flexible catheters in urinary tract procedures, which number roughly 400,000 procedures a year.

Intuitive isn't sweating the competition. Auris' chief executive, interestingly, is Frederic Moll, who founded Intuitive Surgical in 1995. Intuitive's current CEO, Gary Guthart, joined the medical technology firm in 1996 and took over as CEO in 2010.

"We have built technologies and made decisions about our architecture based on first principles, not by looking over our shoulder at what other people are doing, but by really engaging customers deeply and understanding their clinical needs," Guthart said on a recent earnings call.

RBC's Henry notes Auris' Monarch has a 25% larger catheter than Intuitive's to allow for its camera. Intuitive sees a benefit in a smaller catheter that can move deeper into the lungs, Henry wrote in a recent report. That would allow surgeons to potentially use it to remove diseased tissue.

Robotic Surgery Grows

Meanwhile, J&J has teamed up with Google on a company called Verb Surgical. Analysts are unsure what system the team is creating. They do expect it to enter the robotic surgery market in 2020, though.

At the same time, Medtronic is partnered with Mazor. Medtronic also expects its own robotic surgery system to launch in 2020.

It's not unreasonable to suggest Intuitive could keep 80% of the market, Evercore's Kumar told IBD. New robotic surgery companies will have to differentiate themselves.

"They can't have a straightforward, 'me too' product," he said. "Investors have put a pretty punchy marketable valuation on Intuitive Surgical because we're still in the early stages of this robotic conversation."

But, he added, "This market is big enough to sustain multiple players."

That's where companies like Mazor and Zimmer Biomet, which makes systems called ROSA, come in. Both have systems that surgeons use in brain and spinal procedures.

Robotic Surgery Companies: Target Market

Like others, Mazor CEO Ori Hadomi says sizing the opportunity for robotic surgery companies is difficult. Surgeons use the $1.1 million Mazor X system in spinal surgeries. The company's Renaissance system can perform spinal and brain surgeries and costs $500,000.

Disposable instruments and materials comprised 40% to 60% of Mazor's revenue, Hadomi told IBD. For each surgery performed with the Mazor X, the list price is $1,500 in terms of disposable items. An estimated half a million procedures would generate $750 million.

Stakeholders expect spine procedures to grow rapidly.

"People are being more and more active," he said, meaning they will suffer more injuries and require surgery more often. "The procedures will become less invasive. The safer the procedures will become, the more patients will be willing and interested to be treated, to be operated on."

The benefits of robotic surgery are plentiful, Hadomi says. Revision surgery — surgery to correct mistakes or tweak prior surgeries — are significantly lower with a robot assisting. The precision of the robot helps to curb potential errors, he says.

Research By Robotic Surgery Companies

Last October, Mazor unveiled the results of a 379-patient study. It found a fivefold reduction of complications for surgeries performed with its Mazor robotic surgery technology. Notably, there was also a sevenfold reduction in revision surgery compared with freehand lumbar fusion surgeries.

"There's no doubt from the patient's perspective, I would not consider going to surgery without the robot there knowing the chance of going through revision (surgery) is seven times higher," he said. Revision surgery is also costly for the hospital, which can face reimbursement hurdles.

All agree that robotic surgery won't replace human surgeons. Hadomi likens his system and others like it to "the toolbox of the surgeon". These are simply medical technology tools that make operating easier on the surgeon and safer for the patient, he says.

The benefits are also growing for investors, says Robo Global's Capron.

"What's really exciting is the fact that we are at an inflection point where the technologies that enable robotic surgeries and the price point are attractive," he said. "Now there's a lot of action around J&J and Medtronic. I see that as confirmation that this is a substantial, addressable market."

RELATED:

Looking For The Best Stocks To Buy And Watch? Start Here

Can CRISPR And These 3 Small Biotechs Cure 10,000 Diseases?

Amazon Vs. Walmart: Locking Horns In A Battle For Retail's Future

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Will Marijuana Industry Overtake Beer As Legalization Spurs Innovation?

The post AI And Robotics Are Taking Robotic Surgery To New Levels appeared first on Investor's Business Daily.


73. Why Dow's J&J May Try To Sweep Boston Scientific From StrykerВт., 12 июня[−]

Dow Jones component Johnson & Johnson ( JNJ) could engage in a bidding war to sweep Boston Scientific ( BSX) out from under Stryker ( SYK), an analyst said Tuesday following rumors the latter two could merge.

X

A report emerged Monday that Stryker approached Boston with a takeover bid. Boston shares spiked on the rumor as Stryker toppled. But Canaccord analysts say Stryker could be far from the only medical device maker with interest in Boston.

"If the headlines are substantiated and Stryker is in fact making a bid on Boston Scientific, we see a high likelihood that J&J could emerge as another potential bidder," they said in a note to clients. "J&J had been bantered about as a potential Boston Scientific acquirer for years, and if a bidding war emerges, we'd place a high likelihood on J&J being involved."

On the stock market today, Boston stock dipped 1.4% to close at 33.84. Stryker shares plunged 4.3% to 162.54. Even J&J stock looked somewhat dim, easing by a fraction to 122.54.

Will Stryker Acquire Boston Scientific?

The deal had analysts somewhat split on Tuesday.

"Regarding the materiality of this report, we do not find the potential of such a marriage to be shocking," Canaccord analysts said. "Indeed, we see merits to such a combination from the standpoint of product line synergies."

For Stryker, the acquisition would help it add products in sectors with higher potential for growth and in bigger markets. It would also help Stryker to differentiate its portfolio of technologies and compete with large companies like J&J and Medtronic ( MDT).

In Boston's case, the deal would cap a five-year turnaround, allowing it to "end on a high-note," Canaccord analysts said.

"In sum, we definitively think Boston Scientific is game to do a fair deal here," they said.

But RBC analyst Glenn Novarro viewed the deal "unfavorably," though acknowledged from a strategic rationale the it would make sense. It's also likely Boston won't OK any deal for less than $40 per share.

"It would combine two of the premier growth companies in the (medical device) space, and there would be limited product overlap," he said. However, "the bar for value creation is set high given the potential valuations of both companies."

Medtech Consolidation

A combined Stryker-Boston Scientific would have 2019 revenue of around $25 billion. It stands to grow at a sustainable 6% or higher compound annual growth rate in the medium term, Novarro said. It would have an enterprise value of about $61 billion.

Canaccord analysts called the potential deal a "merger of equals." Stryker is only about a third larger than Boston. It could also lead to further med-tech consolidation.

"If consummated, this would create four $100 billion behemoths in (medical devices) with Stryker/Boston Scientific joining Abbott ( ABT), J&J and Medtronic," they said. "We think Edwards Lifesciences ( EW) could be the next potential major acquisition target, but also highlight Smith and Nephew ( SNN) as being the last remaining 'pure-play' total joint operation on the market."

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Trade Stocks: Why Most Penny Stocks Fail To Make Investors Rich

The Basics: How To Analyze A Stock's Cup With Handle

The post Why Dow's J&J May Try To Sweep Boston Scientific From Stryker appeared first on Investor's Business Daily.


74. AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug HeapВт., 12 июня[−]

AstraZeneca ( AZN) and Eli Lilly ( LLY) became the latest Tuesday in a series of pharmaceutical companies to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.

X

The drugmakers discontinued Phase 3 studies of a drug called lanabecestat. An independent data monitoring committee predicted lanabecestat would miss its goals in studies in early Alzheimer's disease and in mild Alzheimer's dementia.

"The complexity of Alzheimer's disease poses one of the most difficult medical challenges of our time," Lilly Research Labs President Daniel Skovronsky said in a written statement. "We are grateful for the contributions of the study participants and their families."

Lanabecestat belongs to a class of drugs called BACE inhibitors, which work to prevent the buildup of a substance called beta amyloid plaque in the brain. Researchers believe the toxic substance is at the center of Alzheimer's disease.

Alzheimer's Disease Frustrations

AstraZeneca and Lilly are far from the only pharmaceutical companies frustrated in their pursuit of an Alzheimer's disease treatment. Dow Jones component Merck ( MRK) ended studies of its drug, verubecestat, in mild-to-moderate and early Alzheimer's disease.

Earlier this year, fellow Dow Jones stock Pfizer ( PFE) abandoned its research into treatments for Alzheimer's and Parkinson's diseases. In May, Johnson & Johnson ( JNJ) stopped studies of its BACE inhibitor in patients with late-stage Alzheimer's disease on liver worries.

In 2016, Lilly stock crashed after another drug missed its goals in a Phase 3 study. Lilly studied the drug, solanezumab, in patients with mild Alzheimer's disease.

The market is increasingly looking to Biogen, which is working on a monoclonal antibody. Its drug, known as aducanumab, works to remove beta amyloid plaques in the brain. Analysts expect Biogen to have data for its key study in 2019 or 2020.

Lilly said Tuesday it doesn't expect significant costs associated with its decision to end these studies of a potential Alzheimer's disease treatment. It reaffirmed its guidance for 2018 and its midterm guidance for the remainder of this decade.

"We are committed to ensuring our findings can be used to inform further research in the Alzheimer's community, given the importance of finding a treatment for this disease," said AstraZeneca spokesperson Menelas Pangalos in a statement.

On the stock market today, Lilly sank a fraction to close at 85.49. Shares are consolidating with a buy point at 89.19. AstraZeneca lost 0.6% to 36.16. Collectively, shares of pharmaceutical companies were flat.

RELATED:

How To Invest In Stocks For Free: New Apps Aim For Beginners

Should You Buy A Stock Ahead Of Its Earnings Report?

What Is Inflation, And Why Does It Matter To The Fed — And You?

The post AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap appeared first on Investor's Business Daily.


75. Why This Biotech Company Is Bounding Closer To A BreakoutВт., 12 июня[−]

Sage Therapeutics ( SAGE) bounded closer to a breakout Tuesday after the biotech company outlined its expedited path to approval for a depression treatment.

X

On the stock market today, Sage shares catapulted 19.6% to close at 175.75. The stock is consolidating with a buy point at 188.92.

The Food and Drug Administration will allow Sage to run a single additional study of its drug, SAGE-217, in major depressive disorder. U.S. regulators also said Sage could use an ongoing study in postpartum depression to support approval for that use.

Both studies will look at dosing SAGE-217 over a short period of time as a depression treatment, Chief Executive Jeff Jonas said in a written statement. Another study will look at episodic use of SAGE-217 in recurrent or new major depressive episodes.

"We are exploring the potential for patients with (major depressive disorder) to feel well within days, with just a two-week course of treatment — similar to how antibiotics are used today — instead of enduring long-term chronic treatment," he said.

Depression Treatment Plans

The FDA's findings allow the company to go ahead with its plans for the drug. Sage expects to have data from an ongoing study in postpartum depression in the fourth quarter. The study is evaluating SAGE-217 vs. a placebo in 140 patients.

The biotech company also plans to begin a Phase 3 study testing SAGE-217 in major depressive disorder in the second half of 2018. Researchers will look at two doses of SAGE-217 compared with a placebo in 450 patients.

"We believe a medicine with rapid onset and robust response could be truly paradigm shifting," Jonas said. "SAGE-217, if successfully developed and approved, may rewrite the textbook on how the tens of millions of people suffering from (major depressive disorder) are treated, ultimately turning depression into a disorder, not an identity."

FDA officials also support Sage's plan to look at SAGE-217 as a treatment for episodes of depression. Sage plans a study of 300 patients for six months and 100 patients for a year.

Sage also expects the FDA to approve its drug, brexanolone, as a postpartum depression treatment by year's end.

RELATED:

How Much Money Do You Need To Start Investing?

Long-Term Retirement Investing Strategies With ETFs

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post Why This Biotech Company Is Bounding Closer To A Breakout appeared first on Investor's Business Daily.


76. Twitter Stock Hits 3-Year High As Advertising Value Seen RisingВт., 12 июня[−]

Twitter ( TWTR) stock hit a three-year high Tuesday as a JPMorgan analyst raised his price target on the social networking company by 28%, based on expectations that advertising is strengthening.

X

JPMorgan analyst Doug Anmuth raised his price target on Twitter to 50 from 39, up 28%, and reiterated a rating of overweight. The new price target is a 17% premium from where the stock closed on Monday.

Anmuth said industry conversations suggest the value for advertisers on the company is increasing. That's a result of user growth showing a double-digit increase for the last six quarters.

The company also has improved its product for both users and advertisers, especially video. It's working through a business recovery that started in the third quarter of 2017.

Twitter shares surged 5% to close at 43.49 on the stock market today.

Anmuth thinks ad revenue growth will accelerate by 27% in the second quarter, from the year-ago quarter, and 29% in the third quarter. He also expects 21% growth in the fourth quarter, which likely remains conservative, he wrote.

Twitter A 'Top Idea'

"Twitter remains one of our top ideas, along with Facebook ( FB) and Amazon ( AMZN), and is on the JPMorgan Analyst Focus List," Anmuth wrote in a research note to clients. "And we believe considerable opportunity remains with large marketers."

In addition, the 2018 FIFA World Cup kicks off Thursday and lasts four weeks. Anmuth believes that will serve as a powerful platform for fans, enabling conversations during matches.

The World Cup is one of the most watched events, reaching a global television audience of 3.2 billion in 2014, according to FIFA.

Twitter reported first-quarter earnings on April 25 that blew past Wall Street forecasts, as did its guidance. Revenue rose 21% to $665 million, with adjusted earnings up 19%.

RELATED LINKS:

Twitter Gets Price-Target Increase, Announces Bond Offering

The post Twitter Stock Hits 3-Year High As Advertising Value Seen Rising appeared first on Investor's Business Daily.


77. Tesla Model 3 Production Tracking Up To 50% HigherВт., 12 июня[−]

Tesla ( TSLA) stock jumped Tuesday after a Wall Street analyst said Model 3 deliveries are tracking about 10,000 higher than previous estimates for the second quarter.

X

KeyBanc Capital Markets analyst Brad Erickson now expects Tesla to deliver between 30,000 to 35,000 Model 3 sedans. That's roughly 10,000 more than his prior estimate for the period ending June 30. It represents an increase of as much as 50%.

"We view this as one of the critical factors in Tesla maintaining its almost legendary status in the eyes of customers," Erickson wrote in a research note to clients.

Tesla shares jumped 3.2% to close at 342.77 on the stock market today. The stock climbed above its 200-day moving average for the first time since March 3. It hit a low of 244.59 on April 2, and is up 36% since then.

The company's profitability, and its future success, depends highly on its Model 3. The all-electric car is positioned as its first mass-produced vehicle. Tesla's stated initial goal is to produce 2,500 Model 3's per week, and ramping that to 5,000.

Tesla Turning Positive

"Our earnings and cash-flow estimates continue to reflect gross margin on the Model 3 turning positive in the third quarter," Erickson wrote. He maintained a rating of sector weight and believes a fair value on the stock would be $300 per share.

"Our rating is built on the core belief that there is significant premium built into the stock on perceptions of the company's innovative superiority around the five critical aspects of the story: manufacturing, batteries, software, AI, and competition," he wrote.

Tesla Chief Executive Elon Musk recently said it he expects to achieve positive net income in the third and fourth quarters. That excludes excluding noncash stock-based compensation. It also expects to achieve "full GAAP profitability" in each of those quarters.

On Friday, Nomura analyst Romit Shah said he believes gross margins for the automaker's Model 3 will improve as it scales to higher production, thus helping it achieve profitability. Shah raised his price target on the stock to 450 from 420 with a buy rating.

During the past few months, Musk says he has endured "production hell" with continuous Model 3 manufacturing woes as he wrestled with the media over negative coverage.

ELATED ARTICLES:

Concerns Mount Tesla Will Need To Raise Bundle Of Cash To Survive

Consumer Reports Gives Tesla Model 3 Its Recommendation After Retest

Tesla Seen Falling Short Of Model 3 Production Goals For A Year

The post Tesla Model 3 Production Tracking Up To 50% Higher appeared first on Investor's Business Daily.


78. Tesla Cutting 9% Of Staff As It Tries To Ramp Up Model 3 OutputВт., 12 июня[−]

Tesla ( TSLA) is cutting 9% of its workforce at a time when the electric-car maker is aggressively ramping production for its Model 3 sedan, the company said Tuesday.

X

"We are conducting a comprehensive organizational restructuring across our whole company," Chief Executive Elon Musk wrote in a memo to employees. "Tesla has grown and evolved rapidly over the past several years, which has resulted in some duplication of roles and some job functions that, while they made sense in the past, are difficult to justify today."

The cutbacks come at a time when Musk has said Tesla will be profitable in the third and fourth quarters. Musk also has talked about a restructuring of its production line, after failing to meet Model 3 goals. In May, Musk announced a " thorough reorganization," which coincided with a broader exodus of top executives.

Tesla started 2018 with about 37,000 employees globally and has hired thousands of employees since then. Year-to-date, Tesla's head count is up roughly 15%.

Won't Hit Model 3 Production

Musk said the cutbacks would not affect the company's ability to reach Model 3 production targets in the coming months.

"These cuts were almost entirely made from our salaried population and no production associates were included, so this will not affect our ability to reach Model 3 production targets in the coming months," Musk said in his note.

A report from a Wall Street analyst, also on Tuesday, estimated that Model 3 deliveries are tracking about 10,000 higher than previous estimates for the second quarter.

The company's profitability, and its future success, depends highly on its Model 3. It sees the all-electric car as its first mass-produced vehicle. Its stated goal is to produce 2,500 Model 3's per week, and ramping that to 5,000 per week.

Tesla shares climbed 3.2% to close at 342.77 on the stock market today.

In a related matter, Musk also said that the company wouldn't renew its pact with Home Depot ( HD) to sell solar energy systems.

"The majority of Tesla employees working at Home Depot will be offered the opportunity to move over to Tesla retail locations," he said in his memo.

RELATED:

Tesla Fourth-Quarter Earnings Beat, Maintains Model 3 Production Target

Tesla Said To Halt Model 3's Line As Broker Cuts Price Target

The post Tesla Cutting 9% Of Staff As It Tries To Ramp Up Model 3 Output appeared first on Investor's Business Daily.


79. Tesla (TSLA) Stock Quotes, Company News And Chart AnalysisВт., 12 июня[−]
X


View TSLA Stock Quote Page
| View TSLA Ratings

Tesla Stock News & Analysis

Stocks Fall Broadly, But New York Times Breaks Out; Time To Take Profits In iQiyi?Sellers still held the upper hand in stocks today as the Nasdaq composite and the Dow Jones industrial average fell between 0.6% and 0.7%. At 3 p.m. ET, the S&P 500 dropped... Read More
Tesla Lawsuit Targets Former Employee, Claims He Hacked InformationA Tesla lawsuit filed Wednesday claims a former employee hacked the company's confidential and trade secret information, transferring several gigabytes of data to outside entities. The Tesla lawsuit claims Martin Tripp stole data... Read More
Trump Tariffs Hit Major Indexes; Tesla Down; Will These 5 Growth Stocks Beat Trade War?A new threat by President Trump to apply 10% tariffs on an additional $200 billion in Chinese imported goods put the U.S. stock market on a slicker path to a potential market... Read More
Tesla Stock Falls As It Confronts Saboteur's Impact On OperationsTesla stock fell Tuesday, halting a seven-day run, after Chief Executive Elon Musk disclosed an alleged saboteur in the company's ranks and warned short-sellers that their position was going to "explode." Musk,... Read More
Dow Slips, Techs Recover, Small Caps Lead; Tesla Extends GainsLingering trade-war fears carried over to the stock market early Monday, but it ended up being a pretty good session for the bulls. Selling was concentrated mostly in blue-chip stocks, while the... Read More

More Technology Stocks Coverage

Latest FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

View More Tech Stocks

The post Tesla (TSLA) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


80. Nintendo, Sony, Ubisoft Bring Out Big Guns At E3 Video Game ShowВт., 12 июня[−]

LOS ANGELES — The annual E3 video game expo kicked off Tuesday after major companies Nintendo ( NTDOY), Sony ( SNE) and Ubisoft detailed their upcoming software lineups.

X

Sony and Ubisoft held media events in downtown Los Angeles on Monday afternoon and evening. Nintendo hosted an online reveal of its latest games Tuesday morning before the show floor opened at the Los Angeles Convention Center.

Nintendo focused on bringing more tried-and-true franchises to its Switch console. They include the company's Super Smash Bros. and Pokemon.

Meanwhile, Sony and Ubisoft mixed familiar franchises with games featuring risky new intellectual property at their E3 events.

Nintendo devoted most of its presentation to family-friendly fighting game "Super Smash Bros. Ultimate." The game comes out on Dec. 7. It features every fighter in the history of the series, plus a few more, such as Inklings from the Splatoon franchise.

Biggest Crossover In Video Game History

"This is the biggest crossover in video game history," famed game designer Masahiro Sakurai said in the online video.

Super Smash Bros. games feature characters from across Nintendo's portfolio as well as characters from other companies such as Solid Snake from Konami and Sonic the Hedgehog from Sega.

Nintendo also plugged "Super Mario Party," due out Oct. 5, and two new Pokemon games, set for release Nov. 16.

The biggest third-party game it announced for Switch was "Fortnite: Battle Royale" from Epic Games. It was made available on the platform Tuesday. It's already available on PCs, Macs, PlayStation 4, Xbox One, and Apple ( AAPL) iOS devices.

Sony Touts PS4 Games

Sony promoted nine games for its PlayStation 4 console. It previewed sequels such as "The Last of Us: Part 2" and Capcom's remake of "Resident Evil 2." It also offered more footage from its upcoming superhero game "Marvel's Spider-Man."

Plus, it showed off new games such as the enigmatic science-fiction-horror title "Death Stranding." There also was samurai game "Ghost of Tsushima" and sci-fi action title "Control."

'Just Dance' Busts A Move

Ubisoft opened its presentation with a marching band and dancers to hype "Just Dance 2019." The game is the next iteration of its popular music and dancing game.

It capped off the program with a detailed look at "Assassin's Creed: Odyssey," the latest in its long-running action-adventure series. The setting for the new game is ancient Greece.

Sticking with the familiar, Ubisoft touted shooter game "Tom Clancy's The Division 2."

But it also stuck its neck out with some brand-new games. They included pirate adventure game "Skull and Bones" and mind-bending psychological thriller game "Transference."

Ubisoft will support all the major platforms with its software, including Nintendo's Switch. It even got Nintendo to agree to let it use characters from its Star Fox games in its upcoming space adventure "Starlink: Battle for Atlas."

"This dream was only made possible by our long-term relationship with Nintendo," Ubisoft Chief Executive Yves Guillemot said at the event.

Streaming Games Called The Future

One major topic at this year's E3 is the emergence of streaming games via the internet. This subscription model is often called games-as-a-service.

Microsoft ( MSFT) announced plans to develop a game-streaming service to unlock console-quality gaming on any device. Electronic Arts ( EA) touted a new subscription streaming service for PC games called Origin Access Premier, which will launch later this summer.

The gaming business has shifted to digital downloads from physical media over the past few years. Now internet cloud gaming appears to be the next big thing, analysts say. But some technical challenges remain, such as removing latency.

"We believe a mixed model of physical and digital ownership and subscription is likely for several years to come, and that established digital distributors Sony and (Microsoft) Xbox will be joined by Amazon, Google, and potentially large publishers to fight for the right to own the consumer relationship," KeyBanc Capital Markets analyst Evan Wingren said in a report.

Microsoft is trying to become the "Netflix of gaming," Morgan Stanley analyst Keith Weiss said in a report. He said it plans to do so by building off its Azure cloud computing infrastructure.

"The current Xbox platform, existing customer and third-party vendor relationships, and a massive Azure Cloud infrastructure give Microsoft a solid start in the game streaming race," Weiss said.

RELATED:

E3 To Show Video Game Industry Vibrancy And Innovation

Video Game Stocks Called 'Must Own' Group Ahead Of E3 Expo

Microsoft Acquires 5 Game Studios, Touts Diverse E3 Software Lineup

EA Enters Battle Royale Games With 'Battlefield 5'

The post Nintendo, Sony, Ubisoft Bring Out Big Guns At E3 Video Game Show appeared first on Investor's Business Daily.


81. Boston Scientific Shares Surge On Possible Merger With StrykerПн., 11 июня[−]

Shares of Boston Scientific ( BSX) surged Monday after a report by the Wall Street Journal that it had been approached by Stryker ( SYK) about a deal between the two medical-device makers.

X

It's unclear whether Boston Scientific is open to a takeover, the Journal said, citing sources it didn't identify. Boston Scientific shares soared by as much as 17%, and ended the regular trading session up 7.4% to $34.32. Stryker shares fell 5.1% to close at $169.78. Trading on both stocks was halted just before 1 p.m. Monday, but neither company commented on merger rumors.

A deal between the two companies would be the latest in a series of large acquisitions in the industry, which has been consolidating to win market share and to package sales to hospitals, doctors and health clinics.

Boston Scientific makes heart devices such as pacemakers and stents, among other products, and is worth an estimated market value of nearly $50 billion. Valued at $65 billion, Stryker makes orthopedic products like artificial hips and knees.

Combining the companies would let them wring costs out of efforts to sell products to a similar set of customers. It would also give a combined firm more market power.

Pressuring Hospitals

Mergers by large health insurers have increased pressure on hospitals to lower expenses. The movement comes amid an ongoing debate about the cost of medical care in the U.S.

"As a matter of company policy, we do not comment on potential M&A," Stryker's Jon Zimmer says in an email. A representative for Boston Scientific didn't immediately respond to a request for comment.

Many of their largest competitors have already executed large takeovers in recent years.

Abbott Laboratories ( ABT) last year bought St. Jude Medical, which makes heart devices, for about $25 billion, then months later completed a takeover of medical testing and diagnostics supplier Alere for about $5 billion. Medtronic ( MDT) bought Covidien, which makes surgical products, for about $46 billion in 2015.

The post Boston Scientific Shares Surge On Possible Merger With Stryker appeared first on Investor's Business Daily.


82. Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing StudyПн., 11 июня[−]

Shares in biotech stocks Crispr Therapeutics ( CRSP), Editas Medicine ( EDIT) and Intellia Therapeutics ( NTLA) crashed Monday after a scientific publication said the companies' gene-editing techniques might cause cancer.

X

Crispr plummeted 12.6% to close at 59.57 on the stock market today. Intellia sank 9.8% to 24.56 while Editas tumbled 7.8% to 36.15.

Nature Medicine published a study on the CRISPR/Cas9 gene-editing platform, designed to help treat serious diseases. The Swedish study said the editing of cell genomes might increase the risk that the altered cells, intended to treat disease, will instead trigger cancer.

"Scientists found that cells whose genomes are successfully edited by CRISPR-Cas9 have the potential to seed tumors inside a patient. That could make some CRISPR'd cells ticking time bombs, according to researchers from Sweden's Karolinska Institute," said a report on the website Statnews.com.

Crispr Technique

Switzerland-based Crispr's gene-editing process removes a receptor on the donor's T cells. The aim is to prevent those cells from wildly attacking unintended targets.

The donor T cells are then engineered to appear as if they belong in the body so the patient's own immune cells won't try to destroy the donor cells.

Shares in Crispr had shot up 189% as of Friday's market close. Shares dipped last week after the Food and Drug Administration delayed an application from the company to begin gene-editing studies in sickle cell disease.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Biotech Stocks Crispr, Editas, Intellia Fall On Gene-Editing Study appeared first on Investor's Business Daily.


83. Facebook To Garner One-Fourth Of Ad Revenue From Instagram By 2020Пн., 11 июня[−]

Look for Instagram to drive advertising growth for Facebook ( FB), one Wall Street analyst said Monday.

X

"As core Facebook matures, Instagram is the key to the next leg of growth," KeyBanc Capital Markets analyst Andy Hargreaves said in a report to clients.

"Instagram is growing at a rapid pace, and we believe it will pass the 1 billion average monthly user mark in the back half of 2018," added Hargreaves. "We believe ad revenue will grow over 100% year-over-year in 2018 to $8.9 billion. We estimate Instagram will make up 26% of Facebook's total ad revenue by 2020 (up from 11% in 2017)."

Hargreaves estimates that Instagram will have 1.4 million users by 2020, with $22 billion in ad revenue.

Facebook Losing Popularity

Further, Facebook's popularity with teenagers has been falling. Kids ages 13 to 17 have been switching to Google's YouTube and Snapchat, said a study released in May by the Pew Research Center.

Only 51% of teenagers use the social media platform, down from 71% three years ago, said the study. Instagram, though, remains popular.

"Core Facebook is clearly maturing, with ad load reaching a saturation point and pricing the last lever to pull, so we see Instagram driving an increasing portion of incremental advertising growth," said the KeyBanc report.

Facebook rose 1.3% to 191.54 on the stock market today. The social media leader has rebounded from a sell-off in February and March tied to allegations of data harvesting by Cambridge Analytica. Still, the stock trades below a buy point of 195.42.

Facebook stock is up 4% for 2018 and 27% from a year ago.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Facebook To Garner One-Fourth Of Ad Revenue From Instagram By 2020 appeared first on Investor's Business Daily.


84. Video Game Stocks Called 'Must Own' Group Ahead Of E3 ExpoПн., 11 июня[−]

Video game stocks have a host of growth drivers that should make them attractive to investors, a Wall Street analyst said ahead of the annual E3 trade show in Los Angeles.

X

"Overall, we believe the sector remains a 'must own' for investors," Baird analyst Colin Sebastian said in a note to clients. "We estimate that the global interactive entertainment industry will reach about $145 billion in revenue by 2020, on track to become the largest segment of media and entertainment globally."

Sebastian reiterated his outperform ratings on video game stocks Activision Blizzard ( ATVI), Electronic Arts ( EA) and Take-Two Interactive Software ( TTWO).

Key areas of growth for video game publishers are digital downloads, microtransactions, esports, mobile games, and streaming and cloud services. Plus, the next generation of living-room game consoles are expected to arrive in 2020 or 2021. That will kick off a new hardware-upgrade cycle, Sebastian said.

"We expect multiple catalysts to drive continued growth and profitability gains for top 'pure-play' publishers including Activision, EA, Ubisoft and Take-Two," he said in the note, released Sunday.

All are making a splash at E3, short for Electronic Entertainment Expo. The conference officially begins Tuesday, but major companies held preshow events as early as Saturday. Activision shares climbed 1% to 75 on Monday. EA was up nearly 1% to 139.16. Take-Two inched down 0.1% to 113.32.

Hot Topics At E3

Among the major topics at the show are the proliferation of battle royale games, led by "Fortnite" from Epic Games, and the rise of subscription services, such EA's Origin Access Premier and Microsoft's ( MSFT) Xbox Game Pass.

EA hosted a news conference on Saturday and Microsoft followed with its own event on Sunday.

Both companies talked about streaming becoming the future of video games. But games stored on a console or PC will be the norm for some time, analysts said.

RELATED:

Microsoft Acquires 5 Game Studios, Touts Diverse E3 Software Lineup

EA Enters Battle Royale Games With 'Battlefield 5'

The post Video Game Stocks Called 'Must Own' Group Ahead Of E3 Expo appeared first on Investor's Business Daily.


85. Workday Acquires Cloud Specialist Adaptive Insights Ahead Of IPOПн., 11 июня[−]

Workday ( WDAY) said it has agreed to buy Adaptive Insights for $1.55 billion ahead of the startup's planned initial public offering this week.

X

The purchase is expected to close in the quarter ending Oct. 31.

Adaptive Insights operates a cloud platform for business planning. Analysts saw the company raising around $120 million in its IPO.

"I am excited to welcome the Adaptive Insights team to Workday and look forward to coming together to continue delivering industry-leading products that equip finance organizations to make even faster, better business decisions to adapt to change and to drive growth," Workday Chief Executive Aneel Bhusri said in a press release.

Expansion Moves

Pleasanton, Calif.-based Workday sells cloud-based software for human relations, payroll and other business functions.

It has expanded from human capital management software into financial management software.

Shares in the enterprise software maker slipped 0.5% to close at 123.24 on the stock market today.

RELATED LINKS:

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Stock Market Today: Track Market Trends And The Best Stocks To Watch

Understand The Market: The Big Picture

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Workday Acquires Cloud Specialist Adaptive Insights Ahead Of IPO appeared first on Investor's Business Daily.


86. Microsoft Acquires 5 Game Studios, Touts Diverse E3 Software LineupПн., 11 июня[−]

LOS ANGELES — Microsoft ( MSFT) shares were off Monday after the software giant showed its commitment to the video game business by announcing the acquisition of five game studios to increase exclusive content for its Xbox One console.

X

The Xbox One trails Sony's ( SNE) PlayStation 4 in unit sales in the current generation of video game consoles, but Microsoft is undeterred.

At a media briefing Sunday ahead of the annual E3 video game show, Phil Spencer, head of Microsoft's gaming business, outlined initiatives to keep the business strong. He boasted that the company's E3 lineup is its "most diverse gaming portfolio in every measure."

E3, short for Electronic Entertainment Expo, officially opens Tuesday, but several large game publishers and hardware makers are holding preshow events. Those events began Saturday with the kickoff of Electronic Arts' ( EA) EA Play fan fest in Hollywood.

Microsoft shares were off 0.6% to 101.05 at the close Monday. The company showed off 52 video games at its press event, including 18 exclusives. The exclusives included the company's "Halo Infinite," "Gears 5" and "Forza Horizon 4."

Spencer announced that Microsoft is adding five game development studios to its Microsoft Studios family. It has acquired U.K.-based Playground Games and has letters of intent to buy Ninja Theory of Cambridge, U.K.; Undead Labs of Seattle; and Compulsion Games of Montreal. Microsoft also is forming a new studio called The Initiative in Santa Monica, Calif., to be headed by industry veteran Darrell Gallagher.

"We embarked on a quest to find creative teams that have the mastery of our art," Spencer said. "We found innovative game designers, master storytellers and exceptional world builders."

Once the acquisitions are complete, Microsoft will have 11 game development studios. It did not reveal financial terms of the studio acquisitions.

New Xbox Console Coming

Microsoft is hard at work developing the future of gaming with artificial intelligence technology, Spencer said. Also, the company's hardware team "is deep into architecting the next Xbox console," he said. That device "will set the benchmark for console gaming."

At its E3 event, Microsoft shined a spotlight on upcoming Xbox One games from third-party publishers. Those games included "Battlefield 5" from Electronic Arts, "Fallout 76" from Bethesda Softworks and "Tom Clancy's The Division 2" from Ubisoft.

Microsoft also showed game footage from updates to "PlayerUnknown's Battlegrounds" from Bluehole coming in winter 2018. One of the first battle royale games, "Battlegrounds" is adding new environments and game modes, including a team-based "war mode."

RELATED:

EA Enters Battle Royale Games With 'Battlefield 5'

The post Microsoft Acquires 5 Game Studios, Touts Diverse E3 Software Lineup appeared first on Investor's Business Daily.


87. EA Enters Battle Royale Games With 'Battlefield 5'Пн., 11 июня[−]

Video game publisher Electronic Arts ( EA) shares were up Monday after it announced its upcoming World War II action game "Battlefield 5" will feature a last-man-standing battle royale mode.

X

Battle royale games, led by the hugely popular "Fortnite" from Epic Games, have taken the industry by storm in recent months. The hot online multiplayer game format is expected to be a big topic of conversation at the E3 show, which officially starts Tuesday in Los Angeles.

EA is the first of several large gaming companies that are holding events ahead of E3, which is short for Electronic Entertainment Expo. EA shares climbed nearly 1% Monday to close at 139.16.

At a media event in Hollywood on Saturday, EA executives provided details on their lineup of upcoming software titles including "Battlefield 5," "Anthem" and the annual releases of its pro sports games, including Madden NFL, FIFA and NBA Live.

EA said it will provide more details on the battle royale mode for "Battlefield 5" later this year. The historical combat game is set for release on Oct. 19. Rival Activision Blizzard ( ATVI) recently announced that it is adding a battle royale mode to its upcoming "Call of Duty: Black Ops 4."

Electronic Arts also announced new content for "Star Wars Battlefront 2," such as missions set during the Clone Wars of the sci-fi franchise. The game, released last November, posted disappointing early sales because of how it handled microtransactions, which fans criticized as a pay-to-win scheme.

EA officials at the event said improvements to the game are based on feedback from players and they pledged to get the game right.

EA also teased a new Star Wars game called "Star Wars: Jedi Fallen Order," which is due out for holiday 2019.

Electronic Arts To Offer New PC Game Service

Electronic Arts Chief Executive Andrew Wilson announced a new subscription streaming service for PC games called Origin Access Premier, which will launch later this summer.

Origin Access Premier will offer gamers full access to new EA releases on PC before anyone else including "Battlefield 5," "Anthem" and "Madden NFL 19," which is returning to PCs after a long absence. The service will provide access to more than 100 games from EA and other publishers through a single subscription.

Origin Access Premier will cost $14.99 per month or $99.99 per year.

In a speech at the event, Wilson said the combination of streaming and subscriptions "will have a profound impact" on the video game industry.

Last month, EA purchased an Israeli-based subsidiary of GameFly that specializes in cloud gaming technology.

RELATED:

'Fortnite,' Esports Set To Rule E3 Video Game Show

The post EA Enters Battle Royale Games With 'Battlefield 5' appeared first on Investor's Business Daily.


88. E3 To Show Video Game Industry Vibrancy And InnovationПн., 11 июня[−]

The state of the video game business is in top condition ahead of the industry's annual E3 trade show, a conference official said Monday.

X

"When it comes to investment, the industry is absolutely at a fantastic point," said Michael Gallagher, chief executive of the Entertainment Software Association.

The group owns and manages the E3 trade show. The three-day event officially opens Tuesday in Los Angeles after three days of preshow events.

E3, short for Electronic Entertainment Expo, will spotlight industry innovation and impact, as well as investment in games, Gallagher says.

Video game sales totaled $36 billion in the U.S. last year and $116 billion worldwide, Gallagher said. Those figures should grow 10% to 12% this year, he said.

60,000 Attendees

This year's show is expected to attract 60,000 attendees, including 3,000 members of the news media. For the second straight year, the show allows game fans to attend but caps consumer attendees at 15,000.

The Los Angeles Convention Center will host more than 200 exhibitors, including gaming giants like Sony ( SNE), Nintendo ( NTDOY), Activision Blizzard ( ATVI) and Ubisoft. More than 3,250 products will be exhibited at E3 2018, up from 2,300 at last year's show.

The console segment of the industry has healthy ecosystems around the three major consoles: Microsoft's ( MSFT) Xbox One, Sony's PlayStation 4 and Nintendo's Switch, Gallagher said. Plus, there are big markets for PC and smartphone games.

Innovation in technology will be on display at E3 in areas such as augmented and virtual reality and advancements in streaming games, Gallagher said.

Esports Big At E3 2018

Esports will have a major presence at the show, with tournaments from Epic Games, Nintendo, Tencent ( TCEHY) and more.

The mainstream success of "Fortnite," the battle royale game from Epic Games, shows gaming's impact on popular culture, Gallagher said.

He noted that "Fortnite" was on the show floor at last year's E3 before it became a global phenomenon.

"You just had to know out of the 2,000 things on the floor that it was going to be the one," Gallagher said.

RELATED:

Video Game Stocks Called 'Must Own' Group Ahead Of E3 Expo

Microsoft Acquires 5 Game Studios, Touts Diverse E3 Software Lineup

EA Enters Battle Royale Games With 'Battlefield 5'

The post E3 To Show Video Game Industry Vibrancy And Innovation appeared first on Investor's Business Daily.


89. Tesla Stock Gets Price-Target Increase As Model 3 Production ImprovesПт., 08 июня[−]

Tesla ( TSLA) stock received a price-target increase Friday from a Wall Street analyst who believes gross margins for the automaker's Model 3 will improve as it scales to higher production, thus helping it achieve profitability.

X

Nomura analyst Romit Shah raised his price target on the stock to 450 from 420 with a buy rating. That's a 40% premium from where the stock currently trades.

Shah believes the average selling price for the Model 3 sedan is rising as buyers of the vehicle are upgrading to higher performance configurations, including all-wheel drive and long-range batteries. He estimates the average selling price of the Model 3 is approaching $60,000. The car was introduced with a base price of $35,000.

"We believe that Tesla can lower per-unit costs considerably in the coming months, driven by improved fixed-cost absorption and higher labor efficiency," Shah wrote in a research note to clients.

Tesla shares rose 0.5% to 317.66 on the stock market today. Tesla stock jumped almost 10% on Wednesday, following the company's annual shareholder meeting.

'Production Hell'

Shah also expects increased deliveries for the Model S and Model X in the second half, further improving gross profit margins.

He forecasts that automotive gross margin will increase to 25.6% by the fourth quarter. That's up from 19.7% in the first quarter.

During the past few months, Musk has endured "production hell" with continuous Model 3 manufacturing woes as he wrestled with the media over negative coverage.

The company has said it will not need to raise capital this year. It expects to achieve profitability by the end of the third quarter.

RELATED ARTICLES:

Concerns Mount Tesla Will Need To Raise Bundle Of Cash To Survive

Consumer Reports Gives Tesla Model 3 Its Recommendation After Retest

Tesla Seeing High Rate Of Model 3 Reservation Holders Wanting A Refund

The post Tesla Stock Gets Price-Target Increase As Model 3 Production Improves appeared first on Investor's Business Daily.


90. Verizon CEO McAdam Steps Down, Former Ericsson Chief To Take OverПт., 08 июня[−]

Verizon Communications ( VZ) said Chief Executive Lowell McAdam will step down effective Aug. 1 and will be replaced by Hans Vestberg, a former Ericsson ( ERIC) executive who joined the company in 2017 as president of global networks and chief technology officer.

X

Vestberg, who served for six years as chief executive of Swedish wireless gear maker Ericsson, has been leading Verizon's push into next-generation, 5G wireless technology.

McAdam, 64, will serve as executive chairman of the board through his retirement from the company at the end of the year.

Verizon Wireless

The naming of a chief with roots in Europe's wireless industry has parallels with an earlier hire.

Verizon in 2016 hired Ronan Dunne, a veteran of the British mobile phone wars, to run its wireless business. Ronan Dunne was formerly head of Telefonica's ( TEF) British unit, branded as O2.

Verizon rose 0.4% to 49.18 on the stock market today.

YOU MAY ALSO BE INTERESTED IN:

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Looking For Breakout Stocks Like Nvidia? Start With These Lists

Stock Market Today: Track Market Trends And The Best Stocks To Watch

Understand The Market: The Big Picture

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Verizon CEO McAdam Steps Down, Former Ericsson Chief To Take Over appeared first on Investor's Business Daily.


91. 'Fortnite,' Esports Set To Rule E3 Video Game ShowПт., 08 июня[−]

Esports and battle royale video games are expected to be among the hot topics at the upcoming E3 interactive entertainment conference in Los Angeles.

X

The three-day show officially kicks off on Tuesday, but preshow events were scheduled to start Saturday.

Major video game publishers such as Activision Blizzard ( ATVI), Sony ( SNE), Take-Two Interactive Software ( TTWO) and Ubisoft will be showing off their latest software titles at the show.

The annual E3, short for Electronic Entertainment Expo, is a place for die-hard gamers and the gaming press to try out new games and get previews of what's ahead.

One of the big trends at this year's show will be the explosion of games using the battle royale format. "Fortnite Battle Royale" from Epic Games and "PlayerUnknown's Battlegrounds" from Bluehole popularized the format. Battle royale games are multiplayer online fighting games where the last player standing wins.

E3 2018 also will be home to several esports competitions, including a major "Fortnite" tournament. Nintendo ( NTDOY) will be hosting tournaments for its big games and ESL is setting up an esports arena in the Los Angeles Convention Center for the show.

Big Game Publishers At E3

Electronic Arts ( EA) is hosting its own event in Los Angeles away from E3. Its three-day EA Play show starts Saturday. It will be touting such upcoming games as "Anthem" and "Battlefield 5."

Activision will be promoting combat game "Call of Duty: Black Ops 4," which will include a battle royale mode.

Take-Two is expected to chat up its Wild West action game "Red Dead Redemption 2" and other titles at the show.

E3 will give Wall Street a chance to evaluate a trio of high-profile games launching within two weeks of each other this fall, Cowen analyst Doug Creutz said in a report Thursday. Activision's "Call of Duty: Black Ops 4" comes out on Oct. 12, followed by EA's "Battlefield 5" on Oct. 19 and "Red Dead Redemption 2" on Oct. 26.

"While the player bases of the titles are not identical, we still expect some cannibalization of demand among the three," Creutz said. "October is going to be brutally competitive."

The popularity of free-to-play game "Fortnite" could spoil the holiday season for Activision, EA and Take-Two, Jefferies analyst Timothy O'Shea said in an E3 preview report Wednesday. Epic makes money on "Fortnite" by selling digital extras that enhance the game experience.

"Epic could shatter streaming and viewership records at its ('Fortnite') event on Tuesday June 12, where it will certainly make several announcements," O'Shea said.

Personal computer and peripherals makers also will be at E3 in force to tout their latest gear for PC gamers. Hardware firms at the show include graphics-chip makers Advanced Micro Devices ( AMD) and Nvidia ( NVDA) and PC giants Dell and Lenovo. Headset makers Logitech ( LOGI) and Turtle Beach ( HEAR) also will be showing their wares.

'Red Dead' Expectations 'Overly Optimistic'

Meanwhile, BMO Capital Markets analyst Gerrick Johnson believes that investor expectations for "Red Dead Redemption 2" could be overly optimistic.

Wall Street is modeling for fiscal 2019 unit sales of 15 million to 18 million for the game, with 25 million units sold in the first 12 months.

"We expect a solid performance (15 million in fiscal 2019 and 17.5 million in the first 12 months) but are concerned about the risk of underperforming lofty expectations," Johnson said in a report.

Johnson downgraded Take-Two stock on Tuesday to market perform from outperform and cut his price target to 116 from 135. Take-Two shares ended the regular session flat at 113.42 on the stock market today.

In addition to concerns about "Red Dead" underperforming, he sees a potential slowdown in sales for the company's "NBA 2K" and "Grand Theft Auto" franchises.

RELATED:

Activision Blizzard Gets High Marks For New 'Call Of Duty' Game

Take-Two Outlook Seen Bright Thanks To 'Red Dead' Game

Video Game Stocks Rise, Shake Off 'Fortnite' Threat

The post 'Fortnite,' Esports Set To Rule E3 Video Game Show appeared first on Investor's Business Daily.


92. Broadcom Beats Wall Street's Fiscal Second-Quarter TargetsПт., 08 июня[−]

Chipmaker Broadcom ( AVGO) late Thursday beat Wall Street's targets for sales and earnings in its fiscal second quarter, but its current-quarter sales guidance came up short.

X

Broadcom earned an adjusted $4.88 a share, up 32% year over year, on sales of $5.01 billion, up 20%, in the quarter ended May 6. Analysts expected the San Jose, Calif.-based company to earn $4.76 a share on sales of $5 billion.

For the current quarter, Broadcom expects to garner sales of $5.05 billion, up 13%. It did not give a target for adjusted earnings per share. Wall Street was modeling the chipmaker to earn $4.57 a share, up 11%, on sales of $5.06 billion in its fiscal third quarter ending Aug. 5.

Broadcom shares dipped 0.3% to 264 in after-hours trading on the stock market today. During the regular session, the stock climbed 0.4% to 264.68. The stock has been consolidating for the past 28 weeks with a buy point of 285.78.

The company signaled weakening smartphone chip sales when it narrowed the range of its revenue guidance for fiscal Q2 on April 30. Broadcom is a top supplier of chips for Apple's ( AAPL) iPhones.

"Our business continues to be very robust and sustainable," Broadcom CEO Hock Tan said in a news release. "This is validated through our strong execution in the second quarter which drove gross margin to a record 66.6% and free cash flow to 42.3% of net revenue."

Broadcom is a leading semiconductor device supplier to the wired, wireless, enterprise storage, and industrial markets.

RELATED:

Chip Stocks To Watch And Semiconductor Industry News

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

Looking For The Next Nvidia? Start With These 3 Steps

The post Broadcom Beats Wall Street's Fiscal Second-Quarter Targets appeared first on Investor's Business Daily.


93. Chip-Gear Maker Flirts With Buy Point After AcquisitionПт., 08 июня[−]

Semiconductor equipment maker Entegris ( ENTG) saw its stock spike to a record high on Thursday after it announced a tuck-in acquisition late Wednesday.

X

The Billerica, Mass.-based company reached an agreement to buy the SAES Pure Gas business from SAES Getters, an advanced functional materials company headquartered in Milan, Italy.

Entegris will pay about $355 million for SAES Pure Gas, which is based in San Luis Obispo, Calif. SAES Pure Gas provides high-capacity gas purification systems used in semiconductor manufacturing and adjacent markets.

Entegris stock jumped as much as 3.4% early Thursday, notching an all-time high of 39.05. But it soon retreated on broader industry concerns that chip-gear sales might be slowing. It ended flat at 37.75 on the stock market today.

The stock briefly hit a buy point of 38.35 out of a 12-week consolidation period.

Entegris supplies specialty chemicals and materials handling systems to the semiconductor industry.

Chip Gear Stocks Fall

Chip gear stocks sank on Thursday after Evercore ISI analyst C.J. Muse said memory chip push-outs could weigh on near-term equipment shipment forecasts for Lam Research ( LRCX). Other industry sector players fell in response.

Lam shares tumbled 5.4% to 188.83. Industry peer Applied Materials ( AMAT) sank 2.4% to 51.25. ASML Holding ( ASML) toppled 2.8% to 207.56. KLA-Tencor ( KLAC) fell 1.3% to 115.93.

RELATED:

Chip-Gear Firm Entegris Posts Beat-And-Raise Quarterly Report

The post Chip-Gear Maker Flirts With Buy Point After Acquisition appeared first on Investor's Business Daily.


94. Vertex Gets Some Breathing Room As Rival Disappoints In Cystic FibrosisПт., 08 июня[−]

Vertex Pharmaceuticals ( VRTX) is getting some breathing room, an analyst said Thursday, as rival Proteostasis ( PTI) tumbled on disappointing results from a study testing cystic fibrosis drugs.

X

Proteostasis tested its drug, PTI-801, in patients also taking Vertex's drug Orkambi. The regimen showed improvements in blood glucose, sweat chloride — an indicator of cystic fibrosis — and weight gain. But patients didn't experience a major improvement in their breathing.

It's "not as easy as it looks," Leerink analyst Geoffrey Porges said in a note. Vertex shares have dipped 10% quarter to date on competitive worries. But the "sell-off can reverse after competitive threats fade," he said.

Vertex rose as much as 2.5% intraday, but ended the regular session down a fraction to 145.75. Shares of Proteostasis crashed 38% to 3.03 on the stock market today. Galapagos ( GLPG), another rival, saw its shares lose 2.5% to 102.67 on Proteostasis' news.

A number of cystic fibrosis drugs work to correct malfunctioning protein made by the CFTR gene. PTI-801 is what's known as a CFTR corrector. Vertex has a portfolio of correctors that work in different patients based on their own genetic mutations.

Combining Cystic Fibrosis Drugs

Vertex, Proteostasis and Galapagos with partner AbbVie ( ABBV) are all working on combinations of drugs to treat cystic fibrosis. The study from Proteostasis was looking to determine the best doses of PTI-801 for double- and triple-pill studies, Leerink analyst Joseph Schwartz said.

The key metric these tests look to improve is forced expiratory volume for one second. In Proteostasis' study, the best result came from a 200-milligram dose of PTI-801 on top of Orkambi. That improved forced expiratory volume for one second by 2.5 percentage points.

But that lagged Vertex's newly approved drug Symdeko — a two-medicine regimen — which improves patients' ability to forcefully expel air by 10% to 11%, Leerink's Porges said. Now, Proteostasis' competitive threat "appears modest," he said

"While Proteostasis' corrector binds to a different site on the CFTR protein than Vertex's medicines, the failure to match the high (effectiveness) bar established by Vertex is a testament to the difficult development path for competitors with small molecule therapies for cystic fibrosis," he said.

Galapagos will likely have data later this month for a study of its second-generation corrector on top of Orkambi.

The results from Proteostasis "suggest that the medicinal chemistry at Vertex may indeed be a durable competitive advantage for the company in the cystic fibrosis indication," he said. But if Galapagos is successful, Vertex could "retrace back to the 160-170 range through June and July."

RELATED:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Next Nvidia? Start With This Simple Routine

The post Vertex Gets Some Breathing Room As Rival Disappoints In Cystic Fibrosis appeared first on Investor's Business Daily.


95. Why Alder's CEO Hire Could Indicate It's Seeking A BuyerПт., 08 июня[−]

Alder Biopharmaceuticals ( ALDR) likely will seek a buyer after its Amgen ( AMGN)-rivaling preventative migraine treatment gets approval, an analyst said Thursday as shares tanked on the hire of a new chief executive.

X

Alder shares dropped 1.9% to 17.80 on the stock market today. Shares broke out of a cup base at an 18.70 buy point earlier in the week. But the rally was short-lived as the stock sank for three consecutive days.

The biotech company hired Robert Azelby, former chief commercial officer at Juno Therapeutics, as its new chief executive. Celgene ( CELG) recently acquired Juno, an immuno-oncology player. Before that, Azelby worked at Amgen where he managed the U.S. oncology business.

But Leerink analyst Geoffrey Porges sees Azelby's tenure as likely a short one.

"The advantages of Mr. Azelby, in our view, are locality and availability, since he was already in Seattle and had presumably become available after the acquisition of Juno by Celgene," he said in a report to clients.

He added: "It's hard to believe that the board views Mr. Azelby as the long-term leader for this company, and the appointment adds to our conviction that the board will ultimately support a sale."

Could Alder Sell?

A sale is unlikely however until Alder gets approval for its preventative migraine treatment, known as a CGRP inhibitor. Amgen gained approval for its drug, Aimovig, in May. Teva Pharmaceutical ( TEVA) and Eli Lilly ( LLY) are also working on similar drugs.

Earlier this year, Alder's founder and former CEO Randall Schatzman unexpectedly stepped down. Alder had planned to submit its application for its migraine treatment in the second half of the year. Now, it expects to submit an application in the first quarter of 2019.

The fact that Alder hired a new CEO isn't surprising, Porges said. "But it is something of a surprise that the individual appointed to the position has no experience in neurology, and has not previously overseen the complex multi-functional elements of a product introduction," he said.

RBC analyst Brian Abrahams, on the other hand, called the hire a "sensible fit" as Alder moves toward its commercial stage. Azelby brings significant experience in commercial strategy across large and small biotechs, and biopharma, he said.

"We believe all of this will be important in launching (preventative migraine treatment) eptinezumab," he said in a note. "We understand he has also been closely involved in regulatory processes at his prior organizations, experience which can help with eptinezumab's (application) filing."

RELATED:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

Investing Basics: How To Sell A Stock

Should You Buy A Stock Ahead Of Its Earnings Report?

The post Why Alder's CEO Hire Could Indicate It's Seeking A Buyer appeared first on Investor's Business Daily.


96. Solar Industry Stocks Get Price-Target Cuts As China Cutbacks RippleПт., 08 июня[−]

First Solar ( FSLR) and two other solar stocks had their price targets lowered by a Wall Street analyst on Thursday, as the industry has been rattled by China's unexpected move to slash incentives.

X

Solar stocks have been in free fall since June 1, after three Chinese agencies on May 31 announced new policies. They are halting the installation of new solar-power farms for the rest of this year. The sudden policy makeover also includes a significant cut in subsidies. China is the largest solar market worldwide.

Credit Suisse analyst Michael Weinstein cut his price target on First Solar to 53 from 59. First Solar shares fell 4.1% to 53.28 on the stock market today. Shares are down 23% since the China announcement.

He slashed his price target on Jinko Solar ( JKS) to 13 from 22. Jinko Solar shares fell 0.8% to 11.92. The stock is down 33% since the announcements.

Weinstein cut his price on SunPower ( SPWR) to 8 from 8.50. SunPower fell 0.6% to 7.28 on Thursday. It is down 15% since China's announcements.

The primary blow has been on companies that build or provide components for solar panels.

U.S. Installers Benefit

Developers of U.S. solar installation projects, such as San Francisco-based Sunrun ( RUN), stand to benefit from lower-than-expected module prices in the short term for contracted projects where they are yet to buy modules, Weinstein said in a research note to clients.

Sunrun shares dropped 2.3% to 12.28 on Thursday. But its shares are up 7% since the announcements.

The actions by China, designed to spur more competition, were expected to happen within years, but the accelerated transition came as a surprise, Weinstein said.

RELATED LINKS:

Solar Companies Get A Power Surge From New California Mandate

Coverage On First Solar, Sunrun, SunPower Initiated At Disruptive Time

The post Solar Industry Stocks Get Price-Target Cuts As China Cutbacks Ripple appeared first on Investor's Business Daily.


97. Amazon Signs With U.K.'s Premier League To Broadcast Pro Soccer GamesЧт., 07 июня[−]

Amazon ( AMZN) has expanded its lineup of streaming sports with a deal with Premier League to broadcast soccer matches in the United Kingdom.

X

The e-commerce giant will show two full rounds of 20 soccer matches per season, starting in 2019 in a three-year deal. Viewers will be able to watch weekly highlights of all Premier League matches throughout the season, the press release said.

The deal will expand awareness of Amazon Prime, the company's lucrative subscription service. A subscription to Prime is required to watch the matches. With that, consumers also get online streaming access to its video channel, among numerous perks, such as streaming music and free shipping.

The company has more than 100 million Prime subscribers around the world, including several million in Britain. Prime costs the equivalent of $106 per year in Britain.

Premier League is a top-level soccer league, consisting of 20 teams. It's one of the most-watched sports leagues in the world. One of its best-known teams is Manchester United ( MANU).

Amazon did not disclose what it paid for the broadcast rights. In April, it outbid Twitter ( TWTR) for rights to broadcast NFL football games on Thursday night.

Amazon Prime Benefits

Amazon and Twitter, along with Facebook ( FB) and the YouTube unit of Alphabet ( GOOGL), have been aggressive in trying to strike deals with sport leagues.

In March, Facebook reached a deal to broadcast 25 Major League Baseball games, available on the Facebook Watch channel. Twitter also has agreements to broadcast MLB games.

The soccer deal extends Amazon's lineup of streaming sports events, which includes professional tennis matches and football games.

Amazon shares fell 0.4% to 1,689.30 on the stock market today. Twitter dropped 1% to 39.70. Facebook slid 1.7% to 188.18.

RELATED LINKS:

Netflix Takes On Media Giants As Video Streaming War Goes Global

Could Facebook, Esports, Media Boom From Legalized Sports Betting?

The post Amazon Signs With U.K.'s Premier League To Broadcast Pro Soccer Games appeared first on Investor's Business Daily.


98. Acacia, Lumentum Gain As U.S. To Lift Ban On ZTE Component SalesЧт., 07 июня[−]

Shares of Acacia Communications ( ACIA), Lumentum Holdings ( LITE) and other optical-component makers climbed Thursday after U.S. Commerce Secretary Wilbur Ross said the Trump administration has hammered out a deal to lift sanctions on Chinese telecom gear maker ZTE. But most of the gains evaporated later in the trading session.

X

U.S. companies such as Acacia and Lumentum had been barred from selling devices to ZTE, China's second-biggest telecom gear maker behind Huawei.

Acacia rose as much as 4.5% intraday, but ended the session down 1% to 33.53. Lumentum gained as much as 2.1% intraday, but closed down 0.4% to 61.10 on the stock market today.

Finisar ( FNSR) rose a fraction to 17.38. NeoPhotonics ( NPTN) rose 1.6% to 7.15, while Oclaro ( OCLR) climbed 1.4% to 9.18.

ZTE said it would be forced to go out of business if its supply of optical components from companies such as Acacia, Finisar and NeoPhotonics dried up.

Commerce officials issued new sanctions on ZTE after determining that the gear maker violated terms of its 2017 settlement agreement with the U.S. involving the shipped gear. The first sanctions followed a probe into illegally shipped equipment to Iran and North Korea.

ZTE Big Acacia Customer

Acacia garners 30% of its sales from ZTE, Wall Street analysts say. Oclara gets about 14% of its sales from ZTE, while Lumentum, Finisar and NeoPhotonics get less than 5%.

The Commerce Department initially probed ZTE's sales to Iran in 2016. The gear maker pleaded guilty last year in federal court in Texas for conspiring to violate U.S. sanctions to Iran. It paid $890 million in fines.

Ross told CNBC that ZTE will pay the U.S. a $1 billion fine and put $400 million in an escrow account. The sanctions on ZTE have been a sore point amid trade talks between the U.S. and China.

RELATED LINKS:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Acacia, Lumentum Gain As U.S. To Lift Ban On ZTE Component Sales appeared first on Investor's Business Daily.


99. DocuSign Stock Jumps As Billings Top Views, Revenue Outlook BeatsЧт., 07 июня[−]

DocuSign ( DOCU) late Thursday said it swung to a profit in its fiscal first quarter as revenue and billings topped expectations. The company also forecast current-quarter revenue above analyst estimates.

X

Shares in the maker of software that digitizes contract paperwork rose 6.5% to 59.60 in after-hours trading on the stock market today.

DocuSign earned an adjusted Q1 profit of one cent, swinging to a profit from a year earlier, with revenue rising 37% to $155.8 million, topping consensus estimates.

A year earlier, DocuSign had a loss of 30 cents a share on sales of $113.4 million. Analysts expected DocuSign to report a loss of 7 cents a share on sales of $146.2 million for the period ended April 30.

Billings blow past estimates

DocuSign said Q1 billings, a sales growth metric, jumped 33% to $169 million, blowing past estimates of $133.5 million. The company added 30,000 new customers, giving it 400,000 overall.

For the July quarter, the company forecast revenue in a range of $157 million to $160 million vs. estimates of $151.6 million.

The software maker raised $629 million in its April initial public offering, with shares priced at $29. Backers included Kleiner Perkins and Google Ventures.

Its main rival is Adobe Systems ( ADBE).

YOU MAY ALSO BE INTERESTED IN:

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Looking For Breakout Stocks Like Nvidia? Start With These Lists

Stock Market Today: Track Market Trends And The Best Stocks To Watch

Understand The Market: The Big Picture

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post DocuSign Stock Jumps As Billings Top Views, Revenue Outlook Beats appeared first on Investor's Business Daily.


100. Carbon Black Stock Rises As Security Firm's Outlook Meets ViewsЧт., 07 июня[−]

Carbon Black ( CBLK) late Thursday reported a narrower-than-expected loss as revenue met expectations in its fiscal first quarter. The computer security firm forecast current-quarter sales and profit roughly in line with analyst estimates.

X

Carbon Black reported an adjusted fiscal Q1 loss of 98 cents a share, nearly flat from a year ago, with revenue rising 35% to $48.4 million. A year earlier, the company had a loss of 99 cents a share on sales of $36 million. Analysts expected Carbon Black to report a loss of $1.27 a share on sales of $48 million for the period ended April 30.

Shares in the maker of computer security software initially fell 3.5% in after-hours trading on the stock market today. But they rebounded and were up 5.3% late. In Thursday's regular session, shares fell 2.6% to 26.31.

The security firm's software detects malware on computer network "endpoint" devices. They include mobile phones, laptops, tablets, and the Internet of Things.

Rivals Include CrowdStrike, Tanium

"Our (Q1) performance was driven by growing demand for our next-generation endpoint security platform, the Cb Predictive Security Cloud," CEO Patrick Morley said in a news release. "The (software) protects customers from today's most advanced cyber threats, including ransomware and new types of attacks that have never been seen before and are undetectable by legacy anti-virus products."

For the July quarter, Black Carbon expects a loss in a range of 41 cents to 42 cents vs. estimates of a 43-cent loss. The company forecast revenue of $48.5 million to $49 million. Analysts had projected $48.2 million.

Waltham, Mass.-based Carbon Black raised $152 million in its May initial public offering, with shares priced at $19. The company competes with big industry players such as Symantec ( SYMC) and McAfee as well as startups CrowdStrike, Tanium and SentinelOne.

YOU MAY ALSO BE INTERESTED IN:

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Looking For Breakout Stocks Like Nvidia? Start With These Lists

Stock Market Today: Track Market Trends And The Best Stocks To Watch

Understand The Market: The Big Picture

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Carbon Black Stock Rises As Security Firm's Outlook Meets Views appeared first on Investor's Business Daily.



 
Каталог RSS-каналов (лент) — RSSfeedReader
Всего заголовков: 100
По категориям:
Все заголовки
AAPL (13)
ABBV (1)
ABT (2)
ACIA (1)
ADBE (2)
ADP (1)
AGN (1)
AI (2)
ALDR (2)
ALKS (1)
ALXN (1)
AMAT (3)
Amazon Stock News (4)
AMD (4)
AMGN (4)
AMZN (15)
ANET (1)
APPF (1)
APPL (1)
Apple Stock News (3)
APTX (1)
Artificial Intelligence (2)
ASML (2)
ATVI (8)
Auto Industry News & Stocks To Watch (1)
AVGO (1)
AVLR (3)
AVRO (1)
AZN (2)
BABA (2)
BAC (1)
BHVN (1)
BIB (1)
BIIB (2)
Biotech And Pharma Stock News (23)
BMWYY (1)
BMY (1)
BOX (1)
BSX (3)
CAKE (1)
CBLK (2)
CBS (2)
CELG (1)
Chart Patterns: Double Bottom (1)
Chinese Stocks To Watch (1)
Chip Stocks Semiconductor Industry News (8)
CHTR (2)
Click (15)
Cloud Computing (4)
CLVS (1)
CMCSA (5)
COF (1)
COOL (1)
COST (1)
CRM (4)
CRSP (1)
CSCO (2)
DBX (1)
DDAIF (1)
DIS (5)
DISCA (2)
DISH (1)
DOCU (2)
Dow Jones Industrial Average Stock News (5)
DVMT (1)
DXC (1)
E3 (11)
EA (8)
Earnings (13)
EBAY (1)
EDIT (1)
ENTG (1)
ERIC (1)
ETSY (2)
EUV (1)
EW (1)
EXPE (1)
Facebook Stock News (1)
FANG Stocks: Facebook Amazon Netflix Google (7)
FB (8)
FMI (2)
FNSR (1)
FOXA (5)
FSLR (1)
FTNT (1)
GILD (2)
GLPG (1)
GOOGL (12)
Google Stock News (2)
GRUB (1)
GSK (3)
HD (2)
HEAR (3)
HPE (1)
HRTX (1)
IART (1)
IBB (1)
Industry Trends And Stock News (8)
INTC (5)
IONS (2)
IPO News (7)
ISRG (1)
JD (1)
JKS (1)
JNJ (5)
JPM (1)
KLAC (1)
KZR (1)
LABU (1)
LBRDA (1)
LGF (2)
LITE (1)
LLY (3)
LOGI (3)
LRCX (3)
LSXMA (1)
MANU (1)
MAR (1)
MCHP (1)
MDT (4)
MGTA (1)
MRK (3)
MSFT (9)
MU (3)
MYL (2)
MZOR (1)
Netflix Stock News (4)
NFLX (10)
NKE (1)
NOW (2)
NPTN (1)
NTDOY (6)
NTLA (1)
NVDA (6)
NVS (2)
OCLR (1)
ORCL (4)
PANW (1)
PAYC (1)
PAYX (1)
PCRX (1)
PCTY (1)
PFE (2)
PTCT (2)
PTI (1)
PVTL (1)
PYPL (3)
PZZA (1)
QCOM (1)
QLYS (1)
QRVO (1)
Retail And E-Commerce Stocks And Industry News (7)
RHHBY (3)
RHT (2)
RP (1)
RS (1)
RUN (1)
S (2)
SAGE (2)
SGH (1)
SHOP (2)
SLDB (1)
SMAR (1)
SMTC (1)
SNE (5)
SNN (2)
SNY (1)
SPOT (1)
SPWR (1)
SQ (3)
SRPT (3)
SYK (4)
SYMC (1)
SYNA (1)
T (9)
TCEHY (2)
TEAM (2)
Tech Earnings (14)
Technology (85)
TEF (1)
Telecom Stocks To Watch And Industry News (5)
Tesla Stock News (5)
TEVA (2)
TGT (2)
TMUS (2)
Trump News: Markets & Investing (1)
TSLA (8)
TSM (2)
TSRO (1)
TTD (1)
TTM (1)
TTWO (6)
TWTR (2)
TWX (4)
ULTI (1)
USB (1)
VIA (1)
VLKAY (1)
VRTX (1)
VZ (5)
W (1)
WDAY (2)
WDC (1)
WFC (1)
WMT (2)
XBI (1)
XERS (1)
YUM (1)
ZBH (2)
ZS (1)
ZUO (1)
По датам:
Все заголовки
2018-06-22, Пт. (1)
2018-06-21, Чт. (15)
2018-06-20, Ср. (12)
2018-06-19, Вт. (8)
2018-06-18, Пн. (7)
2018-06-16, Сб. (4)
2018-06-15, Пт. (3)
2018-06-14, Чт. (13)
2018-06-13, Ср. (9)
2018-06-12, Вт. (8)
2018-06-11, Пн. (8)
2018-06-08, Пт. (8)
2018-06-07, Чт. (4)
По авторам:
Все заголовки
ALLISON GATLIN (21)
BRIAN DEAGON (16)
IBD STAFF (8)
PATRICK SEITZ (25)
REINHARDT KRAUSE (27)
RUSS BRITT (3)